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The  rate  of  nonalcoholic  fatty  liver  disease  (NAFLD)  such  as  steatosis  and
nonalcoholic steatohepatitis (NASH) in populations  is  continuing to grow vigorously
and  became  a  worldwide  public  health  issue.  To  understand  the  liver  disease
progression one needs to investigate complex interactions occurring within biological
systems. Systems biology tries to understand the interactions within biological systems
by  means  of  mathematical  models.  Exploiting  this  approach  I  want  to  describe
interactions of genes, proteins and metabolites that are involved in nonalcoholic fatty
liver disease.  Molecular data from liver tissue samples of three mouse strains (A/J,
C57Bl6  and  PWD)  under  two  different  conditions:  3,5-diethoxycarbonyl-1,4-
dihydrocollidine (DDC)-treated and untreated (control)  were  analyzed. Each of these
mouse strains shows different degrees of the disease under DDC treatment displaying
high,  low,  and  no  steatohepatitis-like  phenotypes  for A/J, C57Bl6  and  PWD,
respectively. 
In this work I performed pathway analysis  using gene expression data of mouse liver
samples and  identified  metabolism  of  histidine,  beta-alanine,  purine  along  with
glycolysis and gluconeogenesis pathways as top hit candidates that may be involved in
liver dysfunction. Furthermore, gene expression and metabolite data of the arachidonic
acid metabolism were found to be deregulated  and this pathway was used for kinetic
modeling. Genes and metabolites of  S-adenosylmethionine (SAMe) metabolism were
found to be perturbed under DDC-treatment.  In addition, I  have  developed a novel
enrichment analysis  approach that may be used for identification of the most relevant
fully  coupled  modules  in  a  disease  context.  The  approach  includes  three  steps: 1)
obtain fully coupled reactions which represent a module, 2) use gene expression data of
a  disease  context  to  obtained  marked  correlated  modules  and 3)  select  modules  in
which  at  least  one  gene  is  differentially  expressed  between  normal   and disease
conditions. Aforementioned steps are used to identify  liver disease specific  modules
such as modules of pentose phosphate pathway and hepatic SAMe metabolism which
are linked to oxidative stress.  Furthermore,  I  also  identified  a module of cholesterol
metabolism which is linked to apoptosis along with a module of pyrimidine catabolism,
for  which  experimentally measured genes  and  metabolites  were also  found  to  be
deregulated.  The goal was to identify modules for which genes and metabolites are
perturbed  under  DDC-treatment.  The  identified  modules  may  be  involved in  liver
disease and they can be used to build kinetic models for better understanding of  the
liver  disease progression.  Thus,  in  addition to  enrichment  analysis  of fully coupled
modules, I developed an approach which is based on elementary flux modes (EFMs). In
this approach initially differentially regulated metabolites due to DDC-treatment were
identified. Then reactions which can produce differentially regulated metabolites were
xused as  a  target  set.  For  each reaction in  the target  set,  50 EFMs that  contain  the
reaction were identified. After that, gene expression data of mouse liver samples were
used to select important EFMs that may be involved in the liver disease progression. I
identified  two  EFMs:  one  EFM  comprises  differentially  regulated  metabolites  L-
arginine, ornithine and putrescine and another EFM comprises differentially regulated
metabolites D-glucose, L-glutamine and L-asparagine.  
I  introduced a  mGX-FBA method  which  is  a  modified  version  of  the  previously
published GX-FBA method.  Differences between metabolic  flux  levels among mouse
strains may provide a better understanding of the reasons behind NAFLD. To address
this, I performed an in silico flux-based analysis using E-Flux and the modified mGX-
FBA method by incorporating gene expression data of the mouse model.  Furthermore,
during  the  course of my thesis  I  compared the results of  both methods,  E-Flux and
mGX-FBA,  and  validated  the  results  with  experimental  data.  The  change  of  flux
through metabolic pathways may change metabolic concentrations. Due to the absence
of  experimental  flux data  for mouse  liver  samples it  is  difficult  to  assess in  silico
predicted flux regulation. However, in silico flux regulation may give a hint about the
regulation of metabolic concentrations. Hence, to observe the flux regulation I colored
metabolic  maps  with  the  deviation  of  fluxes  between  DDC-treated  versus  control.
Different  degrees  of  flux  regulation  was identified  through cholesterol  biosynthesis
among all three mouse strains. The concentration of desmosterol that is a downstream
metabolite of cholesterol biosynthesis  was  found to be regulated at different degrees.
The  regulation  of  desmosterol  concentration  is  inline  with  the  flux  regulation  of
cholesterol biosynthesis among all three strains. In addition, to understand whether one
can speculate  about the prediction of flux regulation in metabolic pathways based on
gene regulation I used bile acid synthesis and cholesterol biosynthesis pathways. For
these pathways, I observed that based on gene expression data it is difficult to estimate
flux regulation, but the integration of gene expression data using E-Flux improves the
prediction of flux regulation.  
I  introduced novel  objective  functions  for measuring  the  readout  of  steatosis  and
steatohepatitis. To construct an objective function for steatosis I used metabolites which
are  involved  in  the  formation  of  lipid  droplets  (LDs),  while  for  steatohepatitis  an
objective function integrating both metabolites that are involved in LDs formation and
metabolites involved  in  oxidative  stress  was used.  Gene  expression  data  of  liver
samples of all three mouse strains were incorporated to a mouse metabolic model and
obtained objective  values  were validated  with  strain's  phenotypic  data. I  also
constructed  an  objective  function  with  metabolites  which  may  be involved  in  cell
proliferation. Cell proliferation is used as a readout of hepatocellular carcinoma (HCC).
Applying  these  functions  I  performed  an  in  silico  drug  target  analysis  in  which
xi
potential  drug  candidates  for steatosis,  steatohepatitis  and  HCC were identified.
Cholesterol  metabolism  and  triacylglycerol  synthesis  were  found  as top  hits that
contain  the largest number of  potential  drug target candidates. Out  of 78  identified
potential  drug candidates,  7  were found  to  be  approved  by  the  Food  and  Drug
Administration (FDA) as anticancer drugs.
Metabolite concentrations can be viewed as end points of perturbations occurring at the
gene level, so that changes of gene expression might explain changes in metabolite
concentrations. I  proposed  a  novel  hypothesis  to  predict  changes  in  metabolite
concentrations between two conditions based on gene expression data.  To address this,
I  have  developed  a  Petri  net-based  method  (MPN)  and used  it  to  simulate  the
arachidonic acid model. As an alternative to MPN, Monte Carlo ODE-based simulation
was used, but  both methods cannot predict  the metabolic concentrations in the  real
range of experimental data. To overcome this, I have developed a fitted detailed kinetic
model of the arachidonic acid metabolism that comprises metabolites that are markedly
deregulated due to DDC-treatment in all three mouse strains. 
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Zusammenfassung (German Summary)
Die Rate der  nichtalkoholischen Fettlebererkrankungen (NAFLD), wie Steatose und
nichtalkoholische Steatohepatitis  (NASH) nimmt kontinuierlich zu und ist  zu einem
weltweiten  Gesundheitsproblem  geworden.  Um  die  Entstehung  dieser
Lebererkrankungen besser zu verstehen bedarf es einer detaillierten Untersuchung der
komplexen  Interaktionsnetzwerke  lebender  Systeme.  Systembiologie  versucht  die
komplexen Netzwerke biologischer Systeme mit Hilfe mathematischer Modelle besser
zu  verstehen.  In  der  vorliegenden  Arbeit  versuche  ich  unter  Verwendung  dieses
Ansatzes  die  Interaktionen   zwischen  Genen,  Proteinen  und  Metaboliten  in  der
nichtalkoholischen Fettlebererkrankung besser zu beschreiben. Für diese Analyse lagen
molekulare Daten zu Leberproben dreier Mausstämme (A/J, C57Bl6 und PWD) vor,
die einer Behandlung mit DDC (3,5-diethoxycarbonyl-1,4-dihydrocollidine) unterzogen
wurden,  die  als  Modellsystem  für  die  nichtalkoholische  Fettlebererkrankung  dient,
wobei die drei Mausstämme unterschiedliche Ausprägungen der Erkrankung zeigen, die
von hoch in A/J über niedrig in C57Bl6 bis zu keiner Steatohepatitis in PWD reicht.
Im Rahmen dieser Arbeit habe ich auf Basis entsprechender Transkriptomdaten eine
Pathway-Analyse durchgeführt, bei der unter anderem der Arachidonsäurestoffwechsel
als dereguliert  gefunden wurde, was auch durch weitere Metabolitdaten untermauert
werden  konnte,  und  daher  Gegenstand  einer  entsprechenden  mathematischen
Modellierung  war.  Des  Weiteren  wurden  Transkriptom-  und  Metabolitdaten  des  S-
Adenosylmethionin  (SAMe)-Metabolismus  als  dereguliert  durch  DDC-Behandlung
gefunden. Ferner habe ich eine neue Methode zur Anreicherungsanalyse entwickelt, die
für  die  Identifizierung  vollständig  gekoppelter  Module  genutzt  werden  kann.  Der
Ansatz beinhaltet drei Schritte: 1) Identifizierung vollständig gekoppelter Reaktionen,
die  ein  Modul  darstellen,  2)  die  Filterung  dieser  Module  auf  Basis  von
Genexpressionsdaten, und 3) die Selektion relevanter Module, in denen wenigstens ein
Gen differentiell reguliert ist zwischen gesundem und krankem Zustand. Dieser Ansatz
wurde verwendet um spezifische Module der Lebererkrankung im Modellsystem zu
finden.  So  wurde  z.B.  ein  Modul  des  Pentosephosphatwegs  oder  des  SAMe-
Metabolismus identifiziert, die mit oxidativem Stress assoziiert sind. Das Ziel war es
somit hier Module zu identifizieren, die sowohl in den Expressionsdaten als auch in den
metabolischen  Daten  im  DDC-Modellsystem  verändert  sind,  und  somit  am
Krankheitsprozess beteiligt  sein können. Die identifizierten Module tragen daher  zu
einem  besseren  Verständnis  der  Krankheitsentstehung  bei  und  können  als
Ausgangspunkt für weitere kinetische Modellierungen dienen. Zudem habe ich einen
entsprechenden Ansatz auch auf Basis von elementaren Flussmodi entwickelt.
Des  Weiteren  habe  ich  eine  modifizierte  Form  der  auf  der  Flux-Balance-Analyse
basierenden  GX-FBA  Methode  entwickelt.  Änderungen  im  metabolischen
Flussverhalten  können  zu  einem  besseren  Verständnis  der  Ursachen  von  NAFLD
beitragen. Hierfür habe ich eine vergleichende Flussanalyse mit Hilfe der Methoden E-
Flux und der  von mir  modifizierten  GX-FBA Methode  auf  Basis  der  vorliegenden
Genexpressionsdaten durchgeführt und diese Methoden diesbezüglich auch verglichen.
Mit  dieser  Analyse  konnten  unter  anderem  Unterschiede  im  Cholesterol-  und
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Gallensäure-Metabolismus identifiziert werden.
Um den Grad von Steatose und Steatohepatitis in silico beurteilen zu können, habe ich
neue Zielfunktionen definiert, die die Bildung von Lipidtröpfchen berücksichtigen. Des
Weiteren wurde eine Zielfunktion erstellt, die den Grad der Zellproliferation beschreibt
und  als  Maßstab  für  die  Leberkrebsentstehung  verwendet  werden  kann.  Diese
Zielfunktionen  wurden  genutzt,  um  neue  Ziele  für  potentielle  Medikamente  für
Steatosis,  Steatohepatitis  oder  Leberkrebs  zu  identifizieren.  Von  den  78  hierbei
identifizierten Kandidaten gibt es schon zu 7 entsprechende Medikamente, die von der
FDA (Food and Drug Administration) zugelassen sind.
Änderungen  in  den  Konzentrationen  von  Metaboliten  können  als  Folge  einer
geänderten  Genexpression  interpretiert  werden.  Um  diesen  Zusammenhang  für  die
qualitative und quantitative Modellierung zu nutzen,  schlage ich hier  eine auf einer
Petri Netz-Simulation beruhenden Analyse vor und vergleiche diese mit einer Monte
Carlo-basierten am  Beispiel  des  hier  entwickelten
Arachidonsäurestoffwechselmodells,  sowie  einem  Modell,  bei  dem  die  kinetischen
Parameter  mit  Hilfe  einer  Parameteroptimierung  an  die  experimentellen  Daten




Liver diseases, such as nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease
(ALD) are  very  common worldwide.  NAFLD includes  a  disease  spectrum ranging from
steatosis, to nonalcoholic steatohepatitis (NASH), to advanced fibrosis and cirrhosis. ALD
develops due to alcohol abuse and it runs a spectrum similar to NAFLD.  NAFLD affects 10
to 24% of  the  population in various countries  (Angulo, 2002). The prevalence of NAFLD
varies with ethnicity (45% in Hispanics; 33% in whites; 24% in blacks) and sex (42% in
white men; 24% in white women) in Western adults (Browning et al., 2004). The prevalence
increases 57.5% to 74% in obese persons along with 90% in morbidly obese persons (those
weighting more than 200 % of their  ideal body weight)  (Angulo,  2002; Machado et  al.,
2006). NAFLD affects 2.6% of children and 22.5% to 52.8% of obese children  (Angulo,
2002). NASH, an advanced form of NAFLD is less common in the normal population. The
prevalence of NASH is estimated to be 2% to 3% in adults, and 37% in morbidly obese
(Dowman  et  al.,  2011;  Neuschwander-Tetri,  2005).  NAFLD  is  closely  associated  with
obesity and insulin resistance.  Accordingly,  it  represents the hepatic manifestation of the
metabolic  syndrome.  Approximately 20% of  alcoholics  and heavy drinkers  develop fatty
liver,  or  steatosis  (Mann  et  al.,  2003).  Fatty  liver  can  be  reversed by reducing  alcohol
consumption substantially. After excessive use of alcohol the fatty liver shows inflammatory
changes that  are  an early sign of more serious liver disease, and may lead to death. Both
NAFLD and ALD have become issues of public health due to these serious health concerns. 
Complex diseases such as NAFLD or cirrhosis develop as a result of the interaction between
the human genome and the environment. The development of complex diseases is difficult to
understand based on individual genetic variants  of the human genome. In contrast, genetic
variation is  usually  causative  of  Mendelian  disorders.  Complex  disease  phenotypes  are
controlled not only by genes but by the dynamics of interaction networks of genes, proteins
and  metabolites  (Strohman,  2002).  These  networks  range  from  signaling  to  metabolic
pathways regulating enzymes  and  metabolites.  Thus,  to understand  the progression  and
development  of  complex  diseases one  needs first  to  understand  complex  interactions  of
biological systems instead of single genes in isolation. As such, systems biology can be seen
as an approach to understand the complex behavior of biological systems.
The term systems biology was introduced a decade ago to understand biology according to a
system's  structure  and  dynamics  (Kitano,  2002a).  In  recent  years,  the  field  has  made
considerable  progress  in  technologies  for  global  cell  measurement,  as  well  as in
computational analysis of these data in order to study and model cell function. The ability to
make genome-wide (proteome- or  transcriptome-wide)  measurements  on a  system is  the
driving force  behind the  rise of systems biology.  Only genome-wide measured data is not
sufficient to study  the real  biological systems. Thus, systems biology comprises methods
which can be used to study with a systems hypothesis-driven approach for the experimental
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1 Introduction 
design (Ideker et al., 2001). 
Detailed knowledge of signaling and metabolic pathways  interactions  is needed  for  many
fields relevant  to medical  research,  such as  hepatology and cancer  biology.  Quantitative
proteomics  enables  a  broader  and  more  unbiased  view  of  the  cellular  signaling  event.
Proteomics data was used to model the epidermal growth factor receptor (EGFR) signaling
network intended  for proliferation and migration  (Wolf-Yadlin et al.,  2006). Furthermore,
diagnostic biomarkers  were identified based on  profiling  gene and protein expression for
complex diseases such as  cancer  and steatohepatitis  (Cheang et  al.,  2008;  Quackenbush,
2006; Starmann et al., 2012). Therefore, high-throughput data, pathway related information
(Croft et al., 2011; Kanehisa et al., 2012), and computational algorithms open an approach to
view human diseases at the system-level. To address this approach,  networks of biological
reaction  systems can  be  created  by  integrating  genetic,  genomic,  biochemical,  cellular,
physiological,  and  clinical  data  that  can  be  used  to  understand  disease  progression  and
therapy. In order to understand disease therapy, one needs not only to define the topology of
disease  related  networks  or  modules,  but  also  to  explore  the  dynamic  response  to
perturbations.
A disease might be a cause of abnormalities in genomic or environmental factors; however,
currently, only approximately 10%  of the known  genes  can be associated with  a  disease
(Amberger et al., 2009). Mutations of hub genes or proteins can be responsible for a disease.
Disease related genes are likely to form a subnetwork which is formed by disease modules
(Loscalzo  and  Barabasi,  2011).  These  modules  can  be  identified  computationally  using
experimentally  data (Loscalzo and Barabasi, 2011). Most biological networks show a  high
degree  of  clustering  that  implies  the  existence  of  topological  modules.  Modules  can  be
obtained based on the similar structure and function among elements of the global network.
However, computing modules is computationally challenging (Ahn et al., 2010; Girvan and
Newman, 2002). 
Systems biology is the study of the interaction between potentially thousands of genes as a
whole system instead of a single gene. We need to perform a quantitative study to understand
the mechanisms of components interacting within the regulatory system. Such a study would
rely  on  an  experimental  design  of  complex  biological  systems.  The  interpretation  of
experimental results requires mathematical particularly often statistical approaches. The data
obtained  by  large-scale  experiments,  such  as  mRNA  microarrays  or  protein-protein
interaction screening can be analyzed  using statistical  methods.  These statistical  methods
provide  initial  insight  into  large  systems,  e.g.,  how  many  genes  that  are  differentially
regulated  can  be  found  by  statistical  testing  methods.  A cellular  network constructed
according  to  graph  theory  provides  a  good  starting  point  for  mapping  large-scale
experimental data within the cells. The undirectional (the link has no direction between the
nodes) network is less informative, whereas the directional (the link has a direction between
nodes, e.g.  A ->B) network can be used to identify motifs, such as feedforward or feedback
2
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loops, and to infer regulatory mechanisms. However, these statistical and graphical methods
are limited to studying the dynamics of cellular regulation. To this end,  predictive models
are much needed to understand the regulation of the system. 
Predictive  models  can  be  built using  quantitative  data  on cellular  levels,  such  as  the
concentration of proteins and metabolites, and on the reaction rates for interactions between
components. Quantitative biochemical models are difficult to build because of the limitations
of  experimental  biochemistry  and  quantitative  molecular  biology  data.  Metabolic
concentrations and other components are likely to vary in different cell types.  In order to
model this, it  is necessary to measure concentrations of those components  in multiple cell
types. Similarly, kinetic parameters require us to determine them under multiple conditions.
Although there is information on metabolic concentrations (Wishart et al., 2007) and kinetic
parameters  (Scheer et al.,  2011; Wittig et al.,  2012), this information  is  limited to model
complex  biological  systems.  In  short,  predictive  models  are  needed  to  understand  a
biological system, but are least likely to be possible due to the often limited availability of
sufficient experimental data.  
An approach is proposed to study the parameter space of the model using a Monte Carlo-
based simulation in which unknown kinetic  parameters  are  sampled from an appropriate
distribution for simulations  (Wierling et al., 2012). This approach may be used to predict
complex and variable phenotypes from genotypes in personalized medicine. Furthermore,
kinetic parameters can be estimated or optimized using an objective function of quantitative
experimental data. Therefore, optimization methods can be used to build realistic and reliable
mathematical models (Raue et al., 2013); however, these are challenging in computation and
limited to  small-scale  modeling.  Moreover,  a  Petri  net-based  non-parametric  strategy is
proposed for characterizing the dynamics of a signaling network (Ruths et al., 2008) which
may be used for large-scale modeling but still remains to be tested.  
Constraint-based modeling is a mathematical approach for analyzing the flow of metabolites
through a metabolic network (Varma and Palsson, 1994; Orth et al., 2010). It can be applied
to genome-scale metabolic networks  (Schellenberger et al.,  2010). Furthermore, it  can be
used to identify coupled reactions (David et al., 2011; Larhlimi et al., 2012) in the metabolic
network. These coupled reactions can be  seen  as  a  module that can be used to explore  a
complex disease and its related data. Taken together, one can study the development and
therapy of  a  complex disease, such as NAFLD, using several systems biology approaches.
Furthermore, several studies can be done in  the  context of NAFLD, e.g, identification of
deregulated modules and pathways,  in addition to metabolic drug targets.
Outline 
In  this  work  I  present  liver  functions  and  related  diseases (section  1.3  and 1.4).  In  the
following section I  will  outline the experimental  data  and systems biology approach for
studying  biological  systems  (section  1.5  and  1.6).  Later,  I  present  the  computational
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modeling approaches.   
Furthermore,  I  present  published  methods  in  detail  such  as  computation  of  shortest
elementary flux modes (section 2.3), integration of gene expression data into a metabolic
model  (section  2.4  and  2.5),  simulation  based  on  Petri  nets (section  2.8).  I  introduce
objective functions for the readout of steatohepatitis and steatosis (section 2.6).
Pathway analysis is performed using gene expression data of mouse liver samples (section
3.1). I introduce modules identification in metabolic networks using fully coupled reactions
as well as elementary flux modes (section 3.2). Furthermore, to predict steady state fluxes I
performed the integration of gene expression data into a metabolic model (section 3.3). I
identified in silico potential candidates of drugs in liver disease through metabolic models
(section 3.4). Arachidonic acid metabolism is identified as a candidate in pathway analysis
and it is used for kinetic modeling (section 3.5).  Results of section 3 are compared with
other studies in section 4. 
1.1 The Liver 
The liver is  an important organ that  is  involved in metabolic and clearance functions. It
fulfills diverse but closely connected functions in the metabolism of carbohydrates, proteins
and lipids, the clearance of toxins and pathogens, and the regulation of immune response.
The food we eat is eventually processed through  the  liver before the body can use it; our
food  is  broken  down  into  small  particles/molecular  subunits,  e.g.,  fats,  proteins  and
carbohydrates. Proteins can be involved in the catalyzation of metabolic reactions. The liver
stores fuels  for  our body, e.g.,  storage of glycogen, fat,  cholesterol, minerals, vitamins and
carbohydrates.  The  liver  sends  these  fuels  through  our blood  for  use  as energy  and  in
building healthy tissue. Finally, the liver makes bile which dissolves fats. 
The liver lobule is the structural unit of the liver. The entire liver consists of thousands of
lobules. Each lobule consists of a roughly hexagonal arrangement of hundreds of hepatocytes
and other types of cells (Figure 1.1). Nutrients- and oxygen-rich blood enters the liver lobule
from the hepatic portal vein and hepatic artery, and is then distributed throughout the lobule.
Within the lobules blood flows between the hepatocytes through small  capillary  channels
called sinusoids. Toxic substances from the blood exit the lobule through the central vein
(i.e., the hepatic venule). The blood close to the hepatic portal vein and hepatic artery has
higher nutrients and oxygen content than  blood close to the hepatic venule. This is due to
much of  the  oxygen and nutrients  already having been extracted from the blood by the
hepatocytes close to the hepatic portal vein and hepatic artery. As a result, the blood close to
hepatic venule contains less oxygen and nutrients (Cunningham and Van Horn, 2003).
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Some of the better well known functions of the liver include the following: 
• Regulation of glucose metabolism
• Regulation of lipoprotein metabolism
• Regulation of  levels of amino acids  in blood, which form the building blocks of
proteins
• Processing of hemoglobin for use of its iron content
• Conversion of poisonous ammonia to urea
• Clearing the blood of drugs and other poisonous substances
The  regulatory  mechanisms concerning  glucose  and  lipoprotein  metabolism  are  of  a
particular  interest  due  to  these  pathways  and  modules  are  identified  in  our  analysis.
Therefore, a detailed overview of both glucose and lipoprotein metabolism is given below. 
1.1.1 Regulation of glucose metabolism
Blood glucose in the human body maintains a narrow range between 4 to 7mM (Saltiel and
Kahn, 2001). Insulin and glucagon are the hormones  that  control glucose homeostasis. In
response to high glucose levels, insulin is released from pancreatic beta cells and converted
to an active form in the blood. Insulin stimulates glycogen accumulation through the increase
in glucose transport (via Glut2) and glycogen synthesis (Figure 1.2). In case of high level of
glucose, insulin inhibits the production of glucose by repressing gluconeogenesis (pyruvate
to glucose) and glycogenolysis (glycogen to glucose). In contrast, low glucose levels cause
secretion  of  the  pancreatic  hormone glucagon from alpha  cells.  Glucagon stimulates  the
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Figure 1.1 The structure of the liver’s functional units, or lobules (from: Cunningham and Van
Horn, 2003). Blood enters the lobules through branches of the portal vein and hepatic artery, then
flows between the hepatocytes through small channels called sinusoids. Blood exits the lobules
through a small vein located in the center of each lobule called the hepatic venule. 
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conversion of the liver glycogen to glucose and the release of glucose back into the blood.
Glucose can also be generated by gluconeogenesis during periods of starvation and intense
exercise. The disruption of glucose homeostasis can cause diabetes, a metabolic syndrome in
which patients do not produce balanced levels of glucose. 
6
Figure 1.2 The regulation of glucose metabolism by  the  liver (modified after Saltiel and
Kahn, 2001).  In  the  liver,  insulin  stimulates the  synthesis of  glycogen  from glucose,  while
repressing glucose synthesis and release. Insulin stimulates the expression of genes encoding
glycolysis (in red; G-6-Pase, F-1-6-pase and PEPCK), while inhibiting the expression of those
encoding gluconeogenesis enzymes (in blue; PK and PFK). Insulin stimulates enzymes of fatty
acid pathway (in  blue;  FAS).  These effects  are  determined by transcription factors  and co-
factors, i.e. sterol regulatory element binding protein (SREBP-1), hepatic nuclear factor (HNF-
4),  the  forkhead  protein  family  (Fox),  Peroxisome  proliferator-activated  receptor  gamma
coactivator (PGC1). Insulin also regulates the activities of some enzymes such as glycogen
synthase  and  citrate  lyase  (in  green),  through  changes  in  the  phosphorylation  state.  GK,
glucokinase; Glucose-6-p, Glucose-6-phosphate; G-6-Pase, Glucose-6-phosphatase; F-1,6-Pase,
fructose-1,6-biphosphatase;  PEPCK,  phosphoenolpyruvate  carboxykinase;  PFK,
phosphofructokinase;  PK  pyruvate  kinase;  ACC,  acetyl-CoA carboxylase,  FAS,  fatty-acid
synthase. 
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1.1.2 Regulation of lipoprotein metabolism
The lipoproteins transport lipids, including cholesterol, to blood streams. The liver plays an
important  role  maintaining cholesterol  levels  through  the  lipoprotein  metabolism.  The
regulation  of  lipoprotein  metabolism involves three  steps  (Figure  1.3).  First,  we see the
metabolism chylomicrons in which chylomicrons  are formed from dietary cholesterol and
the intestine triglyceride. Chylomicrons form chylomicron remnants after secretion of fatty
acids.  Subsequently,  fatty acids and chylomicron remnants are  uptaken by the peripheral
tissues and the liver, respectively.  Second, the liver secrets  very low density lipoproteins
(VLDLs) after loading lipids and cholesterol to the apolipoprotein B (apoB), and VLDLs are
then converted to low density lipoproteins (LDLs). LDLs can be uptaken by the liver through
the LDL receptor. When the free cholesterol is found in higher amounts in peripheral tissues,
then as a third step the reverse transport of cholesterol happens from peripheral tissues to the
liver through high-density lipoprotein (HDL) metabolism. 
1.2 Liver diseases 
Hepatic diseases are a type of damage to or disease of the liver. Some kinds of liver diseases
are caused by infective viruses, e.g.,  the  Hepatitis virus (A, B, and C). Liver disease can
happen due to long-term drug or alcohol intake. Some examples of alcohol related diseases
are  alcoholic hepatitis and alcoholic cirrhosis.  Fatty liver disease can  also occur  with very
little  alcohol  intake,  and then  is called nonalcoholic fatty liver disease (NAFLD). NAFLD
represents a disease progression ranging from simple steatosis to NASH, fibrosis, cirrhosis
and eventually liver cancer. 
1.2.1 Steatosis and steatohepatitis
Steatosis, also known as fatty liver, is a process characterized by the accumulation of fat in
the liver.  Hepatic steatosis is a condition in which intracellular lipids are accumulated and
subsequently form lipid droplets in the cytoplasm of hepatocytes which is associated with an
enlargement of the liver. When steatosis of the liver is further combined with inflammation,
the condition is known as steatohepatitis. Both pathological conditions are included under




An incidence of NAFLD  of  15 to 20% is observed in western populations, and its most
common cause of development is overnutrition  (Amarapurkar et al., 2007; Bedogni et al.,
2005).  Overnutrition-  and obesity-related NAFLD is  observed in patients  with metabolic
syndrome, e.g., obesity and insulin resistance  (Higuchi and Gores, 2003). It is remarkable
that the prevalence of steatosis in patients with obesity is about 75% (Adams et al., 2005;
Browning et al., 2004), and nearly 35% of these develop NASH (Ong et al., 2005; Xanthakos
et al., 2006). It is noteworthy that a considerable fraction of patients with steatohepatitis will
progress to  advanced disease stages, e.g., fibrosis, cirrhosis and hepatocellular carcinoma.
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Figure  1.3 Regulation of  lipoprotein  metabolism (modified  after Rader  and  Daugherty,
2008).  Lipoprotein  metabolism  involves  the  transport  of  lipids,  e.g.,  cholesterol  and
triglyceride,  in  the  blood.  Dietary  fat  from  the  intestine  forms  chylomicrons  (large
triglyceride-rich  proteins),  which  are  transported  to  peripheral  tissue  such  as  muscle  and
adipose tissue, through the blood. The chylomicrons form chylomicron remnants and secrete
fatty acids to the peripheral tissue. The chylomicron remnants are taken up by the liver and
bind to apoB. This complex secrete very-low-density lipoproteins (VLDLs), which further
develop  low-density lipoproteins (LDLs) by activation of lipoprotein lipase. LDLs are then
taken up by the liver through LDL receptors (LDLR) and also it can pass through blood to
other peripheral tissues. In contrast, high density lipoproteins (HDLs) are generated by the
liver and the intestine through secretion of lipid free apoA-1. apoA-I then form nascent HDLs
from cholesterols of these organs by action of the transporter ABCA1. In peripheral tissue and
macrophage, ABCA1 transports free cholesterol to nascent HDLs, while ABCG1 transports
free  cholesterol  to  mature  HDLs.  The  free  (unesterified)  cholesterol  in  nascent  HDLs  is
esterified  to  cholesteryl  ester  by  the  enzyme  lecithin  cholesterol  acyltransferase  (LCAT),
creating mature HDLs. The cholesterol in HDLs is returned to the liver both directly, through
uptake  by the  receptor  scavenger  receptor  class  B member  1  (SR-BI),  and  indirectly,  by
transfer to LDLs and VLDLs through the cholesteryl ester transfer protein (CETP). 
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Typically, middle-aged patients have an increased risk of developing NAFLD. In NAFLD
patients, > 80% of patients are overweight or obese, 80% have hyperlipidemia, 30-70% are
hypertensive and 20% have type 2 diabetes mellitus  (Grattagliano et al., 2007). There  do
exist  pharmacological  means to counteract this development,  which are  weight loss or an
improvement of insulin sensitivity. Nevertheless, these treatments are only partially effective
(Mishra and Younossi, 2007). Due to absence of effective treatment for NASH, the disease is
still to date the subject of studies on morbidity and mortality. The diagnosis of NASH is the
following: 12% death within 10 years (Schuppan et al., 2010). Clearly, liver diseases such as
NASH, are an important and growing public health issue. Cirrhosis due to NASH may now
account for up to 20% of cirrhosis cases and may also play a major role in cryptogenic
cirrhosis.  Furthermore  up  to  10% of  hepatocellular  carcinomas  may  result  from NASH
(Angulo, 2002; Bugianesi et al., 2002; Day, 2005; Farrell and Larter, 2006). 
The molecular mechanism of intrahepatic lipid accumulation and growth of lipid droplets
may arise from 1) increased uptake of lipids, 2) elevated de novo synthesis of fatty acids, 3)
impaired lipoprotein synthesis, or secretion and /or 4) reduced fatty acid oxidation (Anderson
and Borlak, 2008). In this regard, the liver plays a central role in energy homeostasis by
storing glucose as glycogen and distributing fuels to peripheral tissue in form of glucose and
lipids. Dietary lipids in form of chylomicrons are transported from the intestine to the liver
where they are processed with apolipoprotein B 100 to form VLDL. These particles are
secreted and then distribute lipids to adipose tissue. Consequently, dietary increase of lipids
and glucose may result in hepatic lipid accumulation (Bray et al., 2004). 
One  of  most  exciting  questions  in  this  study  pertains  to why  and  how  hepatic  lipid
accumulation leads to the development of liver inflammation. A potential subject of research
to  study  might  look  for  the  factors  responsible  for  switching between  steatosis  and
steatohepatitis. To provide pathophysiologic principles for the progression to steatohepatitis,
the  ’two-hit’  model  is  proposed  (Day  and  James,  1998).  The  ’First-hit’  refers  to  the
intracellular deposition of triacylglycerols which leads to metabolic and molecular alteration
that sensitizes the liver, while the ’second-hit’ refers to oxidative stress and cytokine-induced
liver injury. Lipid accumulation and short- and long-term effects of non-esterified fatty acids
(NEFA) increase oxidative stress, cellular stress, e.g., activation of protein kinase C (PKC),
mitogen-activated protein kinase (MAPK), jun N-terminal kinase (JNK), nuclear factor-κB
(NF-κB),  and expression of pro-inflammatory cytokines,  such as tumor necrosis  factor α
(TNF-α) and interleukin 6 (IL-6) (Reddy and Rao, 2006). In conclusion, steatosis of the liver
may arise from an excess supply of fatty acids and/or glucose, and insulin resistance; its
progression  to  NASH  is  linked  to  the  paracrine  effect  of  pro-inflammatory  cytokines
(Anderson and Borlak, 2008). 
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1.2.2 Histological features of nonalcoholic steatohepatitis
Histology is an anatomical study of the microscopic structure of cells and tissues of plants
and animals. It is an essential tool in biology and medicine. In a histological study, cells and
tissues are sectioned, stained and examined under a light microscope or electron microscope.
Hematoxylin and eosin staining (H & E stain or HE stain) is a popular method in histology. It
is widely used by pathologists to examine the biopsy of patients related to diseases such as
cancer and steatohepatitis. Histologic features of NASH are a)  mixed macrovesicular and
microvesicular steatosis, b)  zonal distribution of steatosis (zone three) in NASH, c) foci of
lobular  inflammation  composed  of  lymphocytes,  d)  Mallory’s  hyaline  stained  with
immunohistochemistry for Ubiquitin, e) nuclear vacuolation in hepatocytes, and f) Apoptosis
(Singh et al., 2010). 
1.2.3 Biological model systems for nonalcoholic fatty liver disease 
The mechanism of progression of NAFLD/NASH has not  yet  been completely elucidated
(Cohen et  al.,  2011). This  may be  a  reason  for  the  availability  of  very few therapeutic
modalities  for  NAFLD/NASH that  include  weight  loss  agents,  bariatric  surgery,  insulin-
sensitizing agents, lipid-lowering agents, antioxidants, probiotics and other agents (Lam and
Younossi, 2010). Applying this study of NAFLD/NASH to humans has limitations, however,
due to genetic variation among individuals of various ethnic groups and long time required
for the occurrence of NAFLD/NASH. Thus, large populations and long periods of time are
required for  the  study incidence of NASH/NAFLD in humans. To overcome this problem,
animal  models  of  NAFLD/NASH  can  be  used  to  demonstrate the  pathogenesis  of
NAFLD/NASH along with therapeutic effects of various agents. 
Histological features of NASH, such as steatosis, ballooning of hepatocytes, apoptosis, and
Mallory bodies, can be reproduced to a variable extent in different mouse models by various
treatments like chronic intoxication with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC),
methionine-choline deficient (MCD) diet, alcohol or high fat diet (HFD) (Anstee and Goldin,
2006; Denk et al., 2000). Previous studies demonstrated that the disease phenotypes of these
animal models were influenced by the genetic background  (Haluzik et al., 2004; Kirsch et
al., 2003). 
1.2.4 Molecular causes of steatosis and steatohepatitis
Steatosis and steatohepatitis  are associated with  several molecular causes and mechanisms
such as nuclear receptors, inflammation mediated by signaling pathways, oxidative stress,
and lipotoxicity (Anderson and Borlak, 2008; Marra et al., 2008). Peroxisome proliferator-
activated  receptor  alpha  (PPARα),  a  nuclear  receptor,  has  been  identified  as  a  master
regulator of liver inflammation and for the metabolism of hepatic lipid metabolism, glucose,




1.2.4.1 Nuclear receptors and transcription factors 
Fatty acid is a metabolic regulator of fatty acid oxidation, and also is known to  act as a
ligand  for  nuclear  transcription  factors,  i.e.,  PPARα and  hepatic  nuclear  factors  (HNFs)
(Rasmussen and Wolfe,  1999).  The lipid  metabolism is  regulated  by major  transcription
factors, i.e., sterol regulatory element binding protein 1 (SREBP-1), PPARα, carbohydrate-
responsive element-binding protein (ChREBP), lipogenic liver X receptor (LXR), forkhead
box  01  (Foxo1),  and  PPARγ,  while  the  lipoprotein  metabolism  is  controlled  by
apolipoprotein AI regulatory protein-1, v-erbA-related protein (EAR-2), EAR-3, and HNF-4
(Canbay et al., 2007; Cha and Repa, 2007; Ide et al., 2003; Ladias et al., 1992). PPARs are
the key player behind lipid accumulation. For instance, liver-specific expression of PPARα is
activated  by  different  ligands  as  xenobiotics  (e.g.,  fibrates),  eicosanoids,  and fatty  acids
(Mehendale,  2000;  Motojima  and  Hirai,  2006).  PPARα  shows  a  negative  regulation  of
inflammation,  possibly  inhibiting the  translocation  of  nuclear  factor-κB  (NF-κB)  to  the
nucleus by interacting with p65 (Delerive et al., 2001). PPARα can prevent the induction of
pro-inflammatory cytokine and enzyme expression, i.e., tumor necrosis factor α (TNF-α) and
cyclooxygenase (COX) II through the inhibition of NF-κB (Yu et al., 2006). A deactivation
of PPARα may reduce  the  liver’s ability to uptake, utilize, and catabolize fatty acids and
thereby it may be causally involved in the development of steatosis (Rakhshandehroo et al.,
2010; Reddy, 2001). 
1.2.4.2 Lipotoxicity 
Lipotoxicity is a metabolic syndrome that refers to a cellular dysfunction due to intracellular
accumulation of lipids.  Elevated  levels of free fatty acid cause inflammation observed in
adipose tissue, obesity, and NASH, and  that is  characterized by elevated plasma levels of
TNF-α  (Crespo et  al.,  2001;  Kern et  al.,  1995;  Valenti  et  al.,  2002).  Fatty acid  induces
synthesis  of  ceramide  via  L-serine  and  palmitoyl-CoA,  catalyzed  by  serine
palmitoyltransferase  (Unger  and  Orci,  2002).  Ceramide  upregulates  the  expression  of
inducible nitric oxide synthase (iNOS), which leads to apoptosis. Lipoapoptotic cell death
provides  an  explanation  for  elevated  apoptosis  rates  in  NASH  and  links  hepatic  lipid
accumulation to inflammation.  As for the involvement of free fatty acids in  activation of
TNF-α, a hypothesis is proposed (Feldstein et al., 2004) that suggests a high-fat diet causing
the  accumulation of lipids and translocation of  the  pro-apoptotic factor bax to lysosomes.
Bax  induces  a  release  of  lysosomal  cysteine  protease  cathepsin  B  (cath  B),  which  is
responsible for degradation of intercellular adhesion molecule (IKK-β) and the activation of




In  the  ’two-hit’ model,  the  first  hit  represents  lipid  accumulation,  while  the  second  hit
represents an increase in oxidative stress  (Day and James, 1998). Oxidative stress can be
caused  by  reactive  oxygen  species  (ROS)  (Pessayre  et  al.,  2002).  ROS  are  chemically
reactive molecules containing oxygen, e.g., oxygen ion and peroxide. Either increases ROS
directly or secondarily (impaired respiration leads to the formation of ROS) can be a cause
for the development of steatohepatitis. Higher ROS formation in steatohepatitis can cause
more lipid peroxidation, cytokine induction, and fibrogenesis than in steatosis  (Pessayre et
al., 2002). Excessive generation of ROS may affect the maintenance of an appropriate redox
environment  to  avoid  oxidative  modification  in  proteins,  lipids  and  DNA  within
mitochondria  (Garcia-Ruiz  and  Fernandez-Checa,  2006).  Mitochondrial  Glutathione
(mGSH)  plays  an  essential  role  in  the  mitochondrial  defense  against  constant  ROS
generation. Thus,  a  marked depletion of mGSH is a critical factor in the development of
steatohepatitis through sensitization of hepatocytes to inflammatory cytokines (Garcia-Ruiz
and Fernandez-Checa, 2006).
1.2.4.4 Inflammation mediated through signalling and metabolic pathways
Activation of the c-Jun N-terminal kinase (JNK) pathway can lead to lipotoxicity and pro-
apoptotic mechanisms in NASH through inflammation  and  oxidative stress  (Leamy et al.,
2013). JNK stimulation has been observed in NASH patients as well as murine models of
steatohepatitis (Puri et al., 2008; Singh et al., 2009).
Arachidonic acid (AA)-derived lipid, such as lipoxin (LXA4) and aspirin-triggered LXA4
(ATL) act as mediators to reduce inflammation and promote resolution (Schwab and Serhan,
2006).  Biosynthesis of the LXA4 and ATL involve the conversion of hepatocyte-derived 15-
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Figure 1.4  Mechanism of lipid formation. A simplified scheme of
the mechanism by which lipids lead to activation of TNF-α 
(Anderson and Borlak, 2008).
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hydroxyeicosatetraenoic acid by the sequential interaction of a 15-lipoxygenase (LO) and a
5-LO expressed in Kupffer cells (Clària and Planagumà, 2005). ATL regulates the expression
of key transcriptional factors (e.g., peroxisome proliferator-activated receptor/PPAR) along
with the cytokine–chemokine axes in hepatic cells (Clària and Planagumà, 2005). An altered
availability  of  arachidonic  acid  may  shift  the  balance  of  lipid  signaling  towards  the
production of inflammatory eicosanoids, thereby possibly contributing to the development of
steatohepatitis (Anderson and Borlak, 2008).
1.3 Molecular data for modeling
In  this  study,  several  sources  of  experimental  data  such  as  genomics,  proteomics,  and
metabolomics were used. Such omics data are useful to determine how the cell is perturbed
by the actions of external signals (e.g. drug treatment), or how cell functions differ between a
normal and a diseased state.
1.3.1 Method for gene expression analysis
Within  the  past  decade high-throughput  technologies  for  transcriptome analysis,  such as
DNA microarray and RNA-Seq, have been developed. 
A DNA microarray is a collection of microscopic DNA spots attached to a solid surface.
Using  such  array, the  expression  levels  of  thousands  of  genes  can  be  measured
simultaneously. First, thousands of spots known as probes are immobilized on a solid surface
(e.g., a nylon filter or a glass slide). Next, the hybridization experiment is performed with the
labeled  mRNA molecules.  After  attaching  to  the  reverse  complementary  sequence  the
amount of bound labeled material is quantified by a scanning device. Finally, spot intensities
are transformed into numerical values that reflect the abundance of each specific probe. 
In contrast to DNA microarrays, RNA-Seq, a sequence-based high-throughput approach that
directly  determines the  cDNA  amount,  is  a  new  method  for  mapping  and  quantifying
transcriptomes  (Wang  et  al.,  2009).  RNA-Seq  can  be  used  to  measure  transcriptome
composition and to discover new exons or genes by direct ultra-high-throughput sequencing
of cDNA (Mortazavi et al., 2008). In general, a library of cDNA fragments with adaptors
attached to one or both ends, is prepared by conversion of a population of RNA (total or
fractionated, such as poly (A)+)  (Wang et al., 2009). A high-throughput manner sequences
each molecule, with or without amplification to obtain short sequences from one end (single-
end sequencing)  or both ends (pair-end sequencing) (Wang et al., 2009). The readings can be
30-400 bp depending on the type of DNA-sequencing technology used (Wang et al., 2009).
Some high-throughput sequencing systems used in the wet-lab are for instance Illumina IG,
Applied Biosystems SOLiD and Roche 454 Life Science (Wang et al., 2009). The readings
obtained  after  sequencing  can  be  mapped to  a  reference  genome  or  transcriptome,  or
assembled de novo without the genomic sequence to produce a genome-scale transcriptional
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structure and/or level of expression for each gene  (Wang et al., 2009). 
RNA-Seq offers several key advantages over DNA microarrays. First of all, RNA-Seq can be
used  to analyze  model  organisms with existing genomic sequence as well  as  non-model
organisms with  genomic  sequences  that  are  yet  to  be  determined.  In  contrast,  a  DNA
microarray is limited to model organism, since you have to know transcripts that correspond
to existing genomic sequence (Wang et al., 2009). For example, using 454 pyrosequencing
data a  de novo  assembly of the Glanville fritillary butterfly transcriptome  was presented,
which had no previous genomic data  (Vera et al., 2008).  Second,  RNA-Seq has very low
background noise compared to DNA microarrays (Wang et al., 2009). Third, RNA-Seq can
be used for more than an 8000-fold dynamic range to quantify gene expression level, while a
DNA microarray has a much smaller dynamic range of 100 to a few hundred-fold (Wang et
al., 2009). 
1.3.2 Proteomics data using reverse-phase protein arrays 
Protein arrays are  designed to detect proteins, monitor their expression levels, screen  for
molecular markers and pathway targets, and investigate protein interactions and functions. In
classical protein arrays only the probes are immobilized; however in a reverse phase protein
array (RPPA) immobilizes the whole repertoire of proteins.  RPPA can be used to measure
proteins  that  represent  the  state  of  individual  tissue  cell  populations  undergoing  disease
transitions (Paweletz  et  al.,  2001).  The  objective  behind  the  RPPA development  was  to
achieve  sensitive  high  throughput  protein  analysis  as  well  as  precision  and  linearity
(Paweletz et al., 2001).  Reverse-phase protein array (RPPA) is a micro-format dot western
blot  that  allows  measurement  of  protein  expression  levels  of  hundreds  to  thousands  of
samples  simultaneously  in  a  qualitative  manner  (Spurrier  et  al.,  2008).  When  specific
antibodies are used, RPPA can generate 1000 times more data points using 10,000 times less
sample  volume than an  ordinary western  blot.  RPPA enables  us  to  monitor  quantitative
proteomic responses for various time-scale and input-dose gradients simultaneously. Hence,
the RPPA method can  be  an excellent  method for  experimental  validation  of  theoretical
protein network models. The use of RPPA may make it possible to answer questions such as
a) is the candidate molecule present or altered in the human disease?; b) is the alteration of
the candidate  molecule correlated with  the  molecular  phenotype altered in  a  majority of
patients?; c) can the altered candidate molecule in the disease state be chosen for treatment?
1.3.3 Metabolomics data using mass spectrometric analysis
Mass spectrometry (MS) is used in drug-metabolite analysis and metabolic research. The
advantages of mass spectrometry include a wide dynamic range,  the ability to observe a
diverse  number  of  molecular  species,  and  reproducible  quantitative  analysis.  Liquid
chromatography mass spectrometry (LC-MS) is the most common approach for metabolite-
profiling studies  (Want et al.,  2005). MS can be used from basic biochemistry to clinical
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biomarker discovery. It generates a comprehensive profile and data analysis, and structurally
characterize physiologically important metabolites. 
1.4 Systems biology 
The term “systems biology” was introduce about a decade ago, and calls for the examination
of the structure and dynamics of biological systems by either perturbing their genes, proteins
and  pathways,  or  formulating  a  mathematical  model  using  molecular  informations  that
describes the structure of the system and its response to individual perturbations  (Ideker et
al.,  2001;  Kitano,  2002a).  In  recent  years,  systems  biology  has  welcomed  many  new
systematic technologies and methods in both experimental and computational areas that were
not available a decade ago (Chuang et al., 2010).
A multitude of biological facts, such as genome sequences and protein properties has been
discovered by molecular systems biology; however, these facts alone are not sufficient for an
interpretation  of biological  systems  (Kitano,  2002b).  Genes,  proteins,  metabolites,  cells,
tissues,  organs,  organisms and ecological  webs are  components  of  an interacting system
whose interactions have been defined by evolution (Kitano, 2002b). Thus, understanding at a
system-level should be the prime goal of biology rather than studying a part of the system in
isolation. In recent years, experimental approaches and technologies have been advanced in
terms  of  accuracy,  quantitative  measurement  and  high-throughput,  and  this  trend  will
doubtlessly continue.  However,  these  methods  are  still  limited  to  the  study  of  intrinsic
complexity in biological systems. Thus, a combined approach, computational biology, which
comprises experimental and computational data is expected to resolve this problem (Kitano,
2002b).  Wolkenhauer,  (2014)  proposed an iterative approach  of data-driven modeling and
model-driven experimentation,  in which alternative hypotheses are postulated and refined
until they are validated. This approach can help in identifying new regulatory interactions in
the biological systems.  
Systems biology has been widely applied in the identification of pathways based biomarkers,
disease genes and drug targets (Chuang et al., 2010; Folger et al., 2011). It has also been used
in biomedicine to better understand a particular  disease and its molecular basis along with
the mechanism of drug action  (Zou et al., 2013). Three computational methods have been
commonly used in drug discovery, such as, network analysis, constraint-based modeling and
dynamical modeling  (Folger et al., 2011; Zou et al., 2013).  These computational methods
and  their  applications  provide  a  framework  for  addressing  disease  mechanism  and
approaching drug discovery that can be useful for clinical benefits, such as novel biomarkers
and promising therapies (Zou et al., 2013).
A systems biology approach was used to identify pathways involved in liver toxicity that is
induced by free fatty acids and TNF-α in human hepatoblastoma cells (HepG2/C3A) (Li and
Chan, 2009). This was done by integrating multiple-level information, i.e., microarray gene
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expression,  metabolite  profile,  toxicity  measurements  and pathways  information  (Li  and
Chan, 2009).
1.5 Pathway analysis 
High-throughput  techniques  of  gene  and  protein  profiling  enable  a  comprehensive
understanding  of  biological  systems,  and  have  revolutionized  the  biological  research.
Researchers in biology may share interest  in the identification of a  differentially expressed
list of genes or proteins from analysis of high-throughput data in a disease context.  Such a
list  is extremely useful to identify  a pathway that may have an important role in a given
phenomenon,  or phenotypes, or disease. However, for many researchers, this list usually
fails  to  give  insight  into  the  underlying  mechanism of  disease or  phenotypes.  Thus,  the
emergence  of  high-throughput  profiling  technologies  introduced  a  new  challenge  in
extracting  meaningful  knowledge  from a  long  list  of  differentially  expressed  gene  and
proteins. An approach has been used to address this challenge, by which a long list of genes
is divided into smaller sets  to reduce the complexity.  Using the knowledge of biological
processes, groups of genes and proteins have already been defined, which represents genes
related to pathways. This makes analysis easier because thousands of genes are reduced to a
few hundred pathways. One use of this idea is to identify a list of pathways based on a longer
list of differentially expressed genes, a process termed pathway analysis.
Pathway analysis can give us some basic insight into the underlying biology of differentially
expressed genes and proteins, as it reduces complexity and increases explanatory power. A
pathway over-representation analysis (ORA) statistically evaluates the fraction of genes in a
particular pathway found among the set of genes showing changes in expression. There are
several  tool  for  pathways  ORA that  include  differentially  expressed  genes  and  proteins
(Huang et al., 2009; Kamburov et al., 2011a). Based on genes and metabolites a combined
pathway analysis can be done (Kamburov et al., 2011b).
1.5.1 Pathway databases
Pathway databases store the knowledge on the molecular interactions and reaction networks.
There are several pathways databases such as KEGG  (Kanehisa et al.,  2012),  Reactome
(Croft et al., 2011), and ConsensusPathDB (Kamburov et al., 2011a).
The KEGG database.  KEGG is integrated with 15 data objects which are known as KEGG
objects for computer representation of molecular systems (Kanehisa et al.,  2012).  KEGG
objects are broadly categorized into systems information (PATHWAY, BRITE, MODULE,
DISEASE, DRUG and ENVIRON), genomic information (ORTHOLOGY, GENOME and
GENES)  and  chemical  information  (COMPOUND,  GLYCAN,  REACTION,  RPAIR,
RCLASS  and  ENZYME).  KEGG  includes  a  collection  of  tools  for  KEGG  PATHWAY,
BRITE and MODULE mapping, which enables integration and interpretation of large-scale
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data  sets.  Different  type  of  informations,  such as  disease genes  and drug targets  can  be
integrated as a part of molecular networks of KEGG.  
The Reactome  database.   Reactome  is  an  open  online  pathway  and  manually  curated
database of human pathways and processes  (Croft  et  al.,  2011).  It  includes compartment
information of entities and transport reactions that transport the entities from one cellular
compartment  to  another.  Entities  represent  nucleic  acids,  small  molecules,  metabolites,
proteins (with or without post-translational modifications) and macromolecular complexes
and this generalization allows  us  to cover several biological processes such as signaling,
metabolism,  transcriptional  regulation,  and  apoptosis  which  can  be  downloaded  in  a
computationally navigable format. A visualization of full pathways is represented in Systems
Biology Graphical Notation which is a standard graphical representation in systems biology,
i.e., every molecule and reaction has a particular shape (Croft et al., 2011; Le Novère et al.,
2009).  Reactome  offers  the  Pathway  Analysis  tool  which  can  be  used  in  ID  mapping,
pathway  assignment,  and  over-representation  analysis  by  user-supplied  lists  of  genes,
proteins and small molecules. Furthermore, it is a resource of human pathways that can be
used for pathway modeling, systems biology, genome analysis and education. 
The ConsensusPathDB database.  ConsensusPathDB is a database that integrates different
types of functional, molecular and reaction interaction networks from several databases such
as  KEGG,  Reactome,  etc.  (Kamburov  et  al.,  2011a). Currently  the  database  comprises
information  of  physical  protein  interactions,  metabolic  and  signaling  reactions  and  gene
regulatory interactions for three different organisms: human, mouse and yeast. The database
integrates currently  (June  2014)  155,432  functional  interactions  and  2,205  biological
pathways in human, 194,480 functional interactions and 734 biological pathways in yeast
and 13648 functional interactions and 1,381 biological pathways in mouse, which originate
from 18 databases  on human and eight  databases  on  yeast  and mouse  interactions  each
(Kamburov  et  al.,  2011a).  This  database  features  an  advanced visualization  by  which
network nodes (physical entities/functional interactions) are movable and can be rearranged
automatically using different layout methods; thus this has advantages for visualizing larger
networks.  Using  the  Web  interface  of  ConsensusPathDB,  pathways  as  well  as  network
module analysis can be done by user defined gene lists. 
Pathway analysis has become the first choice for obtaining meaningful insight  into high-
throughput molecular measurements. Nearly every recent bioinformatics study in a  disease
context  looked for statistically significant  pathways  for  the  biological  interpretation of  a
disease.  In a recent  study several pathway analysis  tools  of the last  ten years  have been
compared and discussed along with their methodological challenges (Khatri et al., 2012). A
first challenge is in the  restriction  of the development of next-generation pathway analysis
methods  due  to  a low  resolution  knowledge  base,  missing  condition-  and  cell-specific
information, and incomplete annotations.  Secondly, they found  limitations  in the  utility of
existing methods due to the fact that these methods do not incorporate the dynamical nature
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inherent to biological systems (Khatri et al., 2012). However, pathway analysis is still useful
for  identifying  deregulated  pathways  in  a  disease  context  that can  be  further  used  for
modeling purposes to better understand the dynamics of biological systems.  
1.6 Computational modeling techniques of biological 
systems
Systems biology is a field of science that studies complex interactions of biological systems
for example at the cellular level (Kitano, 2002a). This field is essential for research in several
areas such as drug development, cellular interactions, and biotechnology. Computer models
can  be  built for  biological  processes using  computational  tools  and  high-throughput
experimental  data.  These  models  might  cover signaling,  gene  regulatory  or metabolic
networks.  To study cellular systems requires a whole-cell modeling system. However, it is
difficult to  develop a whole-cell computational model that integrates and simulates all the
components of a living cell.  The reduction modeling approach (that tends to focus on the
application of interest) is popular due to the enormous size and complexity of computational
cell  models.  Several  modeling frameworks have been used in  systems biology including
constraint-based and dynamic modeling formalisms such as differential equations and Petri
nets.
1.6.1 Constraint-based modeling 
Constraint-based modeling of cellular metabolism  was influenced by the work of Palsson
and contributors (Varma and Palsson, 1994). Constraint-based methods, such as flux balance
analysis,  only require  information  about  metabolic  reaction  stoichiometry,  and metabolic
requirements  for  growth.  These methods overcome  the  limitations  in  the  lack  of
experimental data for parameter estimation inherent  to fully detailed dynamic models,  but
limit the dynamic study of biological systems.  
1.6.1.1 Flux balance analysis
Flux  balance  analysis  (FBA)  is  a  constraint-based  method  for  studying  biochemical
networks,  genome-scale metabolic networks in particular (Orth et al., 2010; Schellenberger
et al., 2010). These networks contain all known metabolic reactions of an organism. The first
step of FBA is to form a stoichiometry matrix S of size m×n , where m and n are number of
metabolites and reactions of  the  network, respectively. The entries of each column are  the
stoichiometric  coefficients  of  the  metabolites  participating  in  the  reaction.  The  negative
coefficient determines a metabolite as a substrate while the positive coefficient determines a
metabolite as a product (Figure 1.5a & b). The steady-state flux through all of the reactions
in a network is represented as vector v of length n. 
In FBA, the representation of constraints  can be in two ways: 1) equations that  balance
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reaction inputs and outputs and 2) inequalities that impose bounds on the system. The system
of mass balance equations at steady state (dx/dt=0) is given in Figure 1.5c: Sv=0, where S is
the stoichiometry matrix,  v is the vector of reaction fluxes, and  x  is a vector of metabolic
concentrations. Usually,  genome-scale  metabolic  networks have more  reactions  than
compounds (n>m)  resulting  in  an  equation  system  with more  unknown  variables  than
equations. Thus there exists no unique solution to this system of equations. Upper and lower
bounds can also be set for every reaction (Figure 1.5d). Upper and lower bounds define the
maximum and minimum allowable fluxes of the reactions.  
FBA is used to maximize or minimize an objective function Z=cTv, which can be any linear
combination of fluxes,  where  c  is  the  weight vector,  indicating how much each reaction
contributes  to  the  objective  function.  For  example,  the  production  of  b2  in  Fig.  1.5 is
maximized by using vector c of zeros with one at the position of reaction or production of b2
(Figure 1.5e). Thus, FBA uses linear programming to solve the equation Sv=0 given a set of
upper and lower bounds on v and an objective function Z. The output of FBA is a particular
flux distribution v which maximizes or minimizes the objective function but need not to be
unique. 
1.6.1.2 Integration of gene expression data with flux balance analysis
The FBA framework has been applied to  many genome-scale  models  with great  success
(Duarte et al., 2007; Sigurdsson et al., 2010) along with the systematic prediction of genetic
knockout phenotypes (Deutscher et al., 2006). However, methods are still missing that can be
performed on genome-scale models as well as integrate data from all cellular levels (e.g.
genomic, transcriptomic, proteomic, metabolomic), and that can accurately predict metabolic
phenomena under different environmental conditions.
The  information  flows  from  DNA to  mRNA and  to  enzymes  that  catalyze  biological
reactions and regulate various cellular functions. Hence, one might expect the expression
levels of mRNA to  correlate directly with the amount of enzymes and thus with the flux
through associated reactions. A method called Gene Inactivity Moderated by Metabolism and
Expression  (GIMME)  proposed  to  produce  the  context-specific  reconstruction  using  the
quantitative gene expression data, the genome-scale reconstruction, and one or more required
metabolic  functionalities  (Becker  and  Palsson,  2008).  To  get  a  context-specific
reconstruction, first, a reduced model is obtained by removing reactions from genome-scale
reconstruction with gene expression data below the pre-defined threshold. Next, reactions are




Another method  is E-Flux  (as  a  combination  of  flux  and  expression)  that  extends  the
technique  of  FBA by using  maximum flux  constraints  as  a  function  of  measured  gene
expression  (section 2.3;  Colijn et al., 2009). The method is similar to setting the width of
“pipes” around particular reactions that represent  the  function of  an  expression state. Low
expression of genes represent thin pipes around reactions that can limit the maximum flux
through  the  reactions.  Thus,  normalized  gene  expression  data  is  used  to  constrain  the
reaction  flux.  This  method  can  be  used  to  obtain  a  metabolic  state  under  a  particular
condition using condition dependent gene expression data. 
A further method  has been proposed that combines gene-expression data with FBA (GX-
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Figure  1.5  Flux  balance  analysis  formulation. a) A  metabolic  network
reconstruction  is  built  that  consists  of  a  list  of  stoichiometrically balanced
biochemical reactions. b) This reconstructed metabolic model is formulated in a
mathematical model by forming a stoichiometry matrix  S, in which each row
represents a metabolite and  each  column a reaction, respectively.  c) At steady
state, mass balance can be represented as Sv=0, where S is stoichiometry matrix
and v  is flux vector of reactions of the network.  d) Additional flux constraints
can be imposed by lower and upper bounds. e) The objective function is defined
as  Z=cTv , where c is vector of weights indicating the contribution of reactions
to the objective function. 
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FBA) (section 2.4; Navid and Almaas, 2012). The method allows modeling of genome-scale
metabolic responses to a broad range of environmental perturbations. The ratio (normal vs
perturbed) of gene expression is used to formulate the objective function for understanding
perturbation effects on metabolic states.   Although the method does not account for capacity
limitations in various enzymes, it is able to impose pseudo-metabolic regulation due to mass
balance and network connectivity.
1.6.2 ODE-based modeling 
In a cell, abundances of cell molecules such as mRNAs, proteins, or metabolites can range
from a few molecules to thousands of molecules or even more, and they vary in time and in
response to external or internal stimuli. The changes of cell molecules can be captured by a
cellular  interaction  network  that  needs  to  be  developed  into  a  dynamic  network  model.
Dynamic network models have as input the interaction network in which nodes represent cell
molecules, the set of equations indicating how the state of each node changes in response to
changes of the state of its regulators, and the initial state of each node in the system (Albert,
2007). For example, suppose x is the concentration of a substrate S (e.g., mRNA, protein and
metabolite); dxdt
=kx , where x is the state variable and k is a parameter. It describe a reaction
rate, i.e., how the concentration of S varies with time.
A dynamic  model  is  needed  to  study  the  dynamics  of  biological  systems.  Differential
equations describe the rate of change of continuous variables. These equations are typically
used for modeling dynamical systems in systems biology as well as in other areas. Systems
of non-linear ordinary differential equations (ODEs) have been used to obtain the amount of
species, such as proteins and metabolites, in the modeled system as a function of time. They
have been applied to pathways related to  metabolism  (Yang et al., 2007), signal processes
(Tyson et al., 2003) and transcriptional regulation (Elowitz and Leibler, 2000). 
A  detailed kinetic  model  can be used to  perform time-course simulations,  to  predict  the
response to  different  inputs,  and to  design system controllers.  However,  building kinetic
models requires reactions rate laws and its kinetic parameters. Kinetic parameters are limited
because they either have to be measured experimentally or estimated based on experimental
data. The lack of kinetic data has limited the scale of the modeled networks. 
1.6.3 Petri net-based modeling
Petri net is a graphical and mathematical modeling language developed in the early 1960s by
Carl Adam Petri.  Petri nets consist of two types of nodes (places and transitions) and arcs.
Arcs join a place to a transition or a transition to a place.  In  the Petri  net  modeling of
biochemical  reactions,  places  represent  e.g.  reactants,  products  and  enzymes  whereas
transitions represent biochemical reactions. 
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A static Petri net N can be written as N= (P, T, F, W, M0)  where, 
• P is the set of places,
• T is the set of transitions 
• F⊆(P×T )∪(T×P ) , where (p, t) or (t, p) are arcs and p is an element of set
P and t is an element of set T.
• A mapping W : F → ℝ, is the weight function W(p, t) assigning each arc (p,
t)  a real number.
• M0 is the initial marking, which contains initial tokens of places of P.
In  Petri  net-based modeling,  biochemical  systems evolve  in  a  sequence  of  steps.  A step
converts a given state into a new state upon the occurrence of reactions. A corresponding
Petri net models a state as a marking of places, and steps as an occurrences of transitions.
The sequences of steps describe the dynamic behavior of nets. 
The Petri net-based modeling has subsequently been adapted and extended in many fields
such as systems biology. A qualitative analysis of a metabolic pathway is performed using
the Petri net-based modeling. Discrete and continuous events can be modeled with Petri nets.
Many studies have modeled discrete and continuous events in pathways using the concept of
Petri nets. Petri  net-based methods have already been used for the modeling of different
biological systems  (Doi et al., 2011; Voss et al., 2011). An extension of Petri nets, hybrid
functional petri net, was  for example  used to model apoptosis induced by Fas ligand, and
Drosophila  circadian  oscillator  (Matsuno et  al.,  2003).  A non-parametric  Petri  net-based
strategy is  proposed for  characterizing  the  dynamics  of  signaling  pathway  (Ruths  et  al.,
2008). A Petri net framework is introduced to investigate biomolecular networks (Rohr et al.,
2010).
1.7 Modules identification in biological networks
Biological  networks  can be seen as  organized in a modular, hierarchical manner.  There is
growing  need  to  identify  modules for  a  better  understanding of  the  modularity  and
organization principle of a  large-scale biochemical network that continues to grow in size
(Kessler  et  al.,  2013).  Such  modules  represent  some  biological  processes,  which
conceptually simplify the function of complex biological networks. This functional module
analysis of metabolism can be performed using pathway analysis,  such as  elementary flux
mode  identification. However  use  of  this  method  is often  hampered  by  combinatorial
explosion due to the complexity of metabolic networks (Schuster et al., 1999).
There  is  usually  intuitive  reasoning  behind  defining  the  network  modules  and  there  are
several ways  to  identify modules.  For example,  a decomposition method  uses  a  distance
definition  derived  from  the  path  length  between  two  reactions  (Ma  et  al.,  2004).
Furthermore,  a network-clustering  method  has  been  developed  to  identify  modules  in
protein-interaction network of the yeast cell (Rives and Galitski, 2003). In addition, Müller
22
1 Introduction
and  Bockmayr,  (2013) presented  a  direct  method  for  computing  flux  modules  of  the
thermodynamically  constrained  optimal  flux  space  of  a  metabolic  network.  Moreover,
modules in biochemical reaction networks can be defined by correlated reaction sets (Co-
Sets)  (Papin  et  al.,  2004).  The group of  reactions  of  Co-Sets  always  appear  together  in
functional states of that network. Thus, they represent a functional module of the reaction
network.  In  this  study,  modules  are  identified  using  Co-Sets  formalism and  elementary
modes. Hence, flux coupling analysis, a method for obtaining Co-Sets along with elementary
flux mode are described in given the following.
1.7.1 Flux coupling analysis
Flux coupling analysis (FCA) is a method to identify dependencies between reaction fluxes.
Blocked reaction can not carry any flux while unblocked reactions can carry flux under the
steady state condition. To find coupled reaction sets and blocked reactions in genome-scale
metabolic  networks,  the  flux  coupling  finder  procedure  was introduced  (Burgard  et  al.,
2004). The set of blocked reactions is identified by maximizing flux through the reactions of
a given network under  the  steady state  condition. If the maximum value of flux through a
reaction is zero, then this reaction is said to be unusable or blocked because it cannot carry
any flux. Let v1 and v2 be fluxes of two unblocked reactions. The coupling relationships are
defined as following: 
1. Directional coupling, if a non-zero flux for v1 implies a non-zero flux for v2 but not
necessarily the reverse. 
2. Partial coupling, if a non-zero flux for v1 implies a non-zero, though variable, flux for
v2 and vice versa. 
3. Full coupling, if a non-zero flux for v1 implies not only a non-zero but also a fixed flux
for v2 and vice versa
Reaction pairs not characterized by one of these categories are classified as uncoupled. 
1.7.1.1 Fully coupled reactions as a module
In  recent  years,  genome-scale  metabolic  networks  of  various  organisms have  been
reconstructed  (Schellenberger et al., 2010) and kinetic modeling of these models is either
impractical or infeasible. Thus, the modularity of a biochemical network gives a way to build
useful  and  simplified  models  of  complex  biological  systems.  Functional  modules  of
biological networks can be a mechanism by which a cell coordinates the functional states
(phenotype)  of  metabolic  interactions  (Resendis-Antonio  et  al.,  2012).  The  cellular
phenotype expressed under certain conditions can be represented by the metabolic fluxes
(Nielsen,  2003).  The  correlation  among  reaction  fluxes  across  network  states  can  be  a
measure  of  functional  dependence  among  enzyme-coding  genes  (Papin  et  al.,  2004).
Recently, the functional associations between metabolic genes (also referred to as “correlated
23
1 Introduction 
reaction sets” or “flux coupling”) of genome-scale metabolic networks can be determined
using  the  developed computational  framework  (Burgard et  al.,  2004; David et  al.,  2011;
Larhlimi et al.,  2012).  There is also another  method implemented in COBRA for finding
coupled  reaction sets  using  an  artificial  centering hit-and-run (ACHR) sampling strategy
(Becker et al., 2007). A combined analysis of gene expressions and flux coupling suggests
that genes with correlated reactions often show signs of co-regulation  (Price et al., 2004).
Hence, fully coupled reactions might be taken as modules to understand the co-regulation of
gene expressions in two different conditions. 
1.7.2 Elementary modes
A pathway,  e.g. glycolysis  as a  part  of a metabolic  network,  can be  defined as a  set  of
consecutive reactions that are linked by common metabolites. Different levels of large-scale
datasets,  such  as  genomics,  transcriptomics,  proteomics,  and  metabolomics  have been
mapped to pathway maps, e.g., KEGG  (Kanehisa et al., 2012), for systematic biological
interpretation.  Identification of alternative paths in complex networks  has been elaborated
by introducing the concept of elementary flux mode (Schuster and Hilgetag, 1994). To get
elementary flux modes (EFMs),  the stoichiometry matrix of  a  metabolic network  can be
investigated to identify direct routes that start and end at external metabolites. 
A flux mode  M is  a  set of flux vectors that represents direct routes through  a  metabolic
network. Mathematically, it is defined as the set 
                                               (1.1)
where v* is an r-dimensional vector fulfilling two conditions: i) steady state Sv=0, where S is
stoichiometry matrix and ii) sign restriction, i.e., the flux direction in v* fulfill the prescribed
irreversibility reactions (Klipp et al., 2009).
A flux mode is  called an EFM if it uses a  minimum set of reactions and cannot be further
decomposed. In other words, an EFM is a minimal set of reactions that can operate at steady
state with all irreversible reactions used in the appropriate direction. There are software tools
for the computation of EFMs, e.g., METATOOL (Pfeiffer et al., 1999), COPASI (Hoops et
al., 2006), FluxAnalyzer (Klamt et al., 2003) and PySCeS (Olivier et al., 2005). An example
of elementary flux modes of a metabolic system is illustrated in Figure 1.6.
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1.8 Objectives 
The main objective of my thesis is to comprehensively describe and model the interactions
of susceptibility genes, proteins, and metabolites in metabolic liver diseases, such as steatosis
and steatohepatitis.  There can be a  great variability in human liver diseases such as steato-
hepatitis due to a broad genetic spectrum of individuals and the environmental risk.  To study
the development of steatohepatitis, different mouse models were used. Three mouse strains
A/J, C57Bl6 and PWD were fed a  5-diethoxycarbonyl-1,4-dihydrocollidine  (DDC) supple-
mented diet, which mimicked different degrees (A/J, high; C57Bl6 low; PWD, unspecific) of
the steatohepatitis-like phenotype. Gene expression, proteomics and metabolic profiles were
available for mouse liver samples and these data  were used  in  this  study to  identify and
model disease-related molecular processes.    
Given this data I want to 1) understand the different degree of steatohepatitis using metabolic
fluxes, 2) identify statistically significant pathways related to liver disease, 3) identify inter-
actions or modules of susceptibility genes, proteins, and metabolites, 4) find novel potential
metabolic drug targets for liver disease,  and  5)  build  a  model of deregulated pathways in
liver disease as well as to use this model for predicting qualitative and quantitative changes
in metabolite concentration based on changes in expression data. 
Understanding the different degrees of steatohepatitis using metabolic fluxes. This goal
can be achieved by integration of gene expression data to the mouse genome-scale metabolic
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Figure 1.6 An example of elementary flux modes. a) Metabolic system
b) stoichiometry  matrix  c)  all  possible  three elementary  flux  modes
represented by red arrows.
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model  (Sigurdsson et al., 2010).  Expression data  of mice under normal as well as treated
states can  be studied (Colijn  et  al.,  2009;  Navid  and  Almaas,  2012).  One  can  identify
consistent results and ask questions such as, are fluxes regulated differently under normal
and treated conditions? Furthermore, the relative fluxes (normal vs treated) can be visualized
by the map of BiGG, and therefore, one can observe whether the three mice exhibit different
degree of flux regulation that may be linked to their degree of steatohepatitis like phenotypes
(Schellenberger et al., 2010). 
Identifying statistical  significant pathways related to liver disease.  Pathways  analysis
allows to gain primary insights into the underlying biology of a  disease from large sets of,
e.g., expression data in  a  disease context. Differentially expressed genes and differentially
regulated metabolites can be identified between treated  vs control mice (Robinson et  al.,
2010). The list of genes and metabolites can be used to identify deregulated pathways using
pathway analysis tools such as ConsensusPathDB (Kamburov et al., 2011a).  Based on the
results of pathway analysis of gene expression and metabolic profiles, statistical significant
pathways can be identified that can be used as a model system to study their dynamics.   
Identifying interactions  or modules of susceptibility genes, proteins, and metabolites.
Cellular functions  might be assumed to be composed in a  modular way and each module
comprises many  species  of  interacting  molecules  which are  participating in  a  common
biological function (Hartwell et al., 1999).  Using a mouse genome-scale metabolic network,
functional modules can be identified  based on correlation among reaction fluxes  (Papin et
al.,  2004).  Correlation  among reaction fluxes  can  be  obtained using  F2C2 and COBRA
(Becker et al., 2007; Larhlimi et al., 2012).  Expression data can be used to identified  flux
modules  that  may  demonstrate  different  degree  of  regulation  of  genes,  proteins  and
metabolites that may be linked to mice phenotypes. Elementary flux mode analysis is a tool
for pathway or module identification, but obtaining a complete set of elementary flux modes
is computationally intensive for large-scale networks and especially genome-scale networks.
However, there is an algorithm to obtain k-shortest elementary flux modes that can be used
for large-scale networks (de Figueiredo et  al.,  2009). Differentially regulated metabolites
(control vs treated) can be used  further  as an intermediate node of  the  shortest elementary
flux  modes  of  the  metabolic  model.  Such  elementary  flux  modes that  pass  through
differentially regulated metabolites can be further investigated whether genes of the modules
are also differentially expressed. Thus, using gene expression and metabolic profiles, one can
identify deregulated  pathways  in  a  disease  context,  which  can  be used for  building  and
validating  small-scale  dynamic  model  helping  to  understand  the  biology  of  the  disease
progress. 
Finding novel metabolic drug target  candidates  for liver disease. There  are very few
therapeutic drugs for hepatic steatosis and steatohepatitis, which are related to weight loss,
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lowering the blood sugar and lowering the lipid  count  (Anderson and Borlak, 2008).  The
decreasing number  of newly released  drugs of hepatic  steatosis,  steatohepatitis  and liver
cancer  urges the need to find  novel metabolic drug targets for liver disease.  An objective
function that mimics liver disease progression can be formulated. This function can be used
for a biomass reaction in metabolic models for finding potential metabolic drug targets. 
Building a  model of deregulated pathways in  liver  disease  to predict  qualitative and
quantitative changes in metabolite concentrations based on changes in expression data.
As I mentioned, pathways and module analysis can be used to identify deregulated pathways
using gene expression data in a disease context. Furthermore, these pathways or modules can
be used to construct kinetic models. The availability of kinetic parameters  is limited because
they  are  normally  measured  in  specific  conditions.  However,  there  are  some  proposed
methods, such as Monte Carlo ODE-based and Petri net-based approaches that are limited to
a  qualitative  or semi-quantitative  level  (Ruths et al., 2008; Wierling et al., 2012).   Here,  I
want to test the prediction of changes in metabolic concentration based on changes of gene
expression  using  both  aforementioned  methods.  Then  results  can  be  compared  to  the
experimental data. These methods can only explain changes of metabolic concentrations at a
qualitative level. However, one can also build a detailed kinetic model by estimating kinetic
parameters  and including regulatory links.  Hence, I envisage to build a  model  that  can be
used in various ways such as understanding the effect on the metabolic concentrations after
changing the enzyme concentrations and single- and multi-drug targets identification.     
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In this section I  describe published models and methods which are used in analysis of this
work, for example, a genome-scale mouse metabolic model (section 2.1) and the algorithm
of  shortest  elementary  flux  modes  (section  2.2).  Methods  which  incorporates gene
expression data with FBA are illustrated (section 2.3 and 2.4). I introduce the Monte Carlo-
based simulation strategy (section 2.5), Petri net simulator (section 2.8), kinetic parameter
optimization (section 2.9),  and the formulation of  an  objective or biomass function which
mimics the readout of steatosis, steatohepatitis and HCC (section 2.6). Experimental data of
mouse liver samples are described in section 2.7.  
2.1 Genome-scale mouse model
A genome-scale mouse metabolic model  that comprises 3727 reactions, 2775 metabolites,
and 1415 genes is used in several studies, such as elementary mode, flux balance analysis,
flux coupling analysis  and drug targets  analysis  (Sigurdsson et  al.,  2010).  The model  is
reconstructed based on Recon1 (Duarte et al., 2007) and denoted in the following as GMM.
The GMM has a pre-defined biomass reaction that mimics cellular growth, has eight cellular
compartments, and has  been  tested  in 260 validation test cases  (Sigurdsson et al.,  2010).
Deletion of essential genes of the GMM model resulted in zero biomass production.  These
essential genes are identified in silico and confirmed with high accuracy in vivo  (Sigurdsson
et al., 2010).
2.2 K-shortest elementary flux mode 
Elementary flux mode (EFM) analysis is a useful tool,  e.g., to elucidate  novel metabolic
pathways in addition to the standard biochemistry text book knowledge. For example, a new
metabolic  pathway  has  been  found  that  catalyzes  glucose  oxidation  via  the
phosphoenolpyruvate-glyoxylate cycle  (Fischer and Sauer, 2003). However, EFM analysis
has a severe drawback: the number of EFMs grows exponentially with network size and this
leads  to  a  large  number  of  possible  EFMs  even  for  medium-sized  models (Klamt  and
Stelling, 2002). For instance, a metabolic network of central metabolism, 112 reactions and
89 metabolites, has 2,450,787 EFMs (Gagneur and Klamt, 2004). To generate an entire set of
EFMs of genome-scale network is computationally prohibitive. To overcome such intensive
computation, some methods have been developed, e.g., to generate random samples of EFMs
without computing the whole set  (Machado et  al.,  2012) and enumerating  the  K-shortest
EFMs (de Figueiredo et al., 2009). Technically, the K-shortest EFM method produces EFMs
in an increasing order of reactions by solving a sequence of discrete optimization problems.
Thus, we have: 1-shortest EFM, the EFM containing the minimum number of reactions; 2-
shortest EFM for the EFM containing the second minimum number of reactions, and so on.
It may be possible for multiple EFM to contain the same minimum number of reactions. If
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this happens then multiple EFM are associated with different K values. 
The detection of K-shortest EFMs can be of interest for several biological applications. For
example, the highest increase in pathways flux is achieved if the identified enzymes (Kacser
and  Acerenza,  1993) or  a  considerable  number  of  enzymes  (Fell  and  Thomas,  1995;
Niederberger et al., 1992) are overexpressed, and shorter pathways can carry higher fluxes
(Meléndez-Hevia et al., 1994; Pfeiffer and Bonhoeffer, 2004). Given below, some constraints















Let  a  metabolic  network  comprise  R  reactions  and  C  compounds,  and scr be  the
stoichiometric coefficient  associated  with  compound  c  (c=1-----,  C)  in  a  reaction  r
(r=1----,R). z r is a binary integer variable, assigned 1 or 0 depending on whether reaction r is
active in  an EFM or not. In addition, t r is a non-negative integer flux associated with each
reaction. Equation (2.1) ensures that no flux pass through the reaction r if z r  = 0. Equation
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(2.2) indicates  that t r is  non-zero if  z r =1.  M is  a  large constant  integer  (M>=1).  In  the
model, reverse reactions are decomposed into two irreversible reactions. A set B={(α, β)} |
reaction α and reaction β are the forward and backward reaction of a reverse reaction} is
defined. Equation (2.3) ensures that backward and forward reaction do no appear at an EFM.
Equation (2.4) is defined for steady state condition where I is the set of internal compounds.
In  order  to  avoid  the  trivial  solution  ( z r = t r =0,  r=1-----,R)  a  constraint  is  defined  in
equation (2.5). The shortest EM is obtained by using  the mathematical optimization of  the
objective  function  (2.6)  in  subject  to  equations (2.1)-(2.6).  A  K-shortest  EFM  can  be
obtained by adding further  a  constraint to eliminate (K-1)-shortest EFMs from the set of
solutions. Constraint (2.7) is used to get the K-th shortest EFM, where the constraint of the
first (K-1) shortest EFMs are accumulated that makes sure that the K-th shortest EFMs are
different from the (K-1) shortest EFMs. 
2.3 E-Flux method
E-Flux is  a  method that  integrates quantitative  gene  expression to  genome-scale  models
(Colijn et al., 2009). Conceptually, the E-flux method can be understood as setting the width
of “pipes” around the reaction and the quantity of widths is evaluated by a function of gene
expression. Figure 2.1 describes a simple metabolic model that comprises 4 metabolites, 4
internal reactions catalyzed by enzymes corresponding to 4 genes, an uptake reaction, and a
biomass reaction. Two different sets of gene expression data are shown in the two panels. In
the top panel, G1 is a poorly expressed gene that is interpreted as a thin pipe around reaction
R1, and limits the maximum flux through reaction R1. In contrast, in the bottom panel, G1 is a
highly expressed gene corresponding to a more possible flux (a wider pipe). After integrating
the expression to the model one could expect more flux through reactions R1 and R2 in the
bottom panel than in the top panel.
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Mathematically, E-Flux modifies FBA as follows. FBA involves solving the following 
optimization problem:




where { S⋅v=0a j≤v j≤b j
(2.8)
 
where  v represents a flux vector for a particular flux configuration,  S is the stoichiometric
matrix, c is a vector of coefficients that defines a linear objective function cTv, and aj and bj
are  the  minimal  and  maximal  fluxes  through  the  reaction  j.  In  the  E-flux  method,  the
maximum flux bj of jth reaction is determined according to the expression level of associated
genes of reaction j.  aj   is determined according to negative value of bj  (i.e.,  aj = -bj)  if  the
reaction is reversible, otherwise aj = 0. 
2.4 Integration of gene expression data into flux balance analysis
A constraint-based approach, GX-FBA,  has been proposed for integrating gene expression
data with FBA (Navid and Almaas, 2012). Perturbation experiments can be studied using
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Figure 2.1. Illustration of E-Flux (source, Colijn et al., 2009). In E-flux,  gene expression is
used  to  set  the  maximum  flux  constraints  on  individual  reactions.  The  quantity  of  gene
expression can be  interpreted as pipes of different widths around each reaction. Here, a simple
model is shown that comprises of 4 metabolites (A-D), 4 internal reactions, an uptake reaction
for A, and a reaction converting D  into biomass.  Gene expression data  for  4  genes whose
enzymes catalyze the 4 internal  reactions (green-lower expression, red-higher expression) is
shown on the left. G1 is a poorly expressed gene in the top panel that can be conceptualized as a
thin pipe around reaction R1 as shown. G1 and G2 are highly expressed genes that correspond to
a wider pipe for these reactions as shown in upper panel. The method would predict more flux
through R1 and R2 in the bottom panel relative to the top panel and R3 and R4. This is shown by
the bars on the right.
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GX-FBA. For example, the change  in  metabolic states has been studied using expression
ratio (perturbed vs. control).  I introduced a “mGX-FBA” method which is slightly modified
from GX-FBA. Steps of mGX-FBA are:
1) Assume that the flux distribution of the genome-scale model represents a reference state
(control  experiment). Thus,  maximize  flux  through  the  biomass  reaction  of  a  metabolic
model and obtain flux distribution ( vc o n t ) which represents the control experiment.
2) Perform flux variability analysis (Müller and Bockmayr, 2013; Mahadevan and Schilling,
2003) to calculate the lower and upper fluxes of each model reaction i         ( v i
mi n  and v i
max
respectively) based on environmental limitations and network connectivity.  Then, calculate
the mean possible flux of each reaction i by averaging v i
mi n  and v i
max .
3)  Identify  the  set  of reactions  S for which expression data  can be integrated.  Note that
reversible reactions are excluded from S.  Calculate the ratio (perturbed vs. control) of gene
expression. For those reactions for which catalyzing enzymes are associated with more than
one gene, the maximal up- or down-regulation value is used unless the gene expression ratio
is inconsistent (mixture of up- and down-regulation). In the inconsistent case, the reaction is
excluded from S.
4)  For  each  reaction  i in  S,   calculate   b i  = r i
R N A  * v i
cont   if  the  gene  expression  is
upregulated,  and  a i  = r i
R N A  * v i
cont  if  it  is  downregulated,  where  r i
R N A  is  the  gene
expression ratio, and use b i  as an upper bound and v i
mi n  as a lower bound or a i  as a lower
bound and  v i
max  as an upper bound.




where  v̄ i  is the mean flux of reaction  i in set  S.  Objective function aims  to maximize the
correlation between differential changes in gene-expression and reaction fluxes.
2.4.1 Comparison of fluxes between control vs perturbed
The relative deviation between the fluxes of a reaction in two conditions is calculated as: 
 
         d r=
x− y
∣x∣+∣y∣
             (2.9)
 where x and y are the flux of a reaction r in condition 1 and condition 2, respectively. 
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2.5. Perturbation based on a Monte Carlo simulation 
strategy
A Monte Carlo method is proposed in which kinetic parameters were sampled from a given
distribution (Wierling et al., 2012). Models were simulated into its steady state. Monte Carlo
simulations can be performed as given in the following:
Suppose a metabolic model M (X1, X2, …, XN; R1, R2, …, RM; E1, E2 …, EM) where, 
X1, X2, …, XN  are metabolites, R1, R2, …, RM  are reactions, and E1, E2  …, EM  are
enzymes.
1. The  model  M is  initialized  with  control  and  perturbed/treated  data  from  the
experiments, such as enzyme and metabolite concentrations, and simulated into its
steady state.
2. M was simulated with a given number of sampled kinetic parameters sets eventually
resulting in S steady state concentration vectors.
3.  (X11, X21, …, XN1)C, (X12, X22, …, XN2)C, …, (X1S, X2S, …, XNS)C and (X11, X21, …,
XN1)T,  (X12,  X22,  …, XN2)T,  …, (X1S,  X2S,  …, XNS)T  are  steady state  concentration
vectors of metabolites for the control and perturbed/treated states, respectively.
4. Geometric means over all steady state concentration vectors were calculated for each
metabolite.
2.6 Biomass reaction for liver disease
Three  biomass  reactions  are  formulated  in  order  to mimic  phenotypes  of  steatosis,
steatohepatitis and hepatocellular carcinoma (HCC). 
2.6.1 Lipid droplet compositions
Lipid  droplets  (LDs)  can  formed  through  the  accumulation  of  lipids.  LDs  comprise
phospholipid, sterol, diacylglycerol, triacylglycerol and sterol ester  (Guo et al., 2009). The
compositions of LDs include cholesteryl esters (34%), triacylglycerol (44%), cholesterol and
diacylglycerol (1.6%), and phospholipid (1.7%)  (Bartz et al., 2007). The GMM metabolic
model  contains  4  phospholipids:  phosphatidylserine,   phosphatidic  acid,
phosphatidylethanolamine and phosphatidylinositol.  I hypothesized that LDs are formed by
triacylglycerol,  cholesteryl  esters,  cholesterol  and  diacylglycerol,  and  aforementioned  4
phospholipids.  The  percentage  of  composition  of  LDs  are  scaled  on  100%,  and  new
compositions  are  triacylglycerol  (54.2%),  cholesteryl  esters  (41.8%),  cholesterol  (1%),
diacylglycerol (1%) and each 4 phospholipids (0.5%).
To obtain a medium growth of the LDs formation the coefficients of the components of LDs
were estimated using aforementioned percentage of the LDs compositions. Substrates  are
cholesterol/chsterol(c),  diacylglycerol/dag_hs(c),  phosphatidic  acid/pa_hs(c),
phosphatidylinositol/pail_hs(c),  phosphatidylethanolamine/pe_hs(c),
phosphatidylserine/ps_hs(c),  triacylglycerol/tag_hs(c)  and  cholesteryl  esters  /xolest_hs(c)
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and their coefficients are 0.001, 0.001, 0.0005, 0.0005, 0.0005, 0.0005, 0.0418, and 0.00542,
respectively.  Range of the coefficients is estimated based on the study of Sigurdsson et al.,
(2010).  The flux through the lipid droplet formation reaction is  interpreted as the steatosis
phenotype.
2.6.2 Biomass reaction of steatohepatitis
A review  was done to  identify  key metabolites  that may participate in characterizing the
steatohepatitis  phenotypes.  A  “two  hit”  model  was proposed  for  the  progression  of
steatohepatitis whereby the first “hit”, steatosis, sensitizes the liver and the second “hit” that
leads to oxidative stress (OS) and cytokine-induced liver injury (Day and James, 1998). OS
is  caused by reactive oxygen species, such as, superoxide anion, hydrogen peroxide, that
damage  to  hepatic  membranes,  proteins  and  DNA and  play  an  important  role  in  the
development of NASH (Koek et al., 2011). The generation of OS mediates palmitate-induced
lipotoxicity and cellular stress  (Srivastava and Chan, 2007)  and the metabolite ceramide,
which belongs to the class of sphingolipids, plays an important role in lipoapoptosis (Unger
and  Orci,  2002).  The  metabolites  alanine  and  glutamate  can  be  used as  biomarkers  for
apoptosis  (Halama et al., 2013). Elevated triacylglycerol levels and ceramides are found in
lipidomics  analysis  of  obesity  related  hepatic  steatosis  (Yetukuri  et  al.,  2007).  A study
proposed  that  a deficiency  of  nutrients,  such  as  glucose  can  activate  the  pro-apoptotic
proteins Bax  and  Bak  and  cause  cell  death  (Mason  and  Rathmell,  2011).  Based  on
aforementioned study, I formulated an objective function to mimic the steatohepatitis.  To
formulated  an objective function  I  used a combination  of phenotypes  that  includes lipid
droplets  (40%),  oxidative  stress  (20%) which may be caused by  hydrogen peroxide and
superoxide, and apoptosis (40%) which may be caused by alanine, glutamate, palamite and
ceramide.  Substrates  and  their  stoichiometry  coefficients  of  the  biomass  reaction  for
steatohepatitis are given in Table 2.1. 
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For cancer an increase in the overall biomass flux was assumed that reflects the increase in
proliferation.  Hence,  a biomass  reaction  was  introduced  to  measure  the  proliferation  in
cancer (Folger et al., 2011).  I formulated a biomass reaction to mimic the readout of HCC.
Substrates of the biomass reaction were used by a proposed study of Folger et al. and their
coefficients were used form the study of Sigurdsson et al., (2010) (Table 2.2).
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Table 2.1.  Biomass reaction for steatohepatitis.  Substrates and
their coefficients are given in the table. 'c' represents cytosol and
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Table 2.2.  Biomass reaction  for  proliferation.  Substrates  and their coefficients  are  given in the table.
Coefficients are used from the biomass reaction of the GMM model. 'c' represents cytosol and short form
of metabolites of GMM model are given in the table.
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2.7 Mouse experimental data 
Data  from  mouse  experiments  were used  to  understand  NAFLD  (e.g.,  steatosis  and
steatohepatitis; unpublished data). Three different mouse strains A/J, C57Bl6 and PWD were
used to study steatohepatitis. A histological analysis of the liver samples of three mice was
conducted after 8 weeks of feeding with  a  DDC supplement diet.  Mice A/J, C57Bl6 and
PWD  show high,  low  and no steatohepatitis-like phenotype, respectively,  but PWD mice
show high fatty liver (steatosis) than A/J and C57Bl6 mice.  RNA-Seq experiments were
performed to obtain expression data. mRNA expression was generated using liver samples of
three biological replicates of each mouse strain in control and DDC-treated conditions. Mass
spectrometry  techniques  were  performed  to  obtain  proteomics  and  metabolomics  data.
Proteomics and metabolomics data are measured for selected proteins and metabolites. 
Differentially expressed genes between DDC-treated and control mice were obtained using 
the edgeR package (Robinson et al., 2010). Three biological replicates of each mouse strain 
A/J, C57Bl6, and PWD for control and DDC-treated states, respectively, were used.
2.8 The signaling Petri net-based simulator
Several studies argued the connectivity of a network alone can provide significant insights
into its dynamics (Aldana and Cluzel, 2003; Kauffman et al., 2004; Klemm and Bornholdt,
2005). Motivated by these studies, Ruths et al.  (2008) proposed a Petri net based modeling
and simulation approach for characterizing the dynamics of signal flow through a signaling
network  using  token  distribution  and  sampling.  This  signaling  Petri  net-based  simulator
(SPN)  is  a  non-parametric  model  of  cellular  signaling  networks.  Based  solely  on  the
network's connectivity the SPN can analyze large-scale networks, and provide insights into
the changes in biomolecule levels generated in response to an external stimulus. 
Here, a description is presented to obtain the SPN formalism from the Petri net formalism. 
Formally, a Petri net is a 4-tuple Q=<P,T,I,O>
1. P={p1, p2, …, pm} is the set of places,
2. T={t1, t2, …, tn} is the set of transitions,
3. I={i1, i2, …, ik} is the set of input arcs where for all (u ,v )∈I , u∈P  and v∈T ,
4. O={o1, o2, …, ol} is the set of output arcs where for all (u , v )∈O , u∈T  and v∈P
.
A number of tokens are assigned to each place that encodes the state of the system and is 
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called a marking, denoted m. A marked Petri net, R=<Q, m0 >, is a Petri net with a marking 
m0, called the initial marking. 
The state of the system changed after  executing the Petri net. This execution accomplished
via changes in marking that are induced by sequential firing one or more transitions. In Petri
net  formalism,  a  transition  should  be  enabled  before  firing.  The  enabling  criteria  of  a
transition  are determined  when the number of tokens in each of its input places is at least
equal to the arc weight going from the place to the transition. When an enabled transition is
fired, the number of tokens removed from input places and added to output places according
to  arc  weights  and  place  capacities.  However,  the  SPN does  not  use  arc  weight which
considers in the very common Petri net formulation.
The SPN is an extension of the synchronized Petri  net paradigm  (Ruths et  al.,  2008). In
synchronized Petri net paradigm, the firing of a transition is triggered by a specific event that
occurs in the environment. Formally, a synchronized Petri net is a 3-tuple (R,E,Sync), where
(Ruths et al., 2008):
R is a marked Petri net,
E={e1,e2,…,es} is a set of events, and
Sync: T→E U{e} is a mapping function from each transition in the Petri net to an event, and
event  e is the  always occurring event. Any enabled transition associated with  e  is always
fired immediately.
A pseudo code is given below for executing the SPN (Ruths et al., 2008). 
1) Set initial marking of S
2) for i =1 to r
       a) Generate random sequence of the events in E.
      b) Simulate the network by executing the transitions associated with the event in the
generated sequence.
       c) Record the number of tokens at each node, for each time step
3) for each node, compute the number of tokens at each time unit t, averaged over r.
Places of the SPN are initialized by the number of tokens (step 2 in pseudo code). The SPN
is executed by two time-scale simulation as illustrated in Figure 2.2 (Ruths et al., 2008). The
smaller time scale referred to as the firing time scale in which a single transition is fired. The
larger time-scale called time blocks in which, firing steps are nested, and each transition is
fired exactly once. Hence, there are |T| firings per block. The simulation need to be run B|T|
firing steps for the specified number of time blocks, B. The SPN method executes many
simulation runs (Step 2 in pseudo code) in order to sample the space of possible transition
rate parameters. The final markings  are obtained by averaging over these runs (Step 3 in
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pseudo code). 
2.9 Kinetic parameter optimization
In the kinetic parameter optimization, parameter values which are optimal in some desirable
sense  (providing a  minimum  to some objective  function)  are  searched.  An  objective
expresses a  desired goal  in  mathematical  terms.  A desired goal  can be to obtain kinetic
parameters which can provide concentrations of the metabolites close to that observed in the
experiment.  An objective function f can be formulated to achieve the goal.  
              
f p=√∑x∈M ( [ x ]e− [x ]s, p )
2   (2.10)
where x is a given metabolite of a set of metabolites M of our metabolic model, [x]e and [x]s
are concentration values of a metabolite  x  from experiments and simulations, respectively,
and p is a set of kinetic parameters. [ x ]s, p  is the steady state concentration of metabolite x
during  simulation  which  depends  on  p and [ x ]e  is  the  experimentally  measured
concentration of x. min f p is an optimization problem which minimizes f over p.
Hoops et al., (2006) introduced the tool COPASI which is equipped with a number of diverse
optimization algorithms that can be used for optimization of a predefined objective function
depending on model parameters. COPASI comprises algorithms such as steepest descent and
Levenberg–Marquardt  which  are based on estimating derivatives of the objective function
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Figure 2.2. Illustration of time structure. a) A toy example of the Petri net (Places p1,
p2, p3 and p4; transitions t1, t2, and t3). In the Petri net model, two different firing order
of the transitions can  give two different tokens distribution of places. b) The evaluation
of transitions during a run. In each time block, every transition is fired once. The firing of
each transition corresponds to one  firing time scale. The order of the transition firing is
shuffled during each time block in order to sample the space of possible transition firing
rates.    
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the Hooke–Jeeves method which is based on geometric concepts  and  a genetic algorithm
with stochastic ranking and a simple random search. I used the genetic algorithm of COPASI
in my analysis. Furthermore,  Dierkes et al.,  (2011)  developed a package,  BioPARKIN,  for




A major  objective of  my thesis is to identify pathways or modules of susceptibility genes,
proteins, and metabolites that may be linked to the liver disease steatosis and steatohepatitis.
In the first part of this chapter I determine relevant pathways that may be involved in liver
disease using pathway databases (section 3.1). In the second and third part of this chapter I
pinpoint most relevant metabolic modules  related to liver diseases using constraint-based
modeling techniques  (section 3.2 and 3.3).  Other  aims  are  to  identify candidates for drug
targets  in  liver  diseases,  to model  most relevant  pathways  that  may  be  involved in liver
diseases for  a  better  understanding  of the  disease progression,  to  describe new potential
metabolic  drug targets for liver disease,  and to  elaborate  on  the prediction of changes of
metabolic concentrations based on changes in expression data.  I have  identified  in silico
candidates  for  drug  targets  in  liver  disease  using  constraint-based  modeling  techniques
(section  3.4).  Furthermore,  I  model  the  arachidonic  acid  pathway that  is  identified  by
pathway analysis of gene expression data as relevant to liver disease (section 3.5). The model
is used to study changes in metabolic concentrations at  qualitative and quantitative  level
(section 3.5). 
To understand the above mentioned human liver diseases one would benefit from analysis of
a broad range of molecular data of normal as well as disease liver samples. However, such
data may not be readily accessible as a large cohort of patients would be required for proper
analysis. As a model system of human liver disease, I have used data from a mouse model
system to  understand  liver  disease  such  as  steatosis  and  steatohepatitis. Three  different
mouse strains A/J, C57Bl6 and PWD were used in this study. Three biological replicates of
each mouse strain were fed a DDC-supplemented diet that can reproduce steatohepatitis-like
phenotypes. Histological analysis of liver samples of mice of all three different strains were
used to correlate the results. Steatohepatitis-like phenotypes  were found to be high in  the
mouse strain A/J, low in the mouse strain C57Bl6, and the mouse strain PWD did not show
such a phenotype. The mouse strain PWD was found to be of higher degree of steatosis or
fatty liver than the mouse strains C57Bl6 and PWD.  RNA-Seq expression data along with
some  selected  proteomics  and  metabolomics  data  were  measured.  These  data  sets  were
generated  within  the  IMGuS  project  and  used  in  this  study  for  pathway  analysis  and
computational modeling to achieve the aforementioned objectives.
3.1 Pathway analysis
High-throughput experimental data by itself does not produce biological findings. However,
the data can for example be interpreted in the context of biological processes using pathway
analysis. Pathway analysis can be used to identify genes, proteins and metabolites associated
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with the etiology of a specific disease.  Therefore, I have applied  pathway analysis  using
gene expression  data  of  mouse  liver  samples  to  identify relevant  pathways  that  may  be
involved in liver disease.
3.1.1  Phenotype,  susceptibility  and  metabolic  model  associated
genes
Phenotypes of liver samples of all three mouse strains after 8 weeks of a DDC-supplemented
diet were characterized by histological analysis  (Figure 3.1a). Based on the degree of the
phenotypes  of  the  mouse  strains,  A/J  and  C57Bl6  can  be  categorized as  high  and  low
steatohepatitis-like phenotypes, while  the mouse strain  PWD  shows no steatohepatitis-like
phenotype. The degree of steatosis in PWD mice was higher than in C57Bl6 and A/J mice.
First,  to  address  the  DDC-treated  effect  irrespective  of  strain-specific  effects  a  principle
component analysis (PCA) was performed based on 2813 genes, which were differentially
expressed in at least one mouse strain due to DDC-treatment (Figure 3.1c). While healthy
mice show strain specific expression profiles,  DDC-treated mice profiles cluster together in
PCA, implying a similar overall response due to DDC treatment irrespective of the strain.
Albeit of these similarities in gene expression changes upon DDC-treatment, it was expected
that severity of phenotypic response is linked to gene sets specifically activated ot repressed
in individual strains. To address this question, differentially expressed genes were identified
between control vs DDC-treated mice for each strain to address the strain-specific response
(section 2.7). The overlap of strain-specific differentially expressed genes is shown in Figure
3.1b. 471 differentially expressed genes were found only in A/J and I call them susceptibility
genes because this strain shows the most significant steatohepatitis phenotype. 
NAFLD has been defined as the metabolic syndrome that is associated with the insulin-
resistance  syndrome  (Marchesini et al., 2003). Hence,  the GMM model was  (section 2.1)
used as a reference to identify metabolic pathways of related genes. Irrespective of strain-
specific  effects,  a  group of  288 genes  coding for  metabolic  enzymes  were identified  as
differentially expressed (p-value < 1e-06) after DDC treatment.  This set of 288 genes was
subsequently used in the pathway analysis to identify affected metabolic pathways due to
DDC treatment.
3.1.2 Pathway analysis using ConsensusPathDB
A pathway analysis of the metabolic profiles and gene expression data was performed with
ConsensusPathDB  to identify steatohepatitis-specific  pathways  (Kamburov et  al.,  2011a).
Pathway  over-representation  analysis  of  the  aforementioned  471  susceptibility genes
obtained only in  A/J  identified  nucleotide,  histidine,  beta-alanine and purine metabolism
upon the top-ranked deregulated pathways.  Within the beta-alanine pathway  I found Srm
encoding spermidine synthase (SPDS) as being upregulated in A/J (2.4 fold in A/J compared
to  0.77,  0.75  for  C57Bl6  and  PWD,  respectively)  as  well  as  the  related  metabolites
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spermidine  (SPD)  and  spermine  (SPM)  that  form  a  module  of  the  hepatic  S-
adenosylmethionine (SAMe) metabolism (Figure 3.1d). SAMe is needed for methylations of
DNA, RNA and lipids, synthesis and catabolism of SAMe is tightly regulated and changes in
SAMe level might lead to fatty liver disease and the development of HCC  (Mato et  al.,
2013).
Measured  transcriptomics values of genes and metabolite concentrations of hepatic SAMe
metabolism were  found to  be  affected  in  the  DDC-treated  state  (Figure 3.1e  and  3.1f).
Expression  of  Mat1a,  Srm,  Sms,  Dnmt1, Ahcy,  and Bhmt and  concentration  changes  of
spermidine, spermine and putrescine show a different behavior between A/J, C57Bl6 and
PWD. Gene expression and metabolic profiles of hepatic SAMe metabolism imply that PWD
has an opposite response than A/J and C57Bl6 after feeding DDC supplemented diet which
resembles the differences in steatohepatitis phenotypes of the strains. The enzyme SAMe
decarboxylase (SAMDC) is activated by putrescine and upregulation of spermidine synthase
(SPDS)  and  spermine  synthase  (SPMS)  might  explain  the  increased concentration of
spermidine (SPD) and spermine (SPM) in A/J.  A higher production of putrescine in  A/J
lowers the Km of SAMDC activating polyamine synthesis that may affect the concentration
of SAMe  (Mato et al., 2013). This might affect methylation of various substrates such as
DNA, RNA and lipids, that might be one reason in disease development, such as NASH.
However, it  remains difficult  to judge the difference in degree of steatohepatitis  because
expression and metabolic profiles show similar response to DDC-supplemented diet in A/J
and C57BL6.
A pathway over-representation analysis was done based on 288 metabolic genes which were
obtained  by aforementioned  metabolic  model  and  19 differentially  regulated  metabolites
which were obtained by a t-test (p-value < 0.05) analysis. The arachidonic acid pathway was
found  in both analysis to be deregulated (p-value 1.2e-5 and 2.5e-4) after DDC-treatment.
Analysis of measured metabolic concentrations of the arachidonic acid / eicosanoid pathway
yield also significant changes due to DDC treatment of some metabolites of this pathway.
The abundances of four metabolites of this pathway are significantly (p-value<0.05) altered
due  to  DDC-treatment:  PGD2,  5-HPETE,  15-HETE,  and  15-HPETE.  Based  on  these








Taken together,  based on  susceptible genes  histidine, beta-alanine and purine metabolism
were identified as relevent pathways that may  be involved in liver disease.  Furthermore,
gene expression data and metabolic concentrations of hepatic SAMe metabolism were found
to  be  deregulated  at  different  levels  among  mice.  Based  on  pathway  analysis  of  gene
expression  data  and  metabolite  data  the  arachidonic  acid  metabolism  was found  to  be
deregulated  under  DDC-treated condition.  Furthermore,  the metabolites PGD2, 5-HPETE,
15-HETE,  and  15-HPETE  of  arachidonic  acid  pathway  were  found  to  be  deregulated
significantly (p-value <0.05) due to DDC-treatment. 
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Figure 3.1 Phenotypes and SAMe metabolism. a) Qualitative rating of histological phenotypes
of the mouse liver samples.  -1 represents the control  or negative phenotype,  0 -  3 indicates
different  degrees  of  the  phenotype.  Immunohistochemistry  is  abbreviated  as  IHC. b)  Venn
diagram of differentially expressed genes due to DDC treatment in A/J, C57Bl6, and PWD mice.
c) Principle component analysis (PCA) of 2813 genes that were found differentially expressed
for at least one mouse strain due to DDC-treatment. * and + indicate control and DDC mice,
respectively; red, green and blue represent A/J, C57Bl6, and PWD mice, respectively. Principle
component 1 (PC1) explains 43% and PC2 29% of the data. d) S-adenosylmethionine (SAMe)
metabolism.  Methionine  (Met)  is  converted  to  SAMe  by  the  enzyme  methionine
adenosyltransferase (MAT1). SAMe is converted into S-adenosylhomocysteine (SAH) by DNA-
methyltransferase  (DMTs)  that  is  subsequently  converted  by  SAH  hydrolase  (AHCY)  into
homocysteine  (Hcy)  which  is  a  substrate  for  Met  formation  by  betaine-homocysteine
methyltransferase  (BHMT).  SAMe  can  also  be  converted  into  spermine  (SPM)  via
decarboxylated SAMe (dcSAMe) and spermidine (SPD). SAMDC, SAMe decarboxylase; SPDS,
SPD synthase; SPMS, SPM synthase. This pathway is regulated by putrescine, which activates
SAMDC.  e)  Means of RPKM values of aforementioned genes for the control and DDC-treated
state  of  mouse  liver  samples.  The  error-bars  indicate standard  deviations  over  biological
replicates. The bar chart shows log2 ratios of RPKM values of DDC-treated vs control. The
genes Mat1a, Srm, Sms, Dnmt1, Ahcy,  and Bhmt encode the enzymes MAT, SPDS, SPMS,
DMTs, AHCY and BHMT, respectively. f) The bar chart shows the median concentrations of the
metabolites  prostaglandin  D2  (PGD2),  leukotriene  D4  (LTD4),  methionine,  spermidine,
spermine and putrescine. The error-bars represent the median absolute deviations.  * indicates
samples without a replicate.
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3.2 Identifying modules and elementary flux modes 
The complex functions of a living cell  may be carried out in  a modular way (Zhao et al.,
2007).  A module  that  shares a  common function  is  known as  a  functional  module. For
example,  a  group of reactions involved in  the  glycolysis pathway  may form a functional
module and a function of this module may be the production of ATP. Identifying functional
modules is crucial for understanding  the basic building blocks of cellular organizations as
well  as  cellular responses to internal  and external  signals.  One  aim  of this  work  was to
identify  modules  of liver  metabolism.  Functional  modules  can  be  defined  as  groups  of
reactions with correlated fluxes. Furthermore, liver tissue specific gene expression data were
used  to identify most  relevant liver-specific  modules  which  may be  helpful for  a  better
understanding  of  liver  disease.  Another  aim  of this  work  was  to  identify  modules  that
comprise deregulated metabolites  (and genes) between two conditions. Such modules were
identified using elementary flux mode (EFM) analysis.     
 
3.2.1 Identification of modules
Functional modules  of metabolic networks may help to get a better understanding  of  the
metabolism of an organism. Here, the goal was to identify most relevant modules that may
be  involved  in  the  liver  metabolism  or  in  the  context  of  liver  disease.  For  better
understanding of liver functions and liver disease progression, first of all, modules based on
correlated fluxes  can be identified  from  a large-scale metabolic model. Then, liver tissue-
specific gene expression data measured in  disease  phenotype  can be used to identify the
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Figure  3.2   Flow  chart  of  module  identification. Flow  chart  diagram  for  the
identification of relevant modules that may be related to liver diseases. 
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modules which may be involved in the disease phenotype (Figure 3.2).    
A group of reactions with  fully  correlated fluxes  or  a  group of fully coupled reactions is
termed a fully coupled module. To achieve the aforementioned goal, first of all, fully coupled
modules were identified using the framework F2C2 (Larhlimi et al., 2012). This framework
resulted in 785 blocked reactions in  the  GMM  model. In addition to F2C2, fully coupled
modules were also  identified by  the  method  identifyCorrelSets  that  is implemented in  the
COBRA toolbox  (Becker et al.,  2007).   Both methods  F2C2  and  identifyCorrelSets were
applied to the  GMM  model  and  they resulted in  248  and  247 fully  coupled  modules
comprising at least 2 reactions and 2 genes. 246 common modules with both methods were
obtained (Figure 3.3a).  Note  that  fully coupled modules  were  identified  based  on  the
structure of the GMM model and the constraint that the fluxes of reactions of these modules
were fully correlated.  For identification of the most relevant modules in a context of liver
disease from the aforementioned 246 fully coupled modules, a kind of enrichment analysis
was implemented using gene expression data of mouse liver samples under DDC-treatment
conditions. 
As  a  perquisite for enrichment analysis,  I tested  the  hypothesis  that genes associated with
fully coupled modules  may show co-expression  under a given condition.  In this study, co-
expressed genes  are defined as genes that have similar expression patterns in the  disease
phenotype  of  interest,  e.g.,.  liver  disease.  To  test  the  aforementioned  hypothesis,  a
correlation analysis  was applied using gene  expression data  of mice  under DDC-treatment
conditions and the fully coupled module. 
Out of 1415 genes given by entrez gene ids of the GMM model 1398 ensemble ids could be
mapped  by  BioMart  (Kasprzyk,  2011).  I  have  applied  a  correlation  analysis  by  using
expression data of these 1398 genes measured under DDC-treatment conditions. For each of
the  aforementioned  246 fully coupled  modules that  were  identified using F2C2,  average
pairwise correlation coefficients were computed for the expression data of genes associated
with each  fully  coupled  module.  This  pairwise  correlation  coefficient  computation  was
performed using 9 expression values (3 biological replicates of each of the mouse strain A/J,
C57Bl6 and PWD under DDC-treatment condition)  for  each  of  pairwise gene. A statistical
analysis was performed to estimate the significance of pairwise Pearson correlation among
genes. In this statistical analysis, first of all, the random distribution of the average pairwise
correlation  coefficients  was  obtained  by  computing the  average  pairwise  correlation
coefficient of 1,000,000 random sets of the aforementioned 1398 genes of the GMM model.
For  each  of  the  identified 246 modules,  p-values (expected  value  based  on  random
distribution) were computed.  Average pairwise correlation coefficients and p-values of 246
fully coupled modules are shown in Figure 3.3c. Out of 246 fully coupled modules that were
identified using F2C2, 146 fully coupled  modules  have significant  (p-value<0.05) average
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pairwise  correlation  coefficient (Figure 3.3c).  This  result  indicates  that  fully  coupled
modules show a moderate degree of co-expression. 
Regulation of the expression of genes associated to the fully coupled modules may change
the throughout flux through these modules. Thus, different degrees of flux regulation may be
expected due to different degrees of regulation of gene expression data in the fully coupled
modules. Therefore, using gene expression data of all three mice, most relevant fully coupled
modules  related  to  mouse phenotypes  may be  identified.  Taken  together, the  aim  is  to
identify  the  fully coupled modules for which  associated  genes  are significantly (p-value <
0.05) co-expressed as well as regulated at different degrees among mice. Therefore, I did a
kind of enrichment analysis to obtain modules that satisfy three criteria (Figure 3.2 step1, 2
& 3):  i) reactions of modules  are fully coupled,  ii) genes of the modules  are significantly
correlated  or  co-expressed (p-value<0.05),  and  ii)  at  least  one  gene  of  the  module  was
regulated  at  different  degree  among  three mouse strains.  To obtain  different  degrees of
regulations  of genes  among  mice  an  analysis  was  done  to identify the  of  number  of
differentially expressed  (DDC-treated vs control) genes  of fully coupled modules (Figure
3.3b). Applying aforementioned 3 criteria most probable modules that are relevant to mouse
phenotypes are illustrated in Figure 3.4.  For some of the genes of the aforementioned most
probable modules, different degrees of regulation among mice were observed (Figure 3.5).
These different degrees of regulation may alter throughout the flux of the most probable
modules which might be linked to mouse phenotypes (Figure 3.4). Thus, these modules were




Figure 3.3. Module analysis. a) Two methods COBRA toolbox (e.g. identifyCorrelSets)
and F2C2 are used to compute fully coupled modules. A fully coupled module is defined
as a set of fully coupled reactions. b) Number of differentially expressed genes related to
metabolism are identified between DDC-treated vs control for all three mouse strains. c)
Average pairwise correlation coefficient and p-values of 248 fully coupled modules are





Figure 3.4. Most relevant modules that may be involved in liver disease. Green nodes
indicate  genes  with  different  degrees  of  regulation  among  mice.  'r' represents  average
pairwise Pearson correlation coefficient of genes associated with the corresponding module.
Pvalue is an expected value of average pairwise correlation coefficient  of  a module based
on random distribution of average pairwise correlation coefficient. 
a) Module of fatty acid metabolism. Phytanic acid is a branched-chain fatty acid which
can be obtain through the intake of dairy products (Brink and Wanders, 2006). Phytanic acid
rapidly converts to pristanic acid in rat (Avigan et al., 1966). Carbon chain of pristanic acid
is one carbon atom shorter than phytanic acid, which means that phytanic acid undergoes
one round of α-oxidation (Brink and Wanders, 2006). The process of α-oxidation consists of
the removal of one carbon atom. In contrast, two carbon atoms are removed in β-oxidation
(Brink  and  Wanders,  2006).  External   phytanic  acid  is  transported  to  cytosol  and  then
converted to phytanyl CoA by solute carrier family 27 member 2 (Slc27a2). Sterol Carrier
Protein 2 (Scp2) is involved in the transport of  phytanyl CoA from cytosol to peroxisome.
Phytanyl  CoA formed  pristanal  by phytanoyl-CoA 2-hydroxylase  (Phyh).  Pristanal,  is
transported  from  peroxisome  to  cytosol,  and  formed pristanic  acid  by  aldehyde
dehydrogenase 3  family,  member A2 (Aldh3a2).  Pristanic  acid derived  from perxisomal
pristanoyl  CoA undergoes the process of β-oxidation in the presence of group of genes
Acox3, Hsd17b4, Accaa1a and Ehhadh. 
b)  Module of creatine metabolism. Creatine is phosphorylated in the presence of ample
supply of ATP and converted to the high energy compound phosphocreatine by creatine
kinase. This reaction   encounters in cytosol and mitochondria matrix.  
c) Module of sucrose metabolism. Glycogen, a polymeric storage form of glucose, is used
as a form of energy storage in animals. The synthesis of a glycogen molecule begins with
“Tyr-194 of apo-glycogenin” protein which  is  formed by covalently attachment of a Tyr
residue in a specialized initiator protein called glycogenin (Mu and Roach, 1998). Tyr-194
of apo-glycogenin protein, acts as primer, and is converted to primed glycogenin that then
mediates the bulk synthesis of glycogen (glycogen, structure 1) by glycogen synthase (Gys1
and Gys2). Structure of glycogen is modified and finally formed Tyr-194 of apo-glycogenin
by the action of glucan (1,4-alpha-), branching enzyme 1 (Gbe1) along with muscle- , liver-,
and brain-  glycogen phosphorylase which are  encoded by genes Pygm, Pygl  and Pygb,
respectively.
d) Fatty  acid  oxidation  and  carnitine  shuttle. A medium-chain  fatty  acyl-CoA,  4,8-
dimethylnonanoyl-CoA, that  forms  from  a  fatty  acid,  4,8-dimethylnonanoic  acid,  by
condensation of the thiol group of CoA with the carboxy group. 4,8-dimethylnonanoyl-CoA
is  converted  to  2,6-dimethylnonanoyl-CoA  in  the  presence  of  acyl-coenzyme  A
dehydrogenase,  C-4 to  C-12 straight  chain  (Acadm).  2,6-dimethylnonanoyl-CoA and L-
carnitine may form 2,6-dimethylnonanoyl carnitine (since reaction is reversible; ↔) that can
be transported from mitochondria, to cytoplasm, and to external medium.
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e) D-alanine metabolism. This module comprised a transport reaction of each metabolite
D-alanine and pyruvate along with a reaction catalyzed by  D-amino-acid oxidase (Dao).
Pyruvate  is  transported  from  cytoplasm  to  peroxisome  by  solute  carrier  family  16  (
Slc16a1 and Slc16a7). 
f) Cholesterol module. This module is a part of cholesterol metabolism and comprises two
reactions.  In  first  reaction,  zymosterol  is  converted  to  zymostenol  by  action  of  24-
dehydrocholesterol reductase (Dhcr24).  In second reaction, zymostenol is converted to 5-
alpha-cholest-7-en-3beta-ol by emopamil binding protein (Ebp). 
g) Pyrimidine  catabolism.  This  module  is  a  part  of  pyrimidine  catabolism  in  which
thymine is converted to 5,6-dihydrothymine by dihydropyrimidine dehydrogenase (Dpyd).
And then 5,6-dihydrothymine is converted to 3-ureido-isobutyrate which can  be  further
converted to 3-amino-isobutanate by ureidopropionase, beta  (Ubp1).  3-amino-isobutanate
is transported from cytosol to extracellular region. 
h) Cystein and methionine module. This module is a part of biosynthesis of L-methionine
from L-cysteine.  L-cysteine  is  converted  to  L-cystathionine  by action  of  cystathionase
(Cth).  L-cystathionine  is  converted  to  L-homocysteine  by  cystathionine  beta-synthase
(Cbs). L-homocysteine is further converted to L-methionine which is not shown in module.
i)  Pentose  module. This  module  comprises non-oxidative  phase  of  pentose  phosphate
pathway,  in  which  alpha-D-ribose  5  phosphate  (5  carbon  sugar)  is  formed  by
interconversion  of  D-fructose  6-phosphate  (6  carbon  sugar)  and  glyceraldehyde  3-
phosphate  (3  carbon  sugar).  This  interconversion  process  completes  in  3  steps:  1)
interconversion of  D-erythrose 4-phosphate (4 carbon sugar) and xylulose 5-phosphate (5
carbon  sugar)  from D-fructose  6-phosphate  and  glyceraldehyde  3-phosphate  from  by
enzyme transketolase that is encoded by genes Tkt, Tktl1, and Tktl2. 2) interconversion of
glyceraldehyde  3-phosphate  (3  carbon sugar)  and sedoheptulose 7-phosphate  (7 carbon
sugar) form D-erythrose 4-phosphate and D-fructose 6-phosphate by enzyme transaldolase
1 which  is  encoded by gene  Taldoa1.  3) interconversion of  alpha-D-ribose 5 phosphate




Figure 3.5. Differentially  expressed  genes  in  fully  coupled  modules. These
genes are involved in fully coupled modules (Figure 3.4). a) Ratio (DDC-treated vs
control). Gene expression data for b) DDC-treated mice and c) control mice.
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Module of the fatty acid metabolism. Applying this approach that I propose here a module
of  the fatty acid metabolism was identified in most relevant modules that may involved in
liver disease (Figure 3.4a). In this module, Aldh3a2 (green node) catalyzes a reaction that is
involved in  conversion  of pristanic  acid  from pristanal. The  expression  of  Aldh3a2  was
upregulated only in A/J mice (Figure 3.5). One may expect that the change of expression of
Aldh3a2 in A/J mice may alter  the  throughout fluxes of  this module  that  may  lead to  a
deregulation of metabolites. This deregulation of this module may be associated to only A/J
mice of a high steatohepatitis-like phenotype. This fatty acid module comprises a reaction of
peroxisomal  beta-oxidation  pathway  that  is  catalyzed  by  enoyl-CoA,  hydratase/3-
hydroxyacyl CoA dehydrogenase (Ehhadh), acyl-CoA oxidase 3, pristanoyl (Acox3), Acetyl-
CoA Acyltransferase 1 (Acaa1a), and hydroxysteroid (17-beta) dehydrogenase 4 (Hsd17b4)
(Figure 3.4a). The expression of Ehhadh was found to be upregulated 1.4 and 1.3 fold in A/J
and C57Bl6 mice with  a  DDC supplemented diet,  while  to be 0.6 fold downregulated  in
PWD mice. Upregulation of Ehhadh may shorten very long chain fatty acids (e.g. pristanoyl
CoA) and produce  more  H2O2 during this shortening process. Accumulation of H2O2 may
lead  to  oxidative  stress  (Rao  and  Reddy,  2001).  Thus,  one  can  speculate  the  elevated
expression  of  Ehhadh in A/J and C57Bl6 mice may lead to  oxidative stress  that may  be
linked to mouse phenotypes.
Module  of  the  creatine  metabolism.  Another module  of  the  creatine  metabolism  is
identified that has marked co-expression  (Figure 3.4b). In this module, the expression of
Ckmt2 was found to be downregulated  in A/J and C57Bl6 mice, and to be upregulated in
PWD mice (Figure 3.5). The expression of Ckm was found to be downregulated for all three
mouse  strains  between  DDC-treatment  and  control (Figure 3.5),  the  degree  of
downregulation of  Ckm being higher  in  A/J  mice  compared to PWD mice.  The  different
degrees of regulation of  Ckm  and  Ckm2 among mice may  alter the fluxes  along with the
creatine  concentration  of  the  module  at  different  levels.  Creatine  plays a  crucial  role  in
reducing the toxic effects that occur by  increasing production of  reactive oxygen species
(ROS) (Lawler et al., 2002). In other words, creatine acts as an antioxidant in the prevention
of  oxidative  stress.  Decline  in  hepatic  functional  capacity  leads  to decreased  creatine
production and lowers serum  creatine levels  (MacAulay et  al.,  2006).  A creatine pool  is
required  to  be  maintained  by  its  continuous  synthesis  and  spontaneous  breakdown  to
creatinine. This module of creatine metabolism is extended by linking to the other pathways
such as urea cycle and creatinine synthesis for better understanding of its function as well as
regulation of creatine level. The extended  module is illustrated in Figure 3.6. Creatine is
synthesized from arginine and glycine by action of enzymes glycine amidinotransferase and
guanidinoacetate  methyltransferase  (Figure 3.6).  Creatine  is  either  spontaneously broken
down to creatinine or converted to phosphocreatine by creatine kinase (Figure 3.6). 
Module  of  the  sucrose  metabolism.  In  Figure  3.4c,  a module  of  starch  and  sucrose
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metabolism is illustrated. In this module, the elevated expression of Pygb was found for all
three  mice  (Figure 3.5).  The  enzyme  encoded  by Pygl  catalyzes  the  reaction  to  release
glucose-1-phosphate from liver glycogen stores. The expression of Pygl  was found to be
downregulated 0.6- and 0.3-fold for C57Bl6 and PWD mice, while it was unchanged for A/J
mice.  A different degree of regulation of  Pygl may deregulate the glycogen content in the
liver.  In  the  study of  Miyazaki  et  al.,  (2007) a  downregulation  of  glycogen  content  is
observed in the mouse fatty liver. PWD mice show high steatosis (section 3.1) and due to a
downregulation of Pygl the deregulation of the glycogen content may be expected which is
inline with the study of Miyazaki et al., (2007). 
Module of the carnitine shuttle system. Another module that was identified is related to the
carnitine shuttle system (Figure 3.4d).  The fluxes of this module are fully correlated to the
module  in Figure 3.4a. The  module  of  carnitine  shuttle  (Figure 3.7d) comprises
mitochondrial L-carnitine shuttle pathway along with a reaction of fatty acid oxidation which
is catalyzed by acyl-coenzyme A dehydrogenase (Acadm).
In liver, the system of carnitine shuttle seems to be an important player in the production of
energy in cells and the perturbation of the expression data of Acadm under DDC-treatment
may indicate  that the  carnitine shuttle  system is perturbed.   The expression of  Acadm was
found to  be  upregulated  1.8- and  1.3-fold  in  PWD and  C57Bl6  mice,  while it  was  not
changed  for  A/J  mice.  The  different  degree  of  regulation  may alter  the  throughout  flux
though the module of fatty acid oxidation and carnitine shuttle (Figure 3.4d). In liver, fatty
acids are converted to acyl-CoA that shuttles into the mitochondria through  the  carnitine
shuttle system for β-oxidation and generation of acetyl-coenzyme A (acetyl-CoA) (Wakil and
Abu-Elheiga, 2009). Therefore, the mechanism of L-carnitine and its shuttle pathway are
elaborated in more detail for better understanding of the function of the module that is shown
in Figure 3.4d. 
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The carnitine shuttle system seems to be perturbed due to different degree of regulation of
the Acadm. Thus, the carnitine shuttle system is described in more detail (Figure 3.7,(Michal
and Schomburg, 2013):
1. Acyl-CoA thioester binds to carnitine and subsequently forms acyl-carnitine by 
carnitine-O- palmitoyltransferase I that is located on the outer mitochondrial 
membrane.
2. Acyl-carnitine enters the mitochondria matrix from cytosol through the shuttle by a 
carnitine-acyl-carnitine translocase 
3. Acyl-carnitine is converted to carnitine by carnitine-O- palmitoyltransferase II that is
located on the inner mitochondrial membrane. Then, carnitine returns to the cytosol. 
In short, the transport of a medium-chain fatty acyl-CoA, 4,8-dimethylnonanoyl-CoA, from
mitochondria to external space via carnitine shuttle system  may be regulated at  different
levels among mice may be because of the different levels of expression of Acadm. 
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Figure 3.6. Creatine metabolism. Creatine is manufactured in the human body from arginine and
glycine via urea cycle. In mammals, the guanidino residue of arginine is transferred to glycine by
action of glycine amidinotransferase and forms guanidino acetate and ornithine. Guanidino acetate
is further methylated by guanidinoacetate methyltransferase and converted to creatine.  Creatine
can be phosphorylated and yields phosphocreatine by action of creatine kinase. In addition to this,
creatine is converted to creatinine for excretion in urine.
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Module of  the  D-alanine metabolism.  A module  of  D-alanine  metabolism is  shown in
Figure 3.4e. In this module, the expression of  Slc16a7 which is a transporter of pyruvate,
was upregulated for all three mice (Figure 3.5). The degree of upregulation of  Slc16a7 for
A/J and C57Bl6 mice was higher than in the PWD mice. Different degree of regulation of
expression data of Slc16a7 may change the throughout flux through this module. A reaction
of this  module is involved in the conversion of pyruvate from D-alanine by action of  Dao
that  encodes  a  peroxisomal  enzyme  D-amino  acid  oxidase  and  during  this  conversion
hydrogen peroxide (H2O2) is produced.  Due to different degree of regulation of expression
data  of  Slc16a7 one  may expect  enhanced production  of  hydrogen peroxide  in  A/J  and
C57Bl6 mice compared to the PWD mice.  Wijeratne et al.  (2005) reveals that  the elevated
concentration of hydrogen peroxide caused cell membrane leakage and DNA damage as well
as oxidative stress. Oxidative stress is known to be an important player in the progression of
disease ranging from steatosis to NASH (Koek et al., 2011). Thus, this module may be linked
to steatohepatitis-like phenotypes to mouse strains A/J and C57Bl6.
 
Module of the cholesterol metabolism. Reactions of this module are catalyzed by Dhcr24
and Ebp (Figure 3.4f).  Dhcr24 encodes an enzyme that catalyzes the reduction of delta-24
double bond of sterol intermediates during cholesterol biosynthesis. The degree of elevation
of expression data of Dhcr24 was higher in A/J and C57Bl6 mice compared to PWD mice.
Thus,  in  A/J  mice  compared to  PWD mice  one  may expect  higher  level  of zymostenol
accumulation. Accumulation of zymostenol is observed in a study of tamoxifen and AEBS
ligand induced apoptosis  (de Medina  et  al.,  2009).  Therefore,  A/J  and C57Bl6 mice  are
expected to be more prone to apoptosis compared to PWD mice, which is inline  with the
apoptosis phenotypes of mice (section 3.1, phenotype description). 
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Figure 3.7. Carnitine shuttle. Acyl-CoA thioester (Acyl-S-CoA) and carnitine formed
Acyl-carnitine  by  carnitine-O- palmitoyltransferase  I. Acyl-carnitine is  transported
from  cytosol  to  mitochondria  matrix  by  carnitine-acyl-carnitine  translocase.  In
mitochondria matrix acyl-carnitine forms carnitine which can be returned back to the
cytosol. (Modified after Figure 6.1-8, p78, biochemical pathways (Michal 1998).
3 Results
Module of  the  pyrimidine catabolism. A  module  related to  pyrimidine catabolism  was
identified (Fig 3.4g).  This module may be involved in the hepatic steatosis due to a previous
study  which  revealed  hepatic  steatosis  is  induced  by  disruption  of  uridine  homeostasis
through the overexpression of an enzyme (e.g. uridine phosphorylase 1) of  the pyrimidine
catabolism and salvage pathway (Le et al., 2013).  Therefore, to understand the function of
this module in more detail the interactions of this module are extended to the other branches
of pyrimidine metabolism, such as salvage pathway and de novo synthesis. The extension of
this module  is illustrated in Figure 3.8.  The expression of  Dypd that encodes a pyrimidine
catabolic enzyme was downregulated for all three mice, but  by degree:  in  A/J and C57Bl6
mice is higher than in PWD mice (Figure 3.5). The downregulation of Dypd may change the
throughout  fluxes  of  this  module as  well  as  change  the  concentration  of  D-3-amino-
isobutanoate that  is  thymine catabolite.  A thymine  catabolite,  beta-aminoisobutyric  acid,
increases fatty acid oxidation in the liver and reduced the accumulation of body fat in mice
fed  a  standard  chow  (Begriche  et  al.,  2008).   Based  on  this  study one  may  expect
deregulation of D-3-amino-isobutanoate that may be involved in the accumulation of fat and
thus also linked to fatty liver of mice.
Module of the L-cysteine and L-methionine synthesis. Another module that was identified
is  the  biosynthesis  of L-cysteine  from  L-methionine  (Figure 3.4h).  In  this  module,  the
protein encoded by Cbs catalyzes the conversion of L-homocysteine to L-cystathionine. The
expression of Cbs was found to be downregulated in A/J and C57Bl6 mice,  while not to be
changed  for  the  PWD  mice  (Figure 3.5).  Cth encodes  an  enzyme  that  catalyzes  the
conversion of L-cystathionine to L-cysteine. The expression of Cth was downregulated 0.57-
and 0.72-fold  in  A/J and C57Bl6 mice,  and was upregulated 1.54-fold  in PWD mice.  The
different degree of regulation of Cth and Cbs may alter the throughout fluxes of this module
as well the concentration of the metabolites (e.g. L-methionine) of the module. L-methionine
is an essential amino acid required for protein synthesis. L-methionine is metabolized mainly
by  the  liver  where  it  participated,  together  with  ATP,  in  the  formation  of  S-




Figure  3.8. Pyrimidine metabolism. A rough  sketch  of  pyrimidine metabolism is
illustrated, which comprises three metabolic process of pyrimidines,  de novo synthesis
(1), salvage pathway (2) and catabolism (3). De novo synthesis of pyrimidine nucleotide
(e.g uridine  5'-phosphate/UMP)  starts  with N-carbomyl-L-aspartate.  L-aspartate  and
carbomyl phosphate are the source of N-carbomyl-L-aspartate. N-carbomyl-L-aspartate
is  converted  to  orotate  in  series  of  steps  (dotted  line).  5-phospho-alpha-D-ribose  1-
diphosphate is added to orotate and then converted to UMP that subsequently converted
to uridine 5'-diphosphate (UDP). UDP is either converted to cytidine-5'-monophosphate
(CMP)  or  converted  to  deoxythymidine 5'-phosphate  (dTMP) via  2'-deoxyuridine 5'-
diphosphate (dUDP). Most of the foods comprise nucleic acid which can survive in the
acid medium of the stomach and then nucleic acid can go through degradation process,
which  result in the release of uracil, thymine and cytidine.  These free pyrimidine are
reconverted to their corresponding nucleotides through salvage pathway.  Animal cells
degrade  pyrimidine  nucleotides  to  their  component  bases  using  dephosphorylation,
deamination, and glycosidic bond cleavages.  The resulting uracil and thymine are then
broken down in the liver through reduction in the catabolism process. This pyrimidine
catabolism  process  comprised  the  conversion  of  uracil  to  β-alanine  along  with  the
conversion of  thymine to  3-amino-isobutanoate.  Enzymes  Dpyd,  Dpys and  Ubp1 are
involved in the series reactions between thymine to 3-amino-isobutanoate. These group
of reactions were identified as a module of pyrimidine catabolism (Figure 3.4 g) in the
module analysis that shown by shaded area.
3 Results
The deregulation of concentration of SAMe may lead to fatty liver disease (e.g. NASH) and
to the development of hepatocellular carcinoma (HCC)  (Mato et al.,  2013).  Alteration of
concentration of L-methionine may deregulate SAMe that may be linked to steatohepatitis-
like phenotypes of mouse strains A/J and C57Bl6. SAMe is not part of this module; thus, one
can extend this module for including SAMe and its interactions. 
Module  of  the  Pentose  phosphate  pathway  (PPP).  A module  of  pentose  phosphate
pathway (PPP)  and  the  oxidative  and  the  non-oxidative  phase  of  PPP are  illustrated  in
(Figure 3.4i & 3.9). In oxidative phase, NADPH is generated, and in non-oxidative phase,
ribose  5-phosphate  is  generated  via  other  sugars  of  glycolysis  pathway,  such  as
glyceraldehyde 3-phosphate and fructose 6-phosphate.  Aforementioned module comprised
the non-oxidative process of PPP  in which  the  enzymes  encoded by Taldo1 and  Tkt are
involved in catalyzing the reactions of the  module  (Figure 3.4i). The expression of  Taldo1
was found to be  (>2-fold) upregulated in  A/J  mice, and  to be not changed in  C57Bl6  and
PWD mice (Figure 3.5). An elevation of the expression of Tkt (>2-fold) was observed in A/J
and C57Bl6 mice, while it was not to be changed in PWD mice (Figure 3.5). Pertubation of
gene expression data of Taldo1 and Tkt may perturbed the throughout fluxes of this module
and  subsequently  deregulate  the  metabolic  concentrations.  Experimentally  measured
concentration  of  ribose  5-phosphate  and  ribulose  phosphate  together  is  found  to  be
upregulated (>1.5 fold) under DDC-treatment condition in all three mice.
Taken together,  I introduced a novel enrichment method to identify fully coupled modules
that  may be related in disease conditions  using metabolic  networks and expression data.
Applying this method  I  described  several important  modules of  a  metabolic network that
may  be  involved in the liver disease. For example, modules of fatty acid, D-alanine and
creatine metabolism  are  linked to  oxidative stress that  may cause  the  steatohepatitis-like
phenotypes.  Within a module related to carnitine shuttle system the transportation of 4,8-
dimethylnonanoyl-CoA is  found to be  affected  at  different  levels  among  the  three  mose
strains.  Furthermore,  a module of cholesterol metabolism  is  linked to apoptosis  that is  a
phenotype  for  the  evaluation  of  the  steatohepatitis.   Moreover,  a  module  of  pyrimidine
catabolism is linked to the steatosis or fatty liver as well as in a module of pentose phosphate
pathway the experimentally measured metabolites and genes are found to be perturbed due to
DDC-treatment. In addition, a module of cysteine and SAMe metabolism is identified and
the deregulation of SAMe may develop steatohepatitis along with hepatocellular carcinoma.
These modules may be used to develop small scale kinetic models for a better understanding




Figure  3.9. Pentose  phosphate  pathway/PPP.  PPP  is  a  process  that  generates
NADPH and Ribose 5-phosphate (5 carbon sugar). It  proceeds in two distinct phases.
The first is oxidative phase which comprises generation of NADPH, and second is the
non-oxidative  synthesis  of  ribose  5-phosphate.  During  oxidative  phase,  glucose  6-
phosphate, is formed in glycolysis pathway, is converted to  ribulose 5-phosphate by
production of NADPH which is used in reductive biosynthesis reactions (e.g fatty acid
synthesis). And then, ribulose 5-phosphate is either converted to ribose 5-phosphate or
converted to xylulose 5-phospahte. During non-oxidative phase, ribose 5-phosphate (5
carbon sugar) is formed from interconversion of glyceraldehyde 3-phosphate (3 carbon
sugar)  and fructose 6-phosphate (6 carbon sugar)  which are produced in glycolysis
pathway.  Enzymes  transketolase  and  transaldolase  1  are  involved  in  non oxidative
phase  of  PPP.  Non-oxidative  phase  of  PPP was  identified  in  the  module  analysis
(Figure 3.4 i). 
3 Results
3.2.2 Identification of elementary flux modes 
The aim of this work is to identify pathways or modules related to liver diseases. To achieve
this, one can identify modules which satisfy the following criteria: metabolites and genes of
the modules are deregulated in the liver disease related molecular data. Such modules may
be identified using elementary flux modes (EFMs) and liver-specific molecular data.  
Elementary flux mode (EFM) analysis is a useful tool to identify pathways of a minimal set
of enzymes that operate at steady state of the cellular metabolism. These pathways represent
independent cellular physiological states. The GMM model (section 2.6) is used in this study
to obtain a complete set of EFMs of the model. Such a task is computationally intensive.
Computation and analysis of EFMs of the GMM model is difficult due to the exponential
growth of the number of EFMs.  de Figueiredo et al.,  (2009) have proposed a method to
obtain k-shortest elementary flux modes from a large-scale network (section 2.2).
Often  only  differentially  regulated  metabolites  between  two  conditions  (e.g.  control  vs
disease) are identified from a list of few hundreds of metabolites. One wants to know why
these identified metabolites are differentially regulated, for example, because of the changes
in the upstream regulatory systems which is accessible via transcriptomics and proteomics
data. There are tools such as ConsensusPathDB which consider both differentially expressed
genes  and  differentially  regulated  metabolites  in  a  pathway  analysis  (Kamburov  et  al.,
2011b). However, such a method does not take into account compartmentalized metabolic
networks as well as cross-talks between metabolic pathways. Alternatively an elementary
flux  modes  enrichment  analysis   may  be  used  in  which,  firstly,  shortest  EFMs  can  be
computed  from  compartmentalized  metabolic  networks.  Secondly,  most  relevant  EFMs
related to disease can be enriched by using its molecular data of disease.  This approach can
have two advantages: 1) it uses a curated compartmentalized metabolic model and considers
cross-talks of metabolic pathways, and 2) identified pathways or modules can be used to
construct a small-scale dynamic model that allows a better understanding of the metabolic
regulation in a disease context.
Here,  I  have  applied  an  EFMs  enrichment  analysis  on  the  metabolic  profiles  and gene-
expression  data of  A/J, C57Bl6 and PWD mice  from the DDC-treatment experiments and
respective  controls.  A t-test  (p-value<0.01)  analysis  was  performed to  get  differentially
regulated  metabolites  between  DDC-treated vs  control  data.  The  assumption  is,  that
perturbation of metabolic concentrations may occur due to perturbation of expression data of
enzyme-coding genes.  I applied a two-step analysis to  identify such EFMs in which both
metabolites and genes were perturbed. In a first step, I identified a set of  shortest EFMs
containing a differentially regulated metabolite. In a  second step, most relevant  EFMs that
may be  involved in  liver  disease were  enriched using  a  set  of  shortest  EFMs and gene
expression data of DDC-treated as well as control conditions.
Several  differentially regulated metabolites  between DDC-treated vs control are present in
the GMM model: putrescine, lanosterol, D-glucose, L-Asparagine, L-glutamate, L-citrulline,
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L-argine, L-aspartate, L-glutamine, ornithine, desmosterol, fumarate,  prostaglandin D2 and
5- and 15-HPETE.  For  each  of  these metabolites,  those reactions were identified from the
GMM model (section 2.1) for which the metabolite is a product. The identified reactions are
members of  a  set  S. An  additional  constraint,  zr=1,  was  included  in  the  method  of  de
Figueiredo et al. (section 2.2). This constraint makes sure that the reaction r is present in the
shortest elementary mode. I have applied such a modified k-shortest EFM method and for
each reaction r  in the  S, 50 shortest EFMs  were computed. However, EFMs could not be
identified within a reasonable time for those reactions that have products lanosterol, 5- and
15-HPETE,  prostaglandin  D2,  and desmosterol.  Thus,  metabolites  lanosterol,  5-  and 15-
HPETE, prostaglandin D2, and desmosterol are not considered in the EFM analysis.  1530
shortest  EFMs  were obtained  through  the  remaining  differentially  regulated  metabolites
putrescine, D-glucose,  L-asparagine,  L-glutamate,  L-citrulline,  L-argine,  L-aspartate,  L-
glutamine, ornithine, fumarate which are used in an EFM enrichment analysis.
Expression  data  was  used  to  reduce  the  size  of  1530  EFMs.  For  identification  of
differentially expressed EFM, a score is defined for which the expression data of the genes




g participate in r
∣log2(ratiog)∣∗∣log10( pvalueg)∣  (3.1)
where, ER is  the  set of reactions of  a given EFM that  is  catalyzed by an  enzyme,  g is the
gene  which encodes an enzyme and  participates in  the  reaction r, ratio is  obtained by the
division of the mean value of expression data over DDC-treated conditions by mean value of
expression data over  control  conditions, p-value is obtained by a  t-test  between expression
data of DDC-treated vs control conditions. 
The EFMs obtained after analysis EFMs were in descending order according to the score and
two EFMs were identified in  top  200  (Figure 3.10)  that  comprise  three  differentially
regulated metabolites. L-arginine,  ornithine  and  putrescine  with  in  the first EFM  (EFM1;
Figure 3.10a) along with D-glucose, L-glutamine and L-asparagine with in the second EFM
(EFM2; Figure 3.10b)  were found to be deregulated  between DDC-treated  vs control  data.
Genes  Aoc3,  Slc7a1,  Gpx2,  Gsr,  Abp1,  Slc7a6 and  Slc3a2 along with  the  metabolites  L-
arginine,  ornithine and putrescine of the first EFM (Figure 3.11a) shown high |log2(ratio)|-
value and  |log10(p-value)|-value. In  the  second  EFM,  an  increase  of  |log2(ratio)| and  |
log10(p-value)| of the metabolites D-glucose and L-Asparagine along with the genes Slc5a1,
Slc1a5 and Slc5a9 were found (Figure 3.11b). 
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Most genes  and metabolites showed a consistent  trend when comparing DCC vs control
mice.  Only few candidates  appeared  as  relevant  when  comparing  different  DDC-treated
mouse strains among each other. However, some genes of EFM1 (Figure 3.10a) were found
to be differentially regulated among mice (Figure 3.11b). The expression of Aoc3 was found
to be upregulated in C57Bl6 and PWD mice, and to be downregulated in A/J mice (Figure
3.11b).  While an elevated expression is found for Gsr, prdx1,Slc9a1 and Aoc2 for all three
mice,  the extend of upregulation was  higher  in A/J and C57Bl6 mice  comparing to PWD
mice (Figure 3.11b). The expression of Arg1 was found to be upregulated in PWD mice, and
to be not changed in A/J and C57Bl6 mice (Figure 3.11b). A downregulation of Slc6a12 was
found in all three mice, and quantitative effect appeared as higher in A/J and C57Bl6 mice
comparing to PWD mice. The expression of Odc1 was found to be highly upregulated in A/J
mice  comparing to PWD mice, and to be downregulated  in C57Bl6 mice.  Experimentally
measured metabolic  concentration of glutamine  was found to be downregulated  in PWD
mice,  but not changed in A/J and PWD mice.  An elevated concentration of  putrescine was
found for all three mice, but the degree of elevation is higher in A/J and C56Bl6 mice than in
PWD  mice.  The  downregulation  of  glucose  concentration  was  found  in all  three  mice.
Glucose was found to be at higher degree of downregulation in PWD mice compare to A/J





Taken together, this analysis shows that in the EFM modules (Figure 3.11) some metabolites
and genes are  found to be deregulated  over  all  mice  (DDC vs control) as well  as to be
deregulated at different degree among mice. This indicates these EFM modules may explain
aspects of the observed steatohepatitis-like phenotypes. Furthermore, these modules can be
of interest for dynamic modeling to better understand their functions. 
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Figure 3.10. Identified EFMs. a) EFM comprises L-arginine, ornithine and putrescine. This
module comprises several reactions from several pathways, such as urea cycle, glutathione,
arginine,  and  vitamine  A metabolism  (pathways  are  shown  with  green  boxes).  In  this
module, L-arginine  (yellow) is transported  from  the  extracellular  space  to  the  cytosol  by
solute carrier family (Slc3a2 , Slc7a6;  yellow) and then converted to ornithine (green) and
produces urea by arginase 1 (Arg1; green). Ornithine is converted to putrescine (green) by
ornithine decarboxylase 1 (Odc1;  green)) that can  be  further converted to 4-aminobutanal
(green) by action of amine oxidase, copper containing 2 (Aoc2;  green). 4-aminobutanal  is
secreted to extracellular region. This module comprised a reaction of glutathione metabolism
by which reduced  glutathione  (blue) is  converted  to  oxidized glutathione  by glutathione
peroxidase (Gpx1,Gpx2; blue).  
b) EFM comprises D-glucose,  L-glutamine  and  L-asparagine.  This  EFM participates  in
transport of  D-glucose, L-glutamine and  L-Asparagine  by action  of  solute carrier family.
Genes, such as Slc5a1, Slc5a2, Slc5a3 encode Sodium/glucose cotransporter that is used to
transport glucose from extracellular to cytosol.  Solute carrier family 1 (neutral amino acid
transporter), member 5 encoded by gene Slc1a5 and is used to transport  L-glutamine and L-
Asparagine from the extracellular space to the cytosol.
3 Results
In  conclusion,  I  proposed  a  novel  method  to  identify  EFMs  which  comprises  both
deregulated metabolites  and genes  between two condition  using metabolic  networks  and
gene expression data and metabolic concentration data.  Applying  this  method on data of
mouse liver samples I identified two EFMs in which  the  first EFM comprised deregulated
metabolite  L-arginine,  ornithine,  and  putrescine  while  second  the  EFM  comprised  D-
glucose,  L-glutamine  and  L-asparagine.  These  EFMs  may  be  used  to  construct  kinetic
models for better understanding of metabolites and enzymes regulations. 
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Figure 3.11 Genes and metabolites of EFMs. Genes and metabolites of the two EFM (EFM1
and EFM2 of Figure 3.10) are shown. a) Values of |log10(p-value)| and | log2(ratio)| of genes in
upper panel and of metabolites in lower panel are shown. Green underline represents first EFM
(Figure 3.10 a) and Red underline represents the second EFM (Figure 3.10  b).  b) The  upper
panel  indicates the  log2 ratio of  the  genes  of  the first  EFM (Figure 3.10a) that have  different
degree of regulation among all three mouse strains. The lower panel indicates log2 ratio of the
metabolites  D-glucose  that  belong  to  the  first  EFM (Figure  3.11 a)  and  putrescine  and  L-
glutamine that belongs to the second EFM (Figure 3.11 b).
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3.3 Flux balance analysis of metabolic models using gene 
expression data 
After feeding 8 weeks a  DDC-supplemented diet  the three  mouse strains A/J, C57Bl6 and
PWD show different degrees (A/J, high; C57Bl6, low; PWD, unspecific) of steatohepatitis-
like phenotypes  (section 3.1.1).  The DDC-supplemented diet  might have changed the  liver
metabolism at different levels for  all three mice, and an analysis of metabolic fluxes may
provide  an  insight  to  understand  the  different  degrees of  liver  metabolism  and
steatohepatitis-like phenotypes.  Thus,  metabolic  flux  analysis  was performed for  both
control and DDC-treated mice.  FBA allows an analysis of metabolic fluxes  of large-scale
biological networks, particularly genome-scale metabolic networks.  An extension of FBA
framework  can be used to  integrate gene expression data  of all three mice  for  the  control
state  as well  as  for  the  DDC-treated  state  into the GMM model  (section 2.1;  Navid and
Almaas, 2012). This integration of expression data into the model may give a hint how the
metabolic  fluxes  are  regulated  at  different  degrees among  all  three  mice.  This  different
degree of regulation can be traced through the GMM model and one can identify which
pathways or modules of the GMM model have different degree of flux regulation that might
be linked to mice phenotypes.  
FBA estimates the intracellular fluxes of a genome-scale metabolic model by optimizing an
objective  function  (e.g.,  biomass  production)  subject  to  constraints  on  fluxes.  The  pre-
defined specific biological objective are less likely to be always valid for cells and different
conditions in multicellular organisms.  Thus, a pre-defined objective function may not be a
true indicator for all kinds of disease or conditions.  One  would  need to validate this pre-
defined objective function before using it  for  any specific conditions.  To circumvent this,
there are some methods for which there is no need to define a pre-defined objective function
(Lee et al., 2012).  There are several methods such as, E-Flux and GIMME, for which it is
needed to formulate a pre-defined objective function, but gene-expression can be integrated
in their modeling approaches (Becker and Palsson, 2008; Colijn et al., 2009). The method E-
Flux is an extension of FBA that incorporates gene expression data into FBA by constraining
the maximum flux constraints  as  a  function of  measured  gene  expression  (Colijn  et  al.,
2009). Whereas GIMME incorporate gene expression data into their models by transforming
gene  expression  levels  to  binary  states.  The  disadvantage  to  GIMME method  is  that  it
requires  a  user-specified  gene  expression  value  as  a  cutoff  to  determine  activity  of  the
reaction. Thus, E-Flux (see section 2.3) is chosen in this study because it can use quantitative
expression data without transforming to binary states. In addition, mGX-FBA is also chosen
for analyzing the perturbation effect which may occur due to the inclusion of relative change
of  expression  data  in  the  optimization  problem  (section  2.4). Using  both  computational
methods the E-Flux and mGX-FBA, expression data of all three mouse strains was integrated
into the GMM model and  obtained metabolic fluxes  were compared.  Due to limitation of
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experimentally  measured  flux  data  these computationally obtained  fluxes  can  not  be
validated.  Thus,  it is  difficult to  judge based  on  computationally  obtained  fluxes  which
methods are better or which methods have true or wrong prediction of fluxes. Of course at
least these computationally obtained fluxes allow us to identify some modules of the GMM
model that  may indicate different degree of flux regulation that might be  linked to  mice
phenotypes.  
3.3.1 Identification of flux using mGX-FBA
For  identification  of  different  degrees  of  flux  regulation  among  all  three  mice,  gene
expression data were integrated into the metabolic model. Based on gene expression data of
all three mouse strains from control as well as DDC-treated conditions, the metabolic fluxes
were estimated using the FBA formalism and the GMM model. The mGX-FBA method was
used (see  section  2.4)  and this method  uses relative change between two conditions (e.g.,
ratio between DDC-treatment and control) in an optimization problem. mGX-FBA performs
the following steps for flux analysis: 
1)  The flux distribution  vc on t  is  obtained by maximizing the flux though a pre-defined
biomass reaction of the GMM model. This flux distribution is used as reference state (control
mice).
2)  v i
mi n and  v i
max  are calculated  using  flux  variability  analysis  (FVA;  Mahadevan  and
Schilling, 2003). v̄ i  is the average of v i
mi n  and v i
max .
3) First of all those genes of the GMM model were selected, for which mean expression
value of three biological replicates were greater than 0.1 RPKM (Gan et al., 2010). Then for
these selected genes, relative fold changes of expression data (DDC-treated vs. control) were
calculated.  A cutoff  was used for moderate  up- (>=1.5 fold) and moderate  down-(<= 0.66
fold) regulated genes.  Reversible reactions  were not included in  this analysis (section 2.4).
Although those reactions are normally reversible, they were selected as  irreversible if they
carry flux in only one direction under the conditions imposed by environmental constraints.
Therefore, a cutoff ( v i
min∧vi
max>1e-06 or v i
min∧v i
max<−1e-06 ) that represents non zero flux,
was used on the result of FVA for obtaining irreversible reactions.
4)  The aforementioned  step 3 was applied  to gene expression data of mouse strains A/J,
C57Bl6 and PWD. As a result, constraints were applied to the 90, 86, and 84 reactions of the
GMM model for A/J, C57Bl6 and PWD mice, respectively (section 2.4; steps 4 and 5).  
Applying the  aforementioned steps of  mGX-FBA, steady state fluxes  were  calculated for
A/J, C57Bl6 and PWD mice in DDC-treated state. Note that, all three control mice steady
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state fluxes are identical because they were obtained by maximizing biomass function  only
subject to  structural constraints of the metabolic network (step1). 
The goal of this analysis was to identify some modules or pathways for which the different
degree  of flux  regulation  might be found  among  mice.  Subsequently,  these  identified
modules  and  their  fluxes might provide  an  insight  about differences in  degree  of  mice
phenotypes. To achieve this goal, first of all, the relative deviation of flux (section 2.4.1) was
calculated  for  measuring the  difference  of  flux  distribution  between  the  control  and the
DDC-treated state (steady state fluxes which obtained by the mGX-FBA method were used
for this calculation). The GMM model is derived from Recon1 model (Duarte et al., 2007),
and most of the reactions are the same in both models. The pathway map of Recon1 can be
found  (Schellenberger  et  al.,  2010) and used for  visualization  of the  GMM model.  The
complete set of metabolic pathways of the Recon1 is divided in three parts, carbohydrate,
amino acid and lipid metabolism. Reactions of these three parts of Recon1 are visualized by
coloring with  relative  flux  deviation  values  using  COBRA (Hyduke  et  al.,  2011). The
colored pathway maps indicate that all three mice have different degree of flux regulation for
some pathways or modules which are part of carbohydrate and lipid metabolism (Figure 3.12
and 3.13).  
A high increase of flux  (DDC-treated  vs.  control) was  observed for  the  pentose phosphate
pathway of the PWD mice in comparison to A/J and C57Bl6 (phenotypes; Figure 3.1). The
pentose phosphate pathway has two distinct phases. In the first oxidative phase NADPH is
generated  and  in  second  non-oxidative  phase  5-carbon  sugar  (ribose-5  phosphate)  is
synthesized from other than 5-carbon sugars, such as glucose-6-phosphate (6 carbon sugar)
(Figure 3.12). NADPH is a reducing agent, which is involved in the protection against the
toxicity of reactive oxygen species (ROS) or oxidative stress. Due to increased flux through
the oxidative phase of pentose phosphate pathway (G6PDH2r and GND) one may expect a
higher  production  of  NADPH in  PWD mice   (Figure  3.12).  Thus,  PWD  mice  may  be
protected better against oxidative stress compared to C57Bl6 and A/J mice. This result is
consistent  with  the  pervious  work  on  steatohepatitis:  As  we  know  from two-hit  theory
oxidative  stress  may  play  an  important  role  for  disease  progression  from  steatosis  to
steatohepatitis  (Day and  James,  1998).  The  flux  analysis  of  the  oxidative  phase  of  the
pentose phosphate pathway may suggest that A/J and C57Bl6 mice are under oxidative stress
than  PWD  mice,  suggesting  another  link  of  ROS  differences  in  the  steatohepatitis-like
phenotypes (section 3.1.1). 
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For PWD mice, a high decrease of flux was found through the reactions of the glycolysis
pathway.  This  pathway  is  driven  by  the  enzymes  phosphofructokinase  (PFK),  fructose-
bisphosphate  aldolase  (FBA),  and  glycerol-3-phosphate  acyltransferase  (GPAD)  among
others (Figure 3.12). The flux through GAPD was found to be downregulated in PWD mice,
while it was not changed in A/J and C57Bl6. Furthermore, the flux through gluconeogenesis
pathway (pyruvate to  glucose) is  observed,  which comprises  three steps:  1)  oxaloacetate
(oaa)  to  phosphoenolpyruvate  (pep)  catalyzed  by  phosphoenolpyruvate  carboxykinase
(PEPCK), 2) D-fructose 1,6-bisphosphate (fd6) to D-glucose 6-phosphate (g6p) catalyzed by
fructose bisphosphatase (FBP), 3) g6p to glucose (glc-D) catalyzed by glucose 6-phosphate
phosphatase (G6PPer).   An increased flux  was  obtained through the  PEPCK  in all  three
mice,  through  the  FBP  in PWD and C57BL6 mice,  and  through  the  G6PPer  in AJ and
C57BL6  mice  (Figure 3.12).  Fluxes  of  glycolysis  and  gluconeogenesis  pathways  are
perturbed at different degrees among mice. The liver plays an important role in regulation of
glucose level. During fast the liver accomplishes via gluconeogenesis to maintain the glucose
level.  The perturbation  of  fluxes  through glycolysis  and gluconeogenesis may affect  the
glucose level. Thus, one may expect perturbation in glucose concentration for all three mice.
Experimental  the  glucose concentration was found to be decreased in  A/J,  C57BL6 and




Figure 3.12. Results of flux analysis performed with mGX-FBA. Glucose metabolism.  a)
Black colored reaction arrows indicate fluxes  that  are very low in  both control and DDC-
treated conditions. Red and black colored reaction arrows indicate  up and down regulation of
fluxes  under  DDC-treatment  conditions.  The  reactions  of  glycolysis,  gluconeogenesis,
pentose phosphate pathway,  TCA cycle,  anaplerotic and cataplerotic are  colored with the
relative flux deviation  value  (DDC-treated vs control).  Full  form of abbreviations can be
found in BiGG (Schellenberger et al., 2010). b) Fold change of glucose concentration.
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Anaplerotic and cataplerotic reactions are very useful to maintain the function of the citric
acid (TCA) cycle. Due to insufficient oxalacetate the first reaction of the TCA cycle, citrate
synthase, that catalyzes the condensation of oxalacetate with acetyl-CoA cannot occur. Thus,
anaplerotic  reaction  e.g.,  pyruvate  carboxylase,  which  synthesizes  oxaloacetate  from
pyruvate  in  the  mitochondrial  matrix, is  required  to  ensure  the  TCA cycle  works.  If
intermediates  (e.g.,  oxaloacetate)  accumulate  in  the  mitochondria,  then  it  is  important  to
remove them. Cataplerotic reactions are involves in the disposal of TCA cycle intermediates.
An  example  of  a  cataplerotic reaction  catalyzed  by  PEPCK  is  the  generation  of
phosphoenolpyruvate from oxalacetate  that is common route for gluconeogenesis.  The flux
through this reaction  was found to be increased for all  three  mice  under  DDC-treatment
(Figure 3.12).  For the flux through the anaplerotic reaction  mediated by  Pcm an elevation
was found in C57Bl6 and PWD mice, but not in A/J mice (Figure 3.12). This may suggest
less production of oxaloacetate in A/J which might affect the TCA cycle. The flux through
one  reaction  mediated  by  ICDHyrm  (substrate,  isocitrate  and  NADP;  product,  2-
oxoglutarate, NADPH, CO2) of the TCA cycle was found to be upregulated for PWD mice,
and found to  be  downregulated  for  A/J  and C57Bl6 mice.  This  may  suggest  the  higher
production of NADPH for PWD mice compared to A/J and C57Bl6 mice.   This further
supports the idea that PWD mice might show a different response to ROS comparing to the
other mouse strains. 
In all three mice the flux analysis also indicates different levels of flux regulation within the
fatty acid and the cholesterol metabolism.  The  fatty acid metabolism  module is shown in
Figure 3.13a. The relative flux deviation through the reaction CSNATr is increased (red) in
C57Bl6 and PWD mice.  Thus, one can expect accumulation of carnitine (antioxidant)  in
C57Bl6 and PWD mice and it may be a reason that mice C57Bl6 and PWD mice is less
vulnerable to oxidative stress in compare to A/J mice. 
The relative  flux  deviation  through the  cholesterol  biosynthesis  metabolism is  shown in
Figure 3.13b. It, is slightly decreased for AJ mice, and is increased for C57Bl6 and PWD
mice.  The  concentration  of  desmosterol  (dsmsterol)  that  is  a  downstream of  cholesterol
biosynthesis pathway is observed to be upregulated in C57Bl6 and PWD mice and slightly
downregulated  in AJ  mice.  That  is  inline  with  relative  flux  deviation  of  cholesterol
metabolism (Figure 3.13b & c). 
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Overall,  this  analysis  suggest that fluxes  through several  independent metabolic modules
might  be  different  in  high  vs.  unspecific  responder  to  DDC.  Interestingly,  metabolites
associated with these reactions are functionally related to ROS response, inline with previous
results presented in this work.  
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Figure 3.13. Result of flux analysis of lipid metabolism. a) A module of fatty acid
metabolism. An increase (red) in the relative flux deviation of the reaction CSNATr
(substrate,  acetylcarnitine  (acrn);  product, carnitine  (crn);  enzyme, carnitine-
acetyltransferase)  is found for C57Bl6 and PWD mice.  b) A module of  cholesterol
biosynthesis.  The relative flux deviation  of  cholesterol  biosynthesis  is found  to  be
decreased (slightly blue) for A/J,  but increased (slightly red) for C57Bl6 and PWD
mice. c) Fold change of desmosterol concentration.
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3.3.2 Identification of flux using E-Flux
One limitation of mGX-FBA is that it uses the same steady state flux for all three controla.
To overcome this, metabolic fluxes were also analyzed by using E-Flux that is combination
of expression and flux (section 2.3). The E-Flux method requires an objective function and I
used an already defined biomass function of the GMM model  (section 2.1).  The  COBRA
tool (Hyduke et al., 2011) was used to identify exchange reactions, i.e., reaction that link the
model to the environment, in the GMM model that resulted in 455 reactions. The lower and
upper  bound  for  each  exchange  reaction  is  set  to  -1  and  +1  (Colijn  et  al.,  2009).
Conceptually,  the E-Flux method can be understood as setting the width of “pipes” around
particular reactions as a function of expression state. Therefore, the low expression indicated
a thin pipe around the reaction or in other words the flux through the reaction is limited. 
Let a vector v = (v1, v2,...,vr,...., vR), where v1, v2,...,vr,...., vR are the components of v and R is
the  number  of  reactions  of  the  GMM  model.  A component  of  v,  vr,  is  derived  from
expression data, where r is a reaction of the model. For example, if a single gene encodes an
enzyme that catalyzes a reaction r then its expression value is equal to  vr. If a reaction is
catalyzed  by  isozymes  that  are  encoded  by  more  than  one  gene  then  the  maximum
expression of  these  genes is used for obtaining  vr. Then,  M=max(v)  is calculated and  v is
normalized between 0 and 1 by dividing all elements by M. Note that, for those reaction for
which either expression data is not available or enzymes information is not associated (e.g.,
decay or some transport reactions), the  vr is used as 1  that allows the maximum flux. For
each reaction r of the GMM model, the upper bound is set to vr as well as the lower bound is
set to 0 or -vr  depending whether r is irreversible or reversible.
Expression data of three biological replicates of A/J, C57Bl6 and PWD mice were integrated
to the GMM model by using the E-Flux method and the flux through biomass reaction was
maximized.   Maximum flux  of  the  biomass  reaction  is  shown  in  Figure  3.14.  A clear
difference of biomass production rate between DDC-treated vs. control is observed for A/J
and C57Bl6 mice, but it is difficult to observe for PWD mice (Figure 3.14). The difference
(DDC-treated vs.  control)  of biomass production rate of mouse strains A/J and PWD are
inline with their steatohepatitis-like phenotypes  (section 3.1.1).  The difference of biomass
production rate is inline with the high steatohepatitis-like phenotypes of the C57Bl6 mouse
strain, but the strain shows low steatohepatitis-like phenotypes. 
To further replicate reasons for different degrees of flux regulations among mouse strains
using an analysis  was performed analogy to mGX-FBA described above.  First, the relative
flux deviation (DDC vs. control) was calculated. Subsequently relative flux deviation values
were used  to  color  the  reactions  of  the  metabolic  maps  of  BiGG  for  all  three  mice.
Furthermore,  the colored metabolic maps of three mice  were compared by observing the
color differences. The relative flux deviation through a module of aminosugar metabolism
and the glycogen synthesis and degradation pathway were found to be decreased in A/J mice,
but it was increased in C57Bl6 and PWD (Figure 3.15a & b). This observation indicates that
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these pathways might show a strain specific response and would be the candidates for further
experimental investigation. The relative flux through glyconeogenesis pathway was found to
be perturbed in all three mice, particularly the flux through FBP was found to be upregulated
in C57Bl6 and PWD, but downregulated in A/J (Figure 3.15c). The pertubation of the flux
through the gluconeogenesis may perturb the glucose concentration which is inline with the
experimentally measured glucose concentration under DDC-treatment. 
The colored map of  lipid metabolism is  observed for A/J,  C57Bl6 and PWD mice.  The
relative  flux  deviation  through  the  reactions  of  desmosterol  (dsmsterol)  production  was
found to be increased  in C57Bl6 and PWD mice,  but not  changed for A/J (Figure 3.16a).
Based  on  this  flux  regulation,  one  may  expect  the  concentration  of  desmosterol  to  be
deregulated  in C57Bl6  and  PWD  during for  DDC-treatment.  Experimentally  measured
concentration of desmosterol was found to be upregulated in C57Bl6 and PWD mice which
is inline with the observation. Furthermore, the relative flux deviation through the bile acid
synthesis pathway was found to be decreased in A/J mice, but to be changed in C57Bl6 due
to DDC-treatment,  while it was increased in PWD mice (Figure 3.16b). An increase of the
flux through the bile acid synthesis pathway in PWD mice may increase the concentrations
of metabolites of this pathway.  Indeed, a  downstream metabolite of  the  bile acid synthesis
pathway, taurocholic acid/tchola measured experimentally to be upregulated (4-fold) in PWD
mice which is inline with the expectation. However, based on the analysis were expected to
show  a  downregulated  flux  flux  through  the  bile  acid  synthesis  pathways,  but  the
concentration of taurocholic acid  was found to be upregulated  experimentally (1.8-fold).  It
may suggest  A/J  has  strain-specific  effect  and to  know the  reason in  detail  one  require
experimental flux data.  Furthermore, Tanaka et al.,  (2012)  observed the disruption of bile
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Figure 3.14. Biomass production rate. Maximum biomass production rate is higher in
DDC-treated state than control for A/J and C57Bl6 mice. 
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acid homeostasis in mice with NASH and also in my study the change of the flux through
this pathway is observed.  
In  a  module  of  fatty  acid  activation,  reactions FACOAL1812  and  FACOAL1813  are
involved in the production of vaccenic and elaidic acid, respectively. Vaccenic acid occurs in
dairy products such as milk and butter. Elaidic acid is trans isomer of oleic acid that occurs in
various animals,  vegetable fats  and oils. The relative flux deviation though the reactions
FACOAL1812  that  and FACOAL1813  was found to be decreased  in A/J mice,  but it was
increased in C57Bl6 and PWD (Figure 3.16c). 
The high flux may lead to accumulation of fatty acid such as  vaccenic and elaidic acid  in
PWD and C57Bl6 mice. The accumulation may form lipid droplets that is a sign of steatosis
which is inline with the high steatosis of PWD mice  (section 3.1.1).   For all three mose
strains, the metabolic pathways cholesterol, bile acid, and fatty acid have different degree of
metabolic response to a DDC-supplemented diet.  This finding suggests that these pathways




Figure 3.15. Glucose metabolism using E-Flux. a)  Aminosugars module.  b)
Glycogen synthesis & degradation. c) Glycogenesis
3 Results
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Figure 3.16. Lipid metabolism using E-Flux. a) Cholesterol module. b) Bile acid synthesis c)
Fatty acid activation. 
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3.3.3 Comparison of the E-Flux and mGX-FBA method
The integration of different sets of gene expression data into the metabolic model may give
different  flux distributions. So,  I  expected the  integration of expression data  of all  three
mouse  strains may  give  different  degree  of  flux  regulation  which  may  be  useful  for
understanding their phenotypes. Thus, E-Flux and mGX-FBA are used  to identify different
degrees of flux regulation among mice. As we have seen in previous sections (3.1.1 and
3.1.2) both methods were able  to identify  some modules or pathways that have different
degree of regulation among mice. In this section results of both methods are compared.
Overlapped results of the E-Flux and mGX-FBA method. A high decrease of flux through
a reaction  of  glycolysis  (FBA)  was found  in  PWD mice  using  both  methods.  The flux
through a reaction of  gluconeogenesis (FBP)  was found to be upregulated  in C57Bl6 and
PWD mice  in the results of both methods.  Due to deregulation of  fluxes of  glycolysis and
gluconeogenesis one may expect deregulation of the glucose concentration.  Experimentally
measured  the  glucose  concentration  was  found  to  deregulated  which  is  inline  with  the
expectation. (Figure 3.12b).
The flux through the cholesterol biosynthesis was found to be upregulated in PWD mice, but
it was  downregulated  in A/J.  However, the  upstream part  of cholesterol biosynthesis  were
identified  by  the  mGX-FBA  method  to  be  delegulated,  while  the  downstream  part  of
cholesterol biosynthesis is identified by the E-Flux method (Figure 3.12b & 3.15b).  Albeit
these discrepancies,  deregulation cholesterol biosynthesis  fluxes may  in the end  alter  the
concentrations  of  metabolites  genereted  by  this  pathway.  Indeed,  the  concentration  of
desmosterol was found to be deregulated which is inline with the expectation.
In  short,  in  silico fluxes of  the  pathway  glycolysis,  gluconeogenesis,  and  cholesterol
biosynthesis were found to be altered and also the concentrations of glucose and desmosterol
were deregulated.  This finding suggest that these pathways may be good candidates for
further experimental investigation. 
Differences in results of the E-Flux and mGX-FBA method. The flux through oxidative
and  non-oxidative phase of  the  pentose phosphate pathway  was found to be increased for
PWD mice in the mGX-FBA method, which is contrast of the E-Flux method. The degree of
flux regulation  of  the  pentose phosphate pathways  is linked to oxidative stress and mice
phenotypes when mGX-FBA is used, while it is not linked to mice phenotypes when E-Flux
is used. For this pathway, mGX-FBA is better than E-Flux in prediction of mice phenotypes.
However, it is difficult to judge the prediction of both methods because lack of experimental
flux data.  
In contrast of using mGX-FBA, the bile acid synthesis pathways is found to be deregulated
at  different  degree  by  using  E-Flux  (Figure  3.16b).  The  concentration  of  taurocholic
acid/tchola  that  is  a  downstream metabolite  of  the  bile  acid  synthesis  pathways  can  be
expected  to  be  upregulated  for  PWD mice  due  to  an  increase  of  flux  through bile  acid
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synthesis  pathway.  Experimentally  measured  concentration  of  taurocholic  acid  was
upregulated (4-fold) in PWD mice, which is inline with the expectation. However, A/J mice
was not inline with the expectation as an increase (1.8 fold) of concentration of taurocholic
acid was found while the flux through the bile acid synthesis pathways was downregulated. 
The alteration of  throughout fluxes of the GMM model using  the E-Flux and mGX-
FBA method. The aim of this work was to study changes in fluxes of metabolic networks in
two conditions. To address this, gene expression data of the mouse strains A/J, C57Bl6 and
PWD  in DDC-treated as well as  control  conditions  were integrated into the GMM model
using the mGX-FBA and E-Flux methods and fluxes were obtained (section 3.3.1 and 3.3.2).
To study the difference of throughout fluxes of the GMM model between DDC-treated and
control conditions, the flux through each and every reactions of the model were compared
using relative flux deviation ( ∣d r∣ ) value (section 2.4.1). To know a marked difference in the
flux value of a reaction r between two conditions a moderate cutoff ( ∣d r∣ >0.5) was set. 
Aforementioned cutoff was applied  on the results of fluxes of the mGX-FBA and E-Flux
methods and the obtained results of both methods were compared.  In the mGX-FBA method
out of 3727 reactions of the GMM model a marked difference (DDC-treated vs control) in
the flux value were obtained for 517, 773 and 596 in mouse strains A/J, C57Bl6 and PWD,
respectively,  while 1089, 878 and 1077 were obtained for A/J, C57Bl6 and PWD in the E-
Flux method (Figure 3.17a). This result suggest that E-Flux method alters fluxes through a
higher number of reactions of the GMM compared to the mGX-FBA method. Out of 3727
reactions,  259, 255 and 266 were common in the both methods for A/J, C57Bl6 and PWD
mice, respectively (Figure 3.17a). 
3.3.4 Comparison of  flux regulation with- and without-integration 
of gene-expression data
The aim of this study is to analyse whether the integration of gene expression data into the
model  (section 3.3.2 and 3.3.3) is  required for understanding the flux regulation or it  is
sufficient to judge the flux regulation based on only regulation of gene expression data.  To
address this, the bile acid synthesis and cholesterol biosynthesis pathways are chosen due to
the metabolic concentrations of these pathways were measured. Thus, these pathways can be
used as a validation such as the regulation of the metabolic concentrations may be estimated
from the regulation of fluxes. 
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The integration of gene expression data into the model has been already done in section 3.3.2
and 3.3.3. On the one hand, for an example of the integration of gene expression data the
different degrees of flux regulation was observed for bile acid synthesis pathway among all
three  mouse  strains  (Figure  3.16b).   The  flux regulation  through the  bile  acid  synthesis
pathway is inline with the regulation of the concentration of taurocholic acid for PWD mice,
while it was not inline with the A/J (section 3.3.3). 
On the other hand, the regulation of gene expression data of the bile acid synthesis pathway
were observed  in  Figure 3.17b. Some genes of this pathway were upregulated while some
were downregulated (Figure 3.17b). For example,  Cyp7a1  was found to be upregulated in
A/J, while  Cyp8b1 was downregulated. In PWD,  Akr1d1 was upregulated and Scp2 along
with  Cyp81b were downregulated.  Thus,  the  judgement  of  regulation  of  the  flux  or  the
concentration  of  bile  acid  synthesis  pathway based  on  only  gene  expression  data  is
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Figure  3.17.  Comparison  of  E-Flux  and  mGX-FBA.  a) Results  of  differences  in
reaction  fluxes  of the mGX-FBA and E-Flux method. b) Fold change (DDC-treated vs
control) of genes of bile acid synthesis pathway. c) Fold change (DDC-treated vs control)
of genes of  cholesterol biosynthesis synthesis pathway. 
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problematic. 
On the one hand,  for another example  of  the integration of gene expression data  the flux
through  cholesterol  biosynthesis  pathway was  observed to be upregulated in C57Bl6 and
PWD mice, while it was slightly downregulated in A/J (Figure 3.17b). The regulation of the
concentration of desmosterol  is inline with the regulation of the flux through this pathway
for  all  mouse  strains (section  3.3.2). On  the  other  hand,  gene  expression  data  of  the
cholesterol biosynthesis were observed in Figure 3.17c. It is difficult to judge the regulation
of  the  flux or the concentration  of this pathway  due to some genes of this pathway  were
upregulated and some genes were downregulated in all three mouse strains. Thus, integration
of gene expression data into the metabolic model can provide a better understanding of flux
regulation than the estimation of fluxes solely based on gene expression data.
Taken together,  to understand different degrees of flux regulation among mouse strains I
performed  an  integrated  analysis  of  gene  expression  data  of  mouse  liver  samples  of a
metabolic  network  using  the  methods  mGX-FBA and  E-Flux.  Both  methods  identified
different  degrees  of  flux  regulation  among  mouse  strains  via  glucose  and  cholesterol
biosynthesis  pathways.  Interestingly,  the measured experimental  concentration of  glucose
and desmosterol are found to be deregulated at different degrees among mice strains due to
DDC-treatment. E-Flux method shows overall flux alteration of a larger number of reactions
of the GMM than the mGX-FBA method. The difference between DDC-treated vs. control of
the flux through the biomass reaction is in line with mouse steatohepatitis-like phenotype
(Figure 3.14). Furthermore, the judgement of flux regulation based only on gene expression
is difficult (Figure 3.17b & c); thus aforementioned methods may be an option to explore in
silico based flux regulation.    
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3.4 Identification of potential drug targets
There are only a few medicines that can cure, prevent or slow the progression of liver disease
such  as,  steatosis,  steatohepatitis  and  hepatocellular  carcinoma  (HCC).  Thus,  the
identification of new  potential  drug target  candidates is a very important task in  bringing
innovative  new  medicines  to  patients. Systems  biology  approaches  are suggested  as  a
promising tool for improving decision making in pharmaceutical development  (Butcher et
al., 2004). High throughput gene-expression and genome-scale models have been used for
identifying potential drug targets in cancer (Folger et al., 2011). One aim of this work is to
identify  potential  drug  targets  in  liver  disease  such  as  steatosis,  steatohepatitis  and
hepatocellular  carcinoma  (HCC)  through  metabolic  networks.  This  aim  may  be
accomplished by applying a constraint based modeling approach to metabolic networks.  A
similar approach for identification of drug targets in cancer was proposed by Folger et al.
(2011).
I have applied a constraint based modeling approach to the GMM model to identify in silico
drug targets in liver disease. In this study, a drug target is a gene which encodes an enzyme
and the activity of this  enzyme might be  inhibited by drugs.  In silico  drug targets were
identified for three different types of the liver diseases: steatosis, steatohepatitis, and HCC. 
Steatosis can be caused by accumulation of lipids and subsequent formation of lipid droplets
(Anderson and Borlak, 2008).  For steatosis,  I  formulated  a  biomass  reaction and the flux
through this reaction was used as a readout of the disease (section 2.6).
Steatohepatitis may be caused by accumulation of lipids, inflammation and oxidative stress.
A second biomass reaction was formulated for  the  steatohepatitis and the flux through the
reaction was used as readout of the disease (section 2.6). 
HCC is one of the most common malignant tumors and accounts for most liver cancers (Li,
2013).  For  readout of  HCC  phenotypes, a  third  biomass reaction was formulated (section
2.6). 
Before  using  the  biomass  reaction  for  the  identification of  drug targets  in  steatosis  and
steatohepatitis,  I  tested whether  the flux through this reaction  can be  used as  a  readout  of
disease phenotypes or not. To achieve this,   I integrated gene expression data to the GMM
model and compared the flux through the biomass reaction with the mouse phenotypes.  The
comparison was performed using gene expression data of the mouse strains A/J, C57Bl6 and
PWD.   In this comparison analysis, first of all, the  flux through  the  biomass reactions  for
steatosis  and  steatohepatitis, was calculated  using  the  combination  of  GMM model  and
expression data.  To address this, the following steps were used: 
1) The  flux  through  the  biomass  reactions  were maximized  by  using  flux  balance




2) In this study, “reaction expression” is termed as the expression of an enzyme or a
group of similar enzymes catalyzing a reaction that is reflected by the enzyme or
enzyme-encoding genes. The  reaction  expression of each enzymatic reaction of  the
GMM model  was computed  either  as  maximum  of  the  expressions  of  enzyme-
encoding genes  or as direct expression value if there is a single enzyme-encoding
gene. Separately, the reaction expressions were computed for 3 biological replicates
(BR) of A/J  and C57Bl6 mice in control as well as in DDC-treated conditions,  and
for 3 BR of PWD mice in control along with 2 BR in DDC-treated conditions. 
3) For  each  reaction  of  the  GMM  model,  the  coefficients  of  variation  (CV)  were
computed  and the computation was performed over the reaction  expressions of the
aforementioned biological replicates of the mouse strains A/J, C57BL6 and PWD in
both  control  and DDC-treated conditions. A set of reactions, SR,  was  identified in
which each reaction has moderate variation (CV>0.65) of reaction expression over
the biological replicates.   To incorporate particular tissue specific data to the GMM
model might be problematic. For example, assume that some genes have very low
expression  or  are  not  expressed  at  all  in  a  particular  tissue.  If  the  reactions
corresponding to  these low expressed genes are  completely blocked in the GMM
model, then it may affect some important functions of the GMM model. Thus, to
avoid complete elimination of flux the reaction expression of each reaction of SR  is





where  rexpi is  reaction  expression of  reaction  i of  the  set  SR,  and  min(rexp) and
max(rexp) are minimum  and  maximum  reaction  expressions  over all biological
replicates, respectively.  
4) Using different levels of gene expression data among mice can change the bound
constraints such as lower and upper bounds of reaction fluxes of the GMM model.
Using flux balance analysis,  to obtain different  degrees  of  flux regulation among
mouse strains I have applied gene expression of mouse strains for constraining the
reaction  of  the  GMM  model.   For  each  reaction  r  of  the  SR,  expression  was
transformed using formula (3.2). Then transformed expression (texp) was used to set
LB(r )=v Ref (r )×texp  of r if v Ref (r )  is negative and UB(r )=vRef (r )×texp  of r if
v Ref (r )  is positive, where LB and UB are lower and upper bound, respectively.
5) The biomass reaction was maximized using gene expression data of aforementioned
biological  replicates  of  A/J,  C57Bl6 and PWD mice  of control  and DDC-treated
conditions.  The flux through the biomass reaction was normalized by dividing the
flux through the biomass reaction that was obtained by step1. This normalized score
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is called  “objective score” and the reference state has an objective score equal to 1.  
For steatosis and steatohepatitis, the objective score of the control mouse strains were lower
than the DDC-treated mouse strains (Figure 3.18a).  The objective score of steatosis readout
in DDC-treated condition was found to be higher in PWD mice compared to A/J and C57Bl6
mice  (Figure 3.18b). The objective score for steatosis is inline with the steatosis phenotypes
of PWD mice (section 3.1.1). For a readout of steatohepatitis in DDC-treated condition, the
objective  score  in  A/J  mice  was slightly higher  compared to PWD  mice (Figure  3.18b;
section 3.1.1).  The objective score for steatohepatitis is inline with the steatohepatitis-like
phenotypes of A/J. 
3.4.1 Selective drug target 
The number of liver drugs that are currently available is not sufficient (Muriel and Rivera-
Espinoza, 2008). Thus, the identification of a range of safe and efficient therapeutic agents as
well as new drug targets is a very important task. Therefore, an analysis  was performed to
identify  novel  potential  drug targets  in  liver  disease  applying  constraint-based  modeling
approach to the GMM model.  To measure a readout of each of steatosis, steatohepatitis and
HCC  separate  biomass reactions were  constructed  (section  2.6). For  each  of  steatosis,
steatohepatitis  and HCC, I  performed  an  in silico  drug targets analysis  which proceeded
through the following steps:  
1) The flux through each objective reaction of the GMM model is maximized and the
steady state flux is obtained for each reaction of the GMM model. 
2) The flux through the ADP/ATP transporter reaction/ATPtm of  the  GMM model is
maximized to obtain the maximum flux through ATP maintenance (ATPtm).  
3) The knockout of each gene of the GMM model was performed by reducing the flux
through  reactions  associated  with  the  gene.  The  flux  through  the  reactions  was
reduced by 90 % of the obtained flux in step 1.







where,  RF(ATPtm) and  RF(BR) represent  the  flux  through  the  ATPtm  and  the
biomass reaction after reducing 90% flux through the reactions associated with G,
OF(ATPtm) and  OF(BR) represent original flux (step 1).  Score 1 and 0 represent
good and bad selective drug targets. After gene knock-down from the GMM model, if
the  flux  through  the  reaction  ATPtm  is  reduced  markedly then  the gene  is  not
consider as a good drug target. Therefore, the term RF(ATPtm)/OF(ATPm) is used in




For each of three liver diseases steatohepatitis,  steatosis  and HCC, aforementioned steps
were used to calculate the score by knocking out one by one gene of the GMM model. After
knocking out a gene of the GMM model, if the score was greater than 0.4 then the gene was
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Figure 3.18. Identification of  drug targets. a) Objective score  used  as a  readout of
steatohepatitis  and steatosis.  Upper pannel and  lower pannel  represents  a readout of the
steatohepatitis  and the  steatosis,  respectively.  b)  Upper  pannel  and  lower pannel
represents the average (over biological replicates) of objective score of the steatohepatitis
and the steatosis in DDC-treated mice. PWD mice  show high degree of steatosis and A/J
mice show high degree of steatohepatitis.  c) Frequency of drug targets in steatohepatitis.
High score indicates potential drug target. d)  Histogram of drug targets in the  steatosis e)
Histogram of drug targets in the HCC. f) Venn diagram of drug targets of the steatosis, the
steatohepatitis and the HCC.
3 Results
identified as an in silico drug target. Histograms of the scores  are depicted for steatohepatitis
(Figure 3.18c), steatosis (Figure 3.18d) and HCC (Figure 3.18e).  The number of drug targets
in aforementioned three disease is shown in a Venn diagram (Figure 3.18f and Table 3.1). In
total 78 drug targets were obtained for aforementioned three diseases, 26 were common in all
three, 5 were common in steatohepatitis and HCC, and 3 were common in steatohepatitis and
steatosis. Out of 78, 17 are annotated as a drug targets in DrugBank (Knox et al., 2011) in
which 7 are FDA-approved anticancer drugs (Table 3.2) that may be used in the treatment of
HCC, and the remaining 61 may act as potential drug targets in liver disease. Furthermore,
an analysis was performed to identify metabolic pathways corresponding to the drug targets
of the aforementioned three liver diseases.  The analysis  identified as the  top two  ranked
pathways, cholesterol and triacylglycerol/triglyceride metabolism  that comprised 13 and 9
drug targets, respectively as well as other pathways which are shown in Table 3.3.
In the aforementioned comparison analysis of potential drug targets in liver disease, 26 drug
targets were common in the steatosis, the steatohepatitis, and the HCC. From 26 drug targets,
13,  6 and  3  were  identified  from cholesterol  metabolism,  triacylglycerol  synthesis  and
inositol  phosphate  metabolism,  respectively.  From  13   identified  drug  targets  related  to
cholesterol  metabolism  were  enriched  for  terpenoid  backbone  biosynthesis  and  steroid
synthesis  of KEGG pathways  (Figure 3.19 & 3.20).  Cholesterol biosynthesis begins with
acetyl-CoA  that  is  converted  to  3-Hydroxy-3-methyl-glutaryl-CoA  by  3-hydroxy-3-
methylglutaryl-CoA synthase 2 (Hmgc2) (Figure 3.19). 3-Hydroxy-3-methyl-glutaryl-CoA is
converted  to  mevalonate  by  3-hydroxy-3-methylglutaryl-CoA  reductase  (Hmgcr)  and
subsequently mevalonate undergoes  a  series of steps and  finally  is  converted to  farnesyl
diphosphate  that  is  a  precursor  of  steroid  biosynthesis.   In  steroid biosynthesis,  farnesyl
diphosphate is converted to squalene by farnesyl diphosphate farnesyl transferase 1 (Fdft1)
(Figure  3.20).  Squalene  is  further  converted  to  cholesterol  in  a  series  of  biochemical
reactions (Figure 3.20). 
Hmgcr, a key enzyme in cholesterol biosynthesis, is identified as a drug target in my in silico
drug targets analysis.  Hmgcr has been  already used as a target of  a class of  statins (e.g.
atorvastatin, pravastatin, and rosuvastatin) drugs which are used to lower cholesterol levels
by inhibiting  the  Hmgcr  (Ekstedt  et  al.,  2007).  Clinical  studies  reported  positive  results
regarding the use  of  statins  in  the treatment  of  NASH  (Anderson and Borlak,  2008).  In
addition to Hmgcr from cholesterol biosynthesis, several other potential in silico drug targets
were found and are highlighted in red in Figure 3.19 and 3.20. These drug targets may one
day  be used as drug targets for  steatosis and the steatohepatitis. However, I did not find
drugs for these targets after a review of  the  literature. These targets  seem to be novel and





Table 3.1. Identified drug targets for steatohepatitis, steatosis and HCC. A set
comparison analysis of drug targets is shown.
Only in 
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Acetyl-CoA carboxylase (Acaca and Acacb) was found to be an in silico potential drug target
in  the steatohepatitis  and  steatosis.  Acetyl-CoA carboxylase  catalyzes  the  reaction  that
provides  malonyl-CoA  from Acetyl-CoA. Malonyl-CoA  is a  precursor of biosynthesis  of
fatty  acid.  Metformin,  is  a  widely  used  drug  in  the  treatment  of  type  2  diabetes,  and
suppresses hepatic steatosis (Zhou et al., 2001). Metformin activates AMP-activated protein
kinase  (AMPK)  in  hepatocytes  that  suppresses  the  activity  of  acetyl-CoA carboxylase
activity (Zhou et al., 2001). My in silico study of drug targets Acaca and Acacb is inline with
the previous study of Zhou et al., 2001. 
In  silico  drug targets  of  glycerolipid  metabolism  are shown in  Figure  3.21.  Glycerol-3-
phosphate acyltransferase that is encoded by gene Agpat6, is involved in the first committed
step  of triacylglycerol  biosynthesis  (Figure  3.21). Liver-directed  overexpression  of
mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis and increased
triacylglycerol  secretion  (Lindén  et  al.,  2006).  Furthermore,  pharmacological  glycerol-3-
phosphate acyltransferase inhibition decreases lipid accumulation in white adipose, brown
adipose,  and  liver  tissues  (Kuhajda  et  al.,  2011).   Glycerol-3-phosphate  acyltransferase
(Agpat6) may be act as a drug target for steatosis based on the study of Kuhajda et al., 2011
and also Agpat6 is found as an in silico drug target in this analysis.
91
Table 3.2. Drug targets and approved drugs.  Genes in the table may be used
as  drug  targets  in  the  HCC.  These  genes  are  targeted  with  some  FDA
approved anticancer drugs. 
Drug target gene FDA-approved drugs
Acaca L-Glutamic Acid
Acacb Alitretinoin







Table 3.3. Involved drug targets in metabolic pathways. 
Pathways Drug targets for liver diesease
Cholesterol Metabolism
Cyp51, Fdft1, Hmgcr, Hsd17b4, 
Lss, Mvk, Sqle, Sc4mol, Pmvk, 
Tm7sf2, Fdps, Mvd, Idi1
Triacylglycerol Synthesis
Dgat1, Gpam, Agpat3, Agpat5, 
Agpat1, Agpat2, Dgat2, Agpat4, 
Agpat6
Transport, Extracellular Atp8a1, Slc7a1, Slc7a2, Slc7a3, Slc6a14, Slc38a2, Slc38a4, Slc38a1
Nucleotides Adsl, Adssl1, Adss, Tyms, Impdh1, Impdh2, Txnrd1, Gmps
Methionine Metabolism Mat1a, Cbs, Mat2b, Ahcyl1, Mat2a,Ahcy
IMP Biosynthesis Gart, Paics, Atic, Ppat, Pfas
Sphingolipid Metabolism Sptlc2, Kdsr, Sgms1, Sptlc1
Inositol Phosphate Metabolism Impa1, Isyna1, Impa2
Glycerophospholipid Metabolism Cdipt, Crls1, Pgs1
Glycine, Serine, and Threonine Metabolism Psph, Psat1, Phgdh
Pyrimidine Biosynthesis Umps, Dhodh, Cad
Glutamate metabolism Glul, Lgsn
Fatty Acid Metabolism Acacb, Acaca
Pentose Phosphate Pathway Prps1, Prps2
Tyr, Phe, Trp Biosynthesis Pah
Alanine and Aspartate Metabolism Asns
Transport, Mitochondrial Atp10a
Folate Metabolism Dhfr




Isyna1, is a key enzyme, which is involved in the myo-inositol biosynthesis pathway (Figure
3.22). Isyna1 catalyzes the rate-limiting conversion of glucose 6-phosphate to myoinositol 1-
phosphate  (Figure  3.22). Carbamazepine  may inhibit  myo-inositol-1-phosphate  synthase
(Isyna1) and reduce inositol  (Lin et al., 2013). Carbamazepine decreases the hepatic load of
mutant α1-antitrypsin proteins  and hepatic fibrosis in mouse model  (Hidvegi et al., 2010).
Isyna1 is found as a potential in silico drug target. Taken together, carbamazepine might be a
novel drug candidate to be tested for the treatment of NAFLD which reduces the activity of
Isyna1, but of course it would require experimental validation. 
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Figure 3.19.Terpenoid backbone biosynthesis. 
Drug targets are shown in red color.  Acetyl  CoA is converted to farnesyl
diphosphate  that  is  a  precursor  of  cholesterol  biosynthesis.  Hmgcr  is
involved in a rate-limiting step of cholesterol biosynthesis.
3 Results
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Figure 3.20. Steroid biosynthesis. 
Farnesyl  diphosphate  is  converted  to  cholesterol  via  a  series  of
biochemical  reactions.  Red   nodes  indicate  drug  targets  that  are
identified in in silico analysis. 
3 Results
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Fig 3.21. Triacylglycerol biosynthesis.
Triacylglycerol  biosynthesis  pathway  begins  with  acyl-CoA
and which  then  is  converted  to  triacylglycerol  through  the
series  of  biochemical  reactions.  Agpat6  catalyzes  a  rate-
limiting step of   triacylglycerol biosynthesis.
3 Results
In  summary,  I  formulated  biomass  reactions  for  steatohepatitis  and  steatosis.  The  flux
through the biomass reactions was able to mimic the steatosis and steatohepatitis phenotypes
of  mouse  strains  after  integrating  gene  expression  data  of  mouse  strains  into  the  GMM
(Figure  3.18b).  Using these  biomass  reactions  as  well  as  a  biomass  reaction  of  HCC I
identified 78 potential candidates for drugs in liver diseases: steatohepatitis, steatosis and
HCC, in which 7 candidates are already found to be FDA-approved anticancer drugs. 26
potential  drug  candidates  are  common  in  aforementioned  liver  diseases  and  reside  in
metabolism of cholesterol and inositol phosphate as well as triacylglycerol synthesis. Hmgcr
was identified as a potential drug candidate in my in silico study and also was used as a
target of statins drugs. In addition, based on a review of literature I propose some novel
potential drug candidates, such as, Agpat6, Isyna1, Acaca and Acacb, but of course it would
require experimental validations. 
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Fig 3.22. Inositol phosphate metabolism. 
In this pathway, D-glucose-6 phosphate that is a product of glycolysis, is converted
to  myo-inositol.  Isyna1  is  involved  in  a  rate-limiting  step  of   myo-inositol
biosynthesis. The identified possible candidates for drug targets are shown in red
color. 
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3.4.2 Reduction of flux through reactions associated with SREBP 
target genes 
Sterol regulatory element binding proteins (SREBPs) are transcription factors that regulate
cholesterol, fatty acid, triacylglycerol and phospholipid synthesis (Eberlé et al., 2004). There
are three isoforms of SREBP, SREBP-1a, SREBP-1c and SREBP2 in mouse. SREBP-1c has
been shown to play a key role in hepatic steatosis (Kim et al., 2010). The SREBP activation
is  essential  for  development  of  diabetic  fatty liver  (Moon et  al.,  2012).  Experimentally
measured  protein  level  of  SREBP-1 and SREBP-2  were found to  be  upregulated  (1.70,
1.31)-fold,  (1.51,  1.34)-fold  and  (1.84,  1.6)-fold  for  the  A/J,  C57Bl6  and  PWD  mice,
respectively. The  upregulation  of  SREBP proteins  may  lend   steatosis  and  it  leads  to
formation of lipid droplets. 
The goal here is to find drug targets for steatosis by knocking out the target genes of SREBP.
To address this, first of all, the target genes of SREBP were obtained from Reactome (Croft
et al., 2011).  Secondly, a  biomass  reaction of steatosis was introduced in the  GMM model
(section 2.6)  and  the  flux  through  the  biomass  reaction  was used  as  a  readout  of the
formation of lipid droplets. The flux through the objective reaction was maximized and the
obtained flux distribution of the GMM model is called by  vopt.  Furthermore,  an  in silico
knock out simulation for each target gene of SREBP was done by imposing a constraint on
the set of target gene associated reactions. If r is a reaction in set of target gene associated
reactions then the upper and the lower bound of the reaction  r  is equal to  vopt (r )×0.5  if
vopt(r) is positive and  −vopt (r )×0.5  if vopt(r) is negative. Rates of reduction of lipid droplets
after knockout gene targets, are shown in Figure 3.23.
To observe whether the expression patterns of SREBP target genes are changed due to DDC-
treatment or not.  Ratios of expression data between DDC-treated vs. control of target genes
are listed in Table 3.4.  In my in silico analysis, the genes Cyp51,  Hmgcr,  Lss,  Sqle,  Pmvk,
Fdps, Mvd have higher upregulation in PWD than in C57Bl6 mice (Table 3.3) and knockout
of these genes reduces the formation of lipid droplets (Fig  3.16).  Thus, these genes may
become drug targets of steatosis. Histological improvement of NAFLD and the reduction in
the  hepatic steatosis  are  found using the treatment with statins  which inhibit  an enzyme
HMG-CoA reductase  (Hmgcr) of cholesterol  biosynthesis  (Ekstedt  et  al.,  2007;  Ji  et  al.,




Table  3.4. Target genes of SREBP.  Ratios between DDC-treated vs
control of expression data are calculated.
Genes A/J_ratio C57Bl6_ratio PWD_ratio
Cyp51 1.38 1.21 1.51
Dhcr7 1.18 0.83 0.65
Fasn 0.82 0.43 0.63
Fdft1 1.16 0.8 1.16
Ggps1 1.53 1.08 1.18
Gpam 0.59 0.7 0.37
Hmgcr 2.31 1.6 11.6
Lss 1.07 1.15 2.51
Mvk 1.02 0.83 1
Sqle 1.42 0.92 1.4
Pmvk 1.05 0.83 1.61
Tm7sf2 0.49 0.4 0.43
Acacb 0.78 0.74 0.34
Acaca 1.87 1.4 0.99
Fdps 1.07 0.72 1.48
Mvd 0.9 0.67 1.78
Sc5d 0.45 0.71 0.36
Idi1 0.96 0.84 1.8
Figure 3.23. Knock out of SREBP targets. 
Glucose and lipid  are used as external source of the GMM model for the formation of lipid
droplets. Each SREBP target gene was knocked-out and the change (before vs after knockout )
of flux through the reaction of lipid droplets are shown. 
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3.5 Qualitative and quantitative modeling
Based  on  over  representation  analysis  of  gene  expression  and  metabolic  profiles  the
arachidonic acid (AA) metabolic pathway was found to be deregulated for DDC-treated mice
(section 3.1.1). Metabolites can be seen as end points of perturbations occurring at the gene
level and the gene expression data might explain the metabolite data (Hoppe, 2012). Hence,
to  predict  the  change  in  metabolic  concentrations gene  expression  data  can  be  used  to
integrate into the metabolic models for in silico studies. Change in metabolite concentrations
can  be  done; for  example,  how many metabolites  are  up-  or  downregulated under  two
conditions. To address this, two modeling approaches Monte Carlo ODE- and Petri net-based
can be used (Ruths et al., 2008; Wierling et al., 2012). In Monte Carlo ODE-based one can
integrate  quantitative  data  (e.g.,  gene  expression  data),  but  cannot  predict  quantitatively.
Hence, the prediction is termed in this study as “semi-quantitative”. An alternative to Monte
Carlo ODE-based, a Petri net-based method proposed by Ruths et al., (2008) can be used for
a qualitative analysis such as, how many predictions are in agreement or disagreement. One
can compare the results of the simulation of Monte Carlo ODE- and Petri net-based methods.
The aim of this study is to understand the perturbation of metabolites of AA pathway that is
identified as a perturbed candidate  due to DDC-treatment.  Both  simulation methods were
used and the results were compared with the experimental data. 
There are only a few kinetic models of the AA metabolism available in the literature. For
instance, Yang et al. (2007) proposed a kinetic model of AA metabolism in human. However,
this model does not include some important metabolites, such as leukotriene D4, leukotriene
C4, prostaglandin I2 and prostaglandin F2α (Yang et  al.,  2007).  Another  example is  the
proposed model of  Gupta et  al.,  (2009) in which leukotriene D4, leukotriene C4 are not
included.  These  proposed models  are  not  large  enough  for  proper description of  the
experimental data. Hence, we compiled for this study a more comprehensive in silico model
of the AA metabolism based on information from KEGG  (Kanehisa and Goto,  2000),  a
biochemical  text  book  (Michal  and  Schomburg,  2013) and  the  thesis  of  Schulz,  (2012)
(Figure 3.24).
3.5.1 Semi-quantitative analysis using Monte Carlo ODE-based 
approach 
An appropriate distribution for the kinetic parameters was derived from 871 kcat values of
mouse enzymes extracted from BRENDA (Scheer et al., 2011). The kcat values follow a log-
normal distribution with mean 0.35 and standard deviation  (SD) 3.5  (Figure  3.25). Here, I
applied a Monte Carlo-based approach to study the biochemical network of AA metabolism,
in which reactions are modeled by mass action kinetics and kinetic parameters were sampled
from  the  aforementioned  log-normal  distribution  (mean=0.35;  SD=3.5; Wierling  et  al.,
2012). This allows to study the biological system using a broader parameter space instead of
using  parameters,  which  were  measured  only  under  specific,  e.g.,  in  vitro conditions.
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Enzyme amounts are assumed to  depend  linearly  on the  respective RNA-Seq-based gene
expression values that were used to model enzyme concentrations.
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Figure 3.24. Model of arachidonic acid metabolism. Reactions, metabolites and enzymes
are represented with rectangular, ellipse and hexagonal boxes, respectively. Dotted lines link
enzymes with their respective reactions and  solid lines indicate the mass flow through the
system. Full names of components of the arachidonic acid metabolism model are abbreviated
according to the following notations:  prostaglandin I2, PGI2; leukotriene A4, LTA4; 5(S)-
Hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic  acid,  5-HPETE;  5-
Hydroxyeicosatetraenoate, 5-HETE; leukotriene B4, LTB4; Thromboxane B2, TXB2; 15(S)-
Hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic  acid,  15-HPETE;  14,15-EET,  14,15-EET;
12-Hydroxyeicosatetraenoate,  15-HETE;  12-Hydroxyeicosatetraenoate,  12-HETE;  6-Keto-
prostaglandin F1alpha, 6k-PGF1alpha; Prostaglandin E2, PGE2; 20-OH-Leukotriene B4, 20-
OH-LTB4; Prostaglandin F2alpha, PGF2alpha; leukotriene C4, LTC4; arachidonic acid, AA;
prostaglandin D2, PGD2; prostaglandin H2, PGH2; thromboxane A2, TXA2; leukotriene D4,
LTD4; leukotriene A4 hydrolase, LTA4H; glutathione peroxidase 3, GPX; arachidonate 5-
lipoxygenase, ALOX5; phosphatidylcholine, PC; phospholipase A2, PLA2; prostaglandin I2
(prostacyclin)  synthase,  PTGIS;  leukotriene  C4  synthase,  LTC4S;  arachidonate  12-
lipoxygenase,  ALOX12;  sink  arachidonic_acid,  Sink_AA;  leukotriene-B4  20-
monooxygenase,  CYP4F;  cytochrome P450, CYP2J; thromboxane A synthase 1,  TBXAS;
prostaglandin  D2  synthase,  PTGDS;  prostaglandin-endoperoxide  synthase  1,  PTGS1;
prostaglandin  E  synthase  ,  PTGES;  arachidonate  15-lipoxygenase,  ALOX15;
geranylgeranyltransferase type I, CGT1; carbonyl reductase 3 , CBR; 
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The AA
release is catalyzed by phospholipase A2 (PLA2). In endothelial cell-pericyte co-cultures of
rat  cells  it  was  shown that  PLA2 is  induced  through the  activation  of  the  MAPK/ERK
cascade  (Anfuso et al., 2007).  PLA2 is involved in inflammation driven liver fibrosis as a
key feature  of  progressive  NASH and  PLA2 deficiency prevented  activation  of  hepatic
stellate cells and infiltration of F4/80-positive macrophages  (Ishihara et al., 2012). Within
our experiments the protein amount of phosphorylated ERK (pERK) was measured for the
control and the DDC-treated mice using the reverse phase protein array (RPPA) technology.
The ratios of pERK from DDC-treated vs. control samples were 1.90, 2.09 and 1.98 for A/J,
C57Bl6 and PWD mouse liver samples, respectively. The effect of pERK on PLA2 activity
was taken into account by multiplying the RNA-Seq expression value of PLA2 for the DDC-
treatment  simulation with the pERK ratio.  I  chose the gene  whose  expression data  have
lowest p-value (DDC-treated vs control) if the enzymes of a reaction is encoded by more
than one gene.
An example  of mapping the  RNA-Seq  expression  to  enzyme concentration  is  described
below. Assume, a mass action kinetic equation, 
                                                                  
              v=k cat×E×S  (3.4)
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Figure 3.25. Distribution of kcat values. Distribution of mouse-specific kcat values from
BRENDA database following a log-normal distribution (mean 0.35, standard deviation 3.5).
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where v is the flux, kcat is the enzymatic turnover number, E is the enzyme concentration, and
S is the substrate concentration. Tissue specific RNA-Seq expression of gene are available
and it can be used as a rough estimation for enzyme concentration. Assumption is that RNA-
Seq expressions are linearly dependent on enzyme concentrations. Thus, the aforementioned
equation is transformed in equation (Stavrum et al., 2013),
                                                                 
          v=k cat×u×rseq×S  (3.5)
where rseq is the experimentally measured RNA-Seq expression value of gene that encode
enzyme  (unitless),  and  u is  a  unit  used  to  convert  RNA-Seq  expression  to  enzyme
concentrations.  Unit  u  must  be  determined  to  obtain  meaningful  absolute  fluxes  and
metabolite steady state concentrations of the biological model. However, the relative change
of  steady  state  concentrations  of  substrates  and  products  of  enzymatic  reactions  is
independent of  u (Stavrum et al., 2013).  I did a qualitative analysis  of relative change of
steady state metabolite concentration in the AA model, and I set an arbitrary value 1nM to u.
Initial  concentrations  of  enzymes  of  the  AA model  are  estimated  based  on  RNA-Seq
expression data  for three mouse strains A/J, C57Bl6 and PWD in control as well as DDC-
treated conditions (Table 3.5). Initial concentrations of every metabolites of the AA model is
set to 1nM. Mass action kinetics is used for every reaction in the AA model.   
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3.5.2 Qualitative analysis using Petri net-based simulator
One goal of this analysis is to understand the perturbation in metabolic concentrations of the
AA pathway that  can  occur  due  to  change in  gene  expression  data.  To address  this,  an
alternative to Monte Carlo ODE-based method, a Petri net-based method was used to know
which method provides a better prediction. The signaling Petri net-based simulator (SPN) is
a simulator that uses Petri net modeling paradigm (Ruths et al., 2008) (section 2.8). The SPN
simulation is used to characterize the dynamics of signaling networks. Here, I modified the
firing scheme of the SPN to understand the metabolic pathways. An original python source
code  (http://www2.informatik.hu-berlin.de/top/pnk/#python)  of  Petri  net  simulator  was
modified  to  implement  the  Petri  net-based  simulator  of  metabolic  pathways  and  this
simulator is abbreviated as MPN in this study. The MPN was used to simulate the AA model.
Furthermore, the prediction of changes in metabolic concentration was tested using MPN for
the AA model.
Petri  net representation of an enzymatic reaction (substrate,  AA; product,  5-HPETE; and
enzyme, Alox5) of the AA model is illustrated in Figure 3.26. This reaction is represented as
the transition t.  Assume that  before execution/fire  of  the transition t,  the places,  AA, 5-
HPETE and Alox5 contains 20, 15 and 15 tokens, respectively. When t fires tokens of AA
can reduce, tokens of 5-HPETE can increase, and tokens of Alox5 remain unchanged. 
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Table 3.5. Initial concentration of enzymes of AA model.  Enzymes are approximated by
RNA-seq expression of genes (RPKM values).
Genes AJ control AJ DDC B6 control B6 DDC PWD control PWD DDC
Lta4h 6.29 8.64 10.27 11.96 11.08 6.91
Gpx3 8.47 55.18 8.38 98.03 8.02 155.78
Alox5 0.08 0.50 0.22 1.04 0.06 0.24
Pla2g12a 8.25 20.87 8.43 35.14 7.14 22.99
Ptgis 1.36 3.57 1.08 9.01 0.55 0.78
Ltc4s 1.24 2.03 4.40 5.16 0.77 2.35
Alox12 0.04 0.16 0.03 0.51 0.04 0.30
Cyp4f18 0.21 6.60 0.67 9.22 0.41 6.62
Cyp2b10 0.46 55.49 0.64 45.23 0.01 83.76
Tbxas1 0.84 4.84 1.00 5.65 0.23 2.99
Hpgds 0.19 1.71 0.06 1.93 0.01 0.26
Ptgs1 3.78 8.04 4.95 6.99 1.02 2.15
Ptges3 4.71 4.95 12.19 5.71 10.84 8.11
Alox8 0.17 0.03 0.03 0.25 0.70 0.06
Ggt1 0.10 2.15 0.02 0.77 0.01 1.13
Cbr3 0.73 61.73 0.71 47.95 0.16 0.80
3 Results
In  the  AA model,  each  place  p  may  act  as  a  substrate,  a  product,  or  an  enzyme  .
Stoichiometric coefficient of substrates and products of a reaction are assigned as a weights
to the edges from a substrate to a transition and from a transition to a product, respectively.
In MPN, when a transition t executes/fires the tokens of places are updated according to the
following steps:
Step 1:  For each substrate, s, of t compute  ⌊m(s )
c
⌋  and put in the set SS where, m(s) and c
are the number of tokens and stoichiometric coefficient of s, respectively,  and SS is the set
which contains  number of  tokens as  an element.  In  case  of  Fig 3.26 a,  AA is  the only
substrate  of  t  and the execution of  step  1 returned 20 tokens ( ⌊ 20
1
⌋=20 ).   The set  SS
contains 20 tokens as an element.
Step  2: Calculate  speed=random(0, min (min (SS ) ,m(e )))  where,  m(e)  is  number  of
tokens of the enzyme e and min(SS) is the minimum of the set SS. In case of Figure 3.26 the
transition t  has an enzyme  Alox5 and a substrate AA and  the evaluation  min(min(20),15)
results in 15 tokens. Now, 15 tokens are used to execute the aforementioned formula of the
speed.  Then  assume that  random(0, 15)  returns 8.  Thus, 8 tokens are  assigned to  speed  or
firing rate of the transition t. 
Step 3: Update tokens after firing t. For each substrate and product of t, c∗speed  tokens are
subtracted  and  added  to  the  corresponding  substrate  and  product.  Enzyme  of  t  remains
unchanged. After firing t, 8 tokens are subtracted from the tokens of AA and added to tokens
of 5-HPETE (Fig 3.25 a). Finally, after firing t a state  illustrated in Fig 3.26 b is obtained.
Tokens of AA, 5-HPETE and Alox5 are 12, 23, and 15, respectively.
Defining the initial state of MPN
The aim of this work is to understand perturbation of metabolic concentrations using the
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Figure 3.26. A Petri net model of a reaction (substrate AA; product  5-HPETE;
and  enzyme  Alox5).  Circular  and  rectangular  node  represents  place  and
transition. Marking state a) before fire of the transition t b) after fire of t.
3 Results
RNA-Seq expression data. To accomplish this, a Petri net-based approach (MPN) is used to
understand changes in metabolic concentrations. Setup of the initial state is required to run
the MPN.  For using the MPN,  experimentally measured expression data is  required to be
transformed in tokens. Using expression data the initial state of enzymes of the AA model is
shown  in  Table  3.5.  This  table  is  used  to  transform  expression  data into  tokens.  For
transformation, first of all, row-wise expression values of each gene in Table 3.5 are used to
calculate mean and standard deviation (SD). A cutoff is set to mean+0.5*SD that is used for
cutoff1 and another cutoff is set to mean-0.5*SD that is  used cutoff2. Expression data was
transformed into tokens using the following steps: 
1) 40 tokens are chosen for the high expression (if expression is greater than the cutoff1) 
(Ruths et al., 2008).
2) 5 tokens are chosen for the low expression (if the expression is less than cutoff2).
3) 20 tokens are chosen if the expression is in between cutoff1 and cutoff2.
Table 3.6 is obtained by using aforementioned steps to Table 3.5 and subsequently Table 3.6
is used to initialize the AA model for MPN simulation. 
The source, phosphatidylcholines (PC), and the sink_AA are fixed components in the AA
model and they are set to 20 tokens. Except source and sink, the remaining metabolites of the
AA model is set to 0 tokens. 
The MPN is simulated by two-time scale approach same as the SPN (section 2.8). 
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3 Results
Comparison of  relative change in metabolic concentrations (Monte Carlo  ODE-based
vs Peri net-based)
Enzymes of the AA model is initialized by Table 3.5 and 3.6 for the strategy Monte Carlo
ODE-based and Petri net-based (MPN), respectively. For three mouse strains in control and
DDC-treated  conditions,  both strategies are  used to  understand the changes  in metabolic
concentrations based on perturbation in gene expression data.
We sampled 1000 sets  of kinetic  parameters from a log-normal distribution (μ=0.35 and
σ=3.5) for the Monte Carlo ODE-based approach  (Wierling et  al.,  2012).  The geometric
mean (geomean) ratios (section 2.5) were calculated for the simulated metabolites. 
The AA model  is  simulated  20000  times using  MPN.  Each simulation runs for  40 time
blocks  (section 2.8).  Average  over  20000  simulations  were  used  as  time  block-course
simulation. After 15 time-blocks a kind of steady state was found for each metabolite of the
AA model.  To judge a kind of steady state for each metabolite of the AA model, first of all, I
calculated  the  mean  concentration  value  and  standard  deviation  of  time  block-course
simulation  from  15 to  40  blocks  and  then  calculated  coefficient  of  variations.  Each
components of the AA model has  <1% variation in concentration between time block 15 to
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LTA4H 5 20 40 40 40 5
GPX 5 20 5 40 5 40
ALOX5 5 20 20 40 5 20
PLA2 5 20 5 40 5 40
PTGIS 20 20 5 40 5 5
LTC4S 5 20 40 40 5 20
ALOX12 5 20 5 40 5 40
CYP4F 5 40 5 40 5 40
CYP2J 5 40 5 20 5 40
TBXAS1 5 40 5 40 5 20
PTGDS 5 40 5 40 5 5
PTGS1 20 40 20 40 5 5
PTGES 5 5 40 5 40 20
ALOX8 20 5 5 20 40 5
GGT1 5 40 5 20 5 40
CBR 5 40 5 40 5 5
3 Results
40.  Thus,  the  AA model  reached  a  kind  steady  state and  aforementioned  the  mean
concentration  value  is  used  as  the  steady  state  concentration. Ratios  (DDC-treated vs.
control) of concentrations were calculated for the simulated metabolites. 
For mouse strains A/J, C57Bl6 and PWD, relative changes between DDC-treated vs control
conditions of metabolic concentrations are shown in Figure 3.27. An analysis of the direction
of  change  was  done,  in  which  the  metabolites  were  classified  as  upregulated or
downregulated. Metabolites  are considered as upregulated if their log2 ratios were greater
than 0.25, as downregulated if their log2 ratios were below -0.25, and as unchanged if their
log2 ratios were  between -0.25  and 0.25.  Based on this  classification,  metabolites were
categorized as in agreement or disagreement between experimental and simulated results. If
both, experimental and simulated metabolite changes went into  the same direction (up or
down), they were considered as correctly predicted.
Out of 13 experimentally measured metabolites of the AA pathway, 5, 5, and 7 metabolites
were  correctly predicted  regarding up/down regulation  using Monte Carlo ODE-based for
the  mice  A/J,  C57Bl6  and  PWD  respectively.  Using  the  MPN  approach  7,  8,  and  9
metabolites were predicted correctly regarding up/down regulation for the mice A/J, C57Bl6
and PWD, respectively. The MPN has higher prediction rate of the metabolic changes than
Monte Carlo ODE-based for the AA model. However, both methods are not able to predict
the quantitative metabolic concentration ranges. 
Using  ODE-based  Monte  Carlo  method  the  metabolites  12-HETE and  14,15-EET were
always  in  agreement  in A/J,  C57Bl6  and  PWD  mice.  Thromboxane  B2  (TXB2)  and
prostaglandin D2 (PGD2) were in agreement  in  C57Bl6 and PWD mice. Leukotriene B4
(LTB4) was in agreement in the A/J and PWD mice. Arachidonic acid (AA), and 15- and 5-
HPETE were in disagreement in all three mice. 
Using Petri  net-based (MPN) method the  metabolites  15-HETE,  15-  and 5-HPETE,  and
14,15-EET were always in agreement  in A/J, C57Bl6 and PWD mice. AA, 12-HETE and
PGD2 were in  agreement  in the C57Bl6 and PWD mice.  Prostaglandin E2 (PGE2)  was




One limitation of both simulation approaches is that they can be only used for the qualitative
or semi-quantitative  prediction. Thus, in the subsequent section I have built a small-scale
kinetic model of the AA pathway for a better understanding of metabolic changes as well as
the range of the absolute experimental concentration. 
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Figure  3.27. Comparison  of  Petri  net-  and  ODE-based  results.
Comparison  is  done  for  the  relative  change  (DDC-treated  vs  control)  of
metabolic  concentration  using  Petri  net-   and  Monte  Carlo  ODE-based
method. Bar associated with '*' indicates that log2 ratio were greater or less
than 2 or -2.  
3 Results
3.5.3 Quantitative model for the arachidonic acid metabolism
Based on pathways analysis of gene expression and metabolic profiles arachidonic acid (AA)
pathways  was identified  as  an affected  candidate  due  to  DDC-treatment  (section  3.1).
Furthermore, the metabolites PGD2, 5-HPETE, 15-HETE and 15-HPETE of the AA pathway
have been observed to  be  significantly (p<0.05)  changed in  concentration  due  to  DDC-
treatment in mouse liver samples. One aim of this study is to construct a small-scale kinetic
model that can explain the deregulation of aforementioned metabolites of the AA pathway. In
addition, the AA kinetic model can be used for  in silico knock-out experiment such as the
identification of drug targets. 
Arachidonic acid (AA) is a fatty acid usually coming from dietary animal sources or being
synthesized  from  dietary  linoleic  acid. AA is  present  in  cell  membranes  as  a  part  of
phospholipids.  AA  is  released  from  phospholipids  by  phospholipase  A2  (PLA2) and
subsequently  it  acts  as  a precursor  of  prostaglandins  and  their  related  compounds,  the
prostacyclins,  thromboxanes  and  leukotrienes.  There  are  several  physiological  effects  of
prostaglandins described in the literature, such as inflammatory response, pain, fever, blood
pressure, blood clotting, and regulation of sleep/wake cycle (Hayaishi, 1991; Miller, 2006).
Cyclooxygenase-1,  also  known  as  prostaglandin  H2  synthase  1  (Ptgs1),  catalyzes  the
reaction  of  arachidonate  to  prostaglandin  H2  (PGH2),  which  is  the  precursor  of  other
prostaglandins,  prostacyclins,  and  thromboxanes.  The  enzyme  5-lipoxygenase  (Alox5)
produces 5-HPETE, which is a precursor of leukotrienes. 
There are only a few kinetic models of the AA metabolism available in the literature to study
anti-inflammatory drugs of human polymorphonuclear leukocytes  (Yang et al.,  2007) and
macrophage cells  (Gupta et al., 2009).  Here, an  in silico model of the AA metabolism in
mouse liver was developed based on information from KEGG (Kanehisa et al., 2012)  and a
biochemical  text  book  (Michal  and  Schomburg,  2013) to  study  the  regulation  of  the
perturbed metabolites using the related transcriptomics and proteomics data. The structure of
the model is depicted in Figure 3.28.
The  downstream  synthesis of  prostaglandins  and  leukotrienes  is  initiated  by signal
transduction  and  subsequent  release  of  AA catalyzed  by  phospholipase  A2  (PLA2).  15-
lipoxygenase (ALOX15) is  an  important regulator of inflammation and apoptosis  and its
expression is regulated by a cytosolic signaling complex with protein kinase C delta (PKCD)
and phosphorylated STAT3 (Bhattacharjee et al., 2006). Thus, RPPA data of phosphorylated
ERK and STAT3 could be used subsequently for the modeling to  describe the activity of
PLA2 and PKCD, respectively.
The eicosanoid pathway is regulated by several feedback mechanisms (see Figure 3.28). The
release of AA is controlled by an inhibitory link between AA and phospholipase A2 (PLA2,
R1 in Figure 3.28,  (Geddis et al., 2004)). The production of leukotriene A4 (LTA4) and 5-
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HPETE is controlled by inhibiting 5-lipoxygenase (ALOX5; R2, R4, (Aharony et al., 1987;
Lepley and Fitzpatrick, 1994)). The synthesis reactions of 15-HPETE, 15-HETE, and PGH2
are controlled by feedback inhibition of 15-lipoxygenase (ALOX15), glutathione peroxide
and PTGS1, respectively (R6, R7 and R9,  (Mahipal et al.,  2007; Yang et al.,  2007). The
synthesis of leukotrienes from AA via 5-HPETE, such as leukotriene A4, is catalyzed by two
different enzymes, ALOX5AP and 5-lipoxygenase (ALOX5; R2, R4).
I hypothesize that changes of metabolite concentrations of the AA pathway can be explained
by changes in mRNA expression. To address this hypothesis, changes in Vmax values of
enzymatic  reactions  were  approximated  by fold  changes  of  RNA-Seq  expression  of  the
respective enzymes due to DDC treatment. The fold change of PLA2 was approximated by
Pla2g4a which is expressed at a low level (<1 RPKM; Gan et al., 2010) but not differentially.
Therefore, I hypothesize that PLA2 is at least present to trigger AA release upon its activity
state,  but it  is not differentially expressed due to DDC treatment. Similarly,  ALOX5 and
ALOX15  are  approximated  by  Alox5  (p-value=0.13)  and  Alox15  (p-value=0.62),
respectively,  which are expressed at  low level  (<1 RPKM) and we hypothesize  that  the
expression of these genes are not affected due to DDC-treatment. PTGDS is approximated
by  Ptgds  expression,  but  it  is  not  significantly  changed  due  to  DDC  treatment  (p-
value=0.64).  If there are several isoenzymes that can catalyze the same reaction the most
significantly  differentially  expressed  gene  was  chosen. For  instance,  GPX  can  be
approximated by Gpx1,  Gpx2,  Gpx3,  Gpx6 and  Gpx7. Since  Gpx3 is significantly affected
(p=2.66e-041) and highly expressed it is used to initialize the GPX expression in the model.
Fold changes of the enzymes PTGS1, ALOX5AP and PKCD are approximated by expression
values of Ptgs1, Alox5ap and Prkcd, respectively. 
Within  our  experiments  the  protein  amount  of  phosphorylated  ERK  (p-ERK)  and
phosphorylated STAT3 (p-STAT3) were measured for both control and DDC-treated mice
using  the  reverse  phase  protein  array  (RPPA)  technology.  p-ERK  and  p-STAT3  are
upregulated due to DDC treatment (fold changes of p-ERK and p-STAT3 in A/J, C57Bl6,
and PWD are 1.90, 2.09, 1.98, and 1.41, 1.42, 2.03, respectively). The effect of p-ERK on
PLA2 is modeled by the product of the RNA-seq expression value of PLA2 for the DDC-
treatment simulation and the p-ERK ratio. Similarly, the effect of the complex formation of
PKCD and p-STAT3 on the ALOX15 activity is described by the product of the RNA-seq
expression value of ALOX15 of the DDC-treatment and the fold  change of  p-STAT3 and
PKCD, respectively.  Phosphatidylcholine (PC) is  modeled as a fixed component and as its
initial  concentration  the  measured  concentration  of  phosphatidylcholine  C33:2 was  used
(Table 3.7). The experimentally identified fold  changes of all enzymes are summarized in
Table 3.7 and were used to approximate the fold changes of the maximum reaction rates





Figure  3.28:  Detailed  kinetic  model of  arachidonic  acid  /  eicosanoid  metabolism.
Abbreviations  of  the  AA  model:  phosphotadicholine  (PC),  arachidonic  acid  (AA),
phospholipase A2 (PLA2), phosphorylated ERK (P-ERK), Cyclooxygenase-1, also known
as  prostaglandin  G/H  synthase  1  (PTGS1),  protein  kinase  C  delta  (PKCD),  signal
transducer  and  activator  of  transcription  3 (STAT3),  arachidonate  15-lipoxygenase
(ALOX15),  arachidonate  5-lipoxygenase  (ALOX5),  arachidonate  5-lipoxygenase-
activating  protein  (ALOX5AP),  prostaglandin  H2  (PGH2),  prostaglandin  D2  (PGD2),
prostaglandin D2 synthase (PTGDS), 15-hydroxyeicosatetraenoic acid (15-HETE), 5- and
15-hydroperoxyeicosatetraenoic  acid  (5-  and  15  -HPETE),  leukotriene  A4  (LTA4),
glutathione peroxidase (GPX).
3 Results
Quantitative modeling requires kinetic parameters for each reaction. Such parameters have
been  mostly  measured  for  very specific  experiments  and  conditions.  The  availability  of
appropriate kinetic parameters to model cellular systems is limited, e.g., kinetic databases
like BRENDA (Scheer et al., 2011) and SABIO-RK (Wittig et al., 2012) can only provide a
limited  number  of kinetic  parameters.   To  build  a  quantitative  model  for  the  AA liver
metabolism kinetic parameters of the model were optimized. Using data of DDC treatment
vs control  I built a quantitative model to explain changes  of metabolites of the eicosanoid
pathway due to treatment by DDC that mimics the NASH phenotype.
Kinetic Equations. Mass action kinetics is used for reactions R3, R5, R8, R11 and R12 as
well as R1, R2, R4, R6, R7 and R9 are model with Michaelis-Menten kinetics (Figure 3.27;
Table 3.8; Yang et al., 2007). Mass action kinetic is used for R10 which is catalyzed by an
enzyme (Figure 3.27; Table 3.8; Gupta et al., 2009). 
Model Optimization.  Model parameters were optimized using experimentally determined
metabolite  concentrations  of  the  model  components.  Metabolite  concentrations  were
measured after 8 weeks of DDC treatment and interpreted as steady state concentrations for
the model. The metabolites PGD2, 5-HPETE, 15-HPETE and 15-HETE have been found as
being affected due to DDC treatment.  These metabolites as well as upstream AA were used
for model optimization.  Therefore,  the model was simulated into its  steady state and the
euclidean  distance  between  simulated  steady  state  concentrations  and  experimental
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Table  3.7. Initial values of the arachidonic acid / eicosanoid metabolism model.
The enzyme concentrations of the control state were always initialized with 1.0
nM. The DDC initial value always reflects the fold change between the DDC-
treated  and  the  control  expression  value.  The  absolute  concentration  of
phosphatidylcholine C33:2 (PC*) comes from MS-analysis  and is  measured in












PTGS1 1.00 2.13 1.00 1.41 1.00 2.09
ALOX5 1.00 1.00 1.00 1.00 1.00 1.00
PTGDS 1.00 1.00 1.00 1.00 1.00 1.00
STAT3 1.00 1.41 1.00 1.42 1.00 2.03
PKCD 1.00 4.30 1.00 4.48 1.00 3.85
GPX 1.00 6.51 1.00 11.70 1.00 19.42
PLA2 1.00 1.90 1.00 2.09 1.00 1.98
ALOX5AP 1.00 4.81 1.00 6.30 1.00 14.23
ALOX15 1.00 1.00 1.00 1.00 1.00 1.00
PC* 269.00 206.00 249.00 209.00 266.00 255.00
3 Results
metabolite data  of the aforementioned metabolites were used in an objective function to
optimize the kinetic parameters using COPASI (Hoops et al., 2006). Parameter optimization
was done  using the metabolic  concentrations  of  C57Bl6 control  and  C57Bl6 DDC mice
(section 2.9).  Kinetic parameters, i.e., the maximum reaction rates (Vmax), Michaelis-Menten
constants (Km) and inhibition constants (Ki) were optimized based on experimental data.
The following five metabolites of the AA model are used to formulate an objective function:
AA,  5-HPETE,  and  15-hydroperoxyeicosatetraenoic  acid  (15-HPETE),  15-
Hydroxyeicosatetraenoic (15-HETE), and  prostaglandin D2 (PGD2).  Let  aforementioned
metabolites be in a set M. A constructed objective function, f, is (section 2.9):
f (K )=sqrt (∑x∈M ( ([ x ]ec−[x ]sc,K )[ x ]ec )
2
+( ([ x]ed−[ x ]sd,K )[ x ]ed )
2
) (3.6)
where, K is set of kinetic parameters of the AA model. “ec” and “sc” represent experimental
and simulated steady state concentration in control condition, while “ed” and “sd” represent
experimental  and  simulated  steady  state  concentration  in  DDC-treated  condition.  The
objective function,  f, is minimized to obtain optimal kinetic parameters of the AA model
using the genetic algorithm of COPASI with a population size of 50 and a generation size
500. The identified kinetic parameters are listed in Table 3.8.  
Table 3.8. Kinetic equations and their parameters of the arachidonic acid / eicosanoid metabolism model.
A,  A1,  A2 and  A3 are the ratios of gene expression or protein levels of the respective enzymes between
DDC-treated vs. control mice. S is the substrate of the corresponding reaction. Squared brackets refer to
concentration values and curly braces indicate fold changes of DDC treatment vs. control. The Km value of




Reactions Kinetic equations Kinetic parameters





Vmax=20.56 nM2s-1, Km=2500 nM(*) , 
Ki=100 nM, A1={PLA2}, A2={PERK}, 
I=[AA] nM, S=[PC] nM





Vmax=0.01 nM2s-1 , Km=0.0107 nM, 
Ki=8.603 nM, A1={ALOX5}, 
A2={ALOX5AP}, I=[5-HPETE] nM, 
S=[AA] nM
R3: 5-HPETE → K cat×S S=[5-HPETE], Kcat=0.0012s-1





Vmax=9.7953 nM2s-1, Km=99.913 nM, 
Ki=0.709 nM, A1={ALOX5}, 
A2={ALOX5AP},  I=[LTA4] nM, 
S=[5-HPETE] nM
R5: LTA4 → K cat×S S=[LTA4] nM, Kcat=0.0012 s-1





Vmax=0.003 nM3s-1, Km=0.067 nM, 
Ki=1.004 nM, A1={ALOX15}, 
I=[15-HPETE] nM, A2={PKCD}, 
A3={PSTAT3}, S=[AA] nM







Vmax=1.098 nMs-1, Km=1.58 nM, 
Ki=0.0106 nM, A1=ALOX15, 
I=[15-HETE] nM, S=[15-HPETE] nM
R8:15-HETE → K cat×S S=[15-HETE], Kcat=0.00127 s-1





Vmax=0.168 nMs-1, Km=3.876 nM, 
Ki=0.013 nM, A={PTGS1}
I=[PGH2], S=[AA] nM
R10: PGH2 → PGD2 V max×S×A Vmax=0.067 nMs-1, A={PTGDS}, 
S=[PGH2]
R11:PGD2 → K cat×S S=[PGD2] nM, Kcat=0.052 s-1




Figure  3.29. Experiment  vs  simulated  metabolites.  Comparison  of  simulated
steady state and experimental metabolite concentrations of all three mouse strains
A/J, C57BI6, and PWD for  a) control  b) DDC treatment, and  c) their respective
ratio.
3 Results
Results of the fitted model for the metabolites AA, PGD2, 5-HPETE, 15-HPETE, and 15-
HETE using the trained C57Bl6 model were compared to the experimental results (Figure
3.29; C57Bl6_sim vs. C57Bl6_exp). Except  of  AA all  of  the aforementioned metabolites
were  upregulated  (>1.5  fold)  in  both,  experimental  and  simulated  data,  due  to DDC  in
C57Bl6 mice (Figure 3.29c). AA was not found altered in the experimental dataset, but was
slightly upregulated in the simulation (1.35-fold).
Using the trained model we predicted DDC-induced metabolite changes for A/J and PWD.
We observed an upregulation (>1.5-fold) of 5-HPETE, 15-HPETE and 15-HETE  in both
strains, which is in line with the experimental data. The concentration of PGD2 is found
increased (>1.5-fold)  in both experimental and simulated data for PWD (Figure  3.29c). In
A/J our modeling approach predicts a 2-fold increase of PGD2 concentration in response to
the  DDC-treatment,  but  the  experimental  data  showed  no  changes  (0.9  fold).  This
disagreement can be strain-specific because one can expect changes in the concentration of
PGD2 due to an upregulated gene expression of PTGS1 which is located upstream in the
metabolic pathway. AA is upregulated (>=1.5-fold) in DDC-PWD mice, which is concordant
with the experimental data,  while for A/J,  AA is not found as changed (0.9 fold) in the
experimental data, whereas a minor upregulation of 1.2-fold was predicted from simulated
data (Figure 3.29c).
Key regulatory enzymes of the DDC mouse model. To identify key regulatory enzymes of
the AA/eicosanoid pathway in DDC treated mice, a kind of sensitivity analysis of the trained
model was performed. Starting with DDC-treated mice of the A/J strain, each enzyme or
enzyme combinations were reverted to its/their activity in normal, untreated condition. This
analysis was performed for ALOX5AP, GPX, PKCD, PTGS1, pERK, and pSTAT3  whose
activity was found to be perturbed due to DDC-treatment.  A reference state was defined
where the activity of all enzymes is equal to the normal condition. Results of this analysis are
depicted in Figure 3.30. Reverting a single enzyme or combinations of two enzymes are not
sufficient  to  bring  the  DDC-treated  state  back  to  normal  because  it  affects  only  some
branches of the model as for example a change in the activity of ALOX5 has an effect on the
regulation of downstream metabolites 5-HPETE and LTA4 (cf. Figure 3.28). We found that
combinations of the enzymes ALOX5AP, PKCD and PTGS1 with either pERK or pSTAT3
can bring the DDC-treated metabolic state back to normal, with the exception of 15-HETE
and  AA.  Only  the  combination  ALOX5AP,  PERK,  PKCD,  STAT3,  and  PTGS1  or  the
combination of all six enzymes is able to bring back the DDC-treated state to normal.
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Simulating drug effects of DDC mouse model. To study potential drug targets for steatosis
or inflammation in silico drug tests were performed. For instance, cyclooxygenase-2 (COX-
2) is a frequent target of anti-inflammatory  drugs  (Jüni et al., 2002). The activity of each
enzyme of the A/J DDC model was inhibited by 3-, 6- and 9-fold, respectively. The effects of
those enzyme inhibitions on  the  regulation of metabolites are shown in Figure 3.31.  The
inhibition of PTGS1 and ALOX5AP leads to a downregulation of the respective downstream
components  (either  PGH2 and PGD2 or  5-HPETE and LTA4).  ALOX15 is  activated by
PKCD and pSTAT3, and the inhibition of PKCD or pSTAT3 leads to a downregulation of the
downstream components 15-HPETE and 15-HETE. It can be expected that the inhibition of
glutathione peroxidase (GPX) leads to a downregulation of the downstream component 15-
HETE, but the model predicted an upregulation of 15-HPETE and no change in 15-HETE.
This is due to the complex regulation of ALOX15, i.e., an activation of the complex PKCD
and pSTAT3 and an inhibition of GPX by 15-HETE.
In  conclusion,  I  propose  a  novel  hypothesis:  the  prediction  of  changes  in  metabolic
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Figure  3.31. In  silico  drug  analysis. An  in  silico drug  testing  of  the  arachidonic  acid/
eicosanoid  metabolism  model  was  done  by  simulation  of  individual  models  with  a
downregulated concentration of each enzyme as given by their respective expression value of
the A/J DDC data by a 1/3, 1/6 and 1/9 times. 
Figure  3.30. Heat  map of  sensitivity  analysis. A sensitivity  analysis  of  the  arachidonic  acid/
eicosanoid  metabolism model  was  done  by  simulation  of  individual  models,  which  brought  in
normal condition from A/J DDC state by the combination of enzyme as given by their respective
expression value of  the A/J control  data.  Color key indicates log 2-ratios.  Black dots  represent
corresponding enzymes got back from DDC-treated state to normal state. Red dots indicate that
combination of enzymes are able to bring back DDC-treated to normal conditions.
3 Results
concentrations based on gene expression data.  The  AA model is used to demonstrate the
hypothesis. To understand the changes of metabolic concentrations at  a  qualitative level I
used Monte Carlo ODE- and Petri net-based methods. In addition,  I modified simulation
algorithm of the Petri net-based method SPN in such a way that it can also handle metabolic
reactions.  The modified simulation method predicts  changes of metabolites at  qualitative
level with higher accuracy than than Monte Carlo ODE-based. Both methods cannot predict
the correct range of metabolic concentrations. Thus, I also build a detailed kinetic model of
AA to understand quantitative metabolic  concentrations and the model is  able to predict
changes of metabolic concentrations at qualitative and quantitative levels. The model  was
used to identify key regulatory enzymes and to simulate drug effects of DDC mouse model.




High-throughput  techniques  based  on  RNA-Seq technology  provide  a  flood  of  data
associated with biomolecules  at large scale. These data can be analyzed using  methods of
bioinformatics  and  systems  biology  in  a  variety  of  ways  depending  on  the  purpose  of
research. Identification of biomarkers for a disease is one of the common tasks where RNA-
Seq  data  can  be  effectively  employed. Several bioinformatics  methods  for  identifying
candidate disease genes were published (Chen et al., 2009; van Driel and Brunner, 2006). In
systems biology, a living organism is interpreted as an interacting and dynamical network of
genes, proteins, and biochemical reactions which regulate the function and behavior of that
organism (Chen and Wu, 2012). Systems biology is considered as a useful approach to reveal
the essential mechanisms of initiation and progression for complex diseases such as cancer,
steatohepatitis,  cardiovascular  disease,  and  diabetes  (Chen  and Wu,  2012).  The classical
biomedicine based on experimental biology which is mainly based on  studying individual
genes and proteins as simple systems has made marked progress in the comprehension of
diseases  progression.  However,  this  biomedicine  area  still  faces  challenges  in  the
understanding  of  complex  diseases (Chen  and  Wu,  2012).   Therefore,  systems  biology
techniques may be useful for analyzing the molecular mechanisms of complex diseases and
providing new insights to cure these complex diseases.  
Nonalcoholic  fatty  liver  disease  (NAFLD)  comprises  a  wide  spectrum of  liver  damage,
ranging from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis  (Alba and
Lindor,  2003).  To  better  understand the NAFLD progression  a mouse model system  was
used.  Using molecular data of  mouse  liver  samples  I have performed pathway analysis  to
identify pathways that may be involved in liver disease (section 3.1). Moreover, I performed
module analysis to identify most relevant modules related to liver disease based on fully
correlated  fluxes  and elementary  flux  modes  (section  3.2).  In  section 4.1 most  relevant
pathways and modules that may be involved in liver disease are discussed. 
To identify different degrees of flux regulation in all three mouse strains I have applied flux-
based analysis in which gene expression data  of  mouse liver samples are integrated into a
genome-scale metabolic model (section 3.3). I discuss the results of the integration of gene
expression data into the metabolic model in section 4.2. 
Furthermore,  I  have  identified  in  silico drug  targets  for  the  liver  disease:  steatosis,
steatohepatitis and HCC (section 3.4).  In  section 4.3 most  relevant candidates for potential
drug targets are discussed. 
Finally,  I  constructed  the arachidonic  acid  (AA) metabolic  model  that  is  identified  as a
deregulated candidate in molecular data of liver. The model was applied for the prediction of
changes of metabolic concentrations using gene expression data (section 3.5). In section 4.4,
I  discuss results related to arachidonic acid metabolic model. 
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4.1 Pathways and modules related to liver disease
To understand NAFLD progression  a mouse model system was used. Three mouse strains
were  fed a DDC-supplemented diet  that produces steatohepatitis-like phenotypes (section
3.1.1). Histidine, beta-alanine and purine metabolisms were identified as relevant pathways
that may  be  involved in liver diseases  using gene expression data of mouse liver samples
(section  3.1).  Furthermore,  the  hepatic  SAMe metabolism  was found to  be  perturbed  at
different levels among mouse strains (section 3.1). Therefore, the hepatic SAMe metabolism
may  be  linked  to  the  mouse phenotypes.  Using  expression  and metabolic  profiles  the
arachidonic acid (AA) metabolism was found to be deregulated under DDC-treated condition
in all three mouse strains. In addition, based on expression profiles fatty acid metabolism and
peroxisome proliferator-activated receptors  (PPAR) signalling pathways  were found to be
deregulated. Jin et al., (2012) analyzed microRNA data in a rat model of steatohepatitis and
identified beta-alanine, purine and fatty acid metabolism along with PPAR signalling which
is inline with my study. Some pathways such as histidine, hepatic SAMe and AA metabolism
are identified in my study but not in the study of Jin et al., while calcium signaling pathway
was identified in the study of Jin et al. but not in my study. This discrepancy might be due to
the different systems were analysed, namely in this study mouse data is used while in Jin et
al.  human data  is  used.  Furthermore,  Haque et  al.,  (2010)  identified  pathways  including
xenobiotics by cytochrome P450, arachidonic acid metabolism, PPAR signaling pathway,
and pyrimidine pathway in a mouse model of steatohepatitis which is induced by methionine
and choline (MCD) diet. These pathways are inline with my analysis in which mice were fed
a DDC diet. This indicate that DDC and MCD diets affect similar set of genes.
The genes Mat1a, Srm, Sms, Dnmt1, Achy and Bhmt and metabolites spermidine, spermine,
putrescine  and  methionine  of  SAMe  metabolism  along  with  prostaglandin  E2  and
leukotriene D4 of AA metabolism  were  found to be deregulated at different levels  among
mouse strains (Figures 1e & f).  SAMe is a key methyl-group donor for phosphatidylcholine
synthesis that is required, e.g., for the export of very-low-density lipoproteins (VLDL) and
triglycerides from the liver (Cano et al., 2011). SAMe and methionine metabolism was found
to be perturbed in NASH patients (Kalhan et al., 2011) and it may play role in development
of NAFLD, such as NASH (Mato et al., 2013). A study suggests that depletion of hepatic
anti-oxidants (e.g. reduced glutathione and SAMe) promotes oxidative stress and may induce
a histological steatohepatitis  (Anstee  and Goldin, 2006).  Gene  Mata1  is expressed in liver
and is a marker of hepatocyte differentiation (Mato et al., 2002). The expression of Mata1
was found to be downregulated in A/J mice and it may lead to reduction of SAMe production
from dietary methionine.  When the  level  of  SAMe  expression  reduces markedly then  it
causes liver injury and subsequently  leads to the development of steatohepatitis,  cirrhosis
and HCC (Mato et al., 2002). Thus, SAMe  metabolism may explain susceptibility of A/J
mice to DDC-treatment.
The concentration of  putrescine  was found to be upregulated  for  this  study in  A/J mice
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(Figure 1e)  and  the  Dettmer et  al.,  (2011)  study of  HFD-fed mice.  On the contrary,  the
concentrations of  spermidine  was found to be upregulated  (Figure 1e)  which is not inline
with the study of  Dettmer et al.,  (2011).  This discrepancy may be due to different type of
model systems. 
Prostaglandin E2 (PGE2) is found to be upregulated  in only A/J and C57Bl6 mice (Figure
1e). PGE2 promotes inflammation after binding to prostaglandin E receptor 2 (EP2) (Miller,
2006) which regulates an inflammatory marker tumor necrosis factor alpha (TNFα) in NASH
mouse model (Tosello-Trampont et al., 2012). To explain inflammation phenotypes through a
path PGE2-EP2-TNFα  I  observed mRNA expression of  tnf  which corresponds to  TNFα,
which is markedly upregulated for A/J and C57Bl6 mice. Upregulation of PGE2 and TNFα
for A/J and C57Bl6 mice may explain NASH development by inflammation.
Identification of modules. Fully coupled modules may capture the functional associations
between  genes  and  consequently  may  provide  refined  insights  into  the  modes  of
transcriptional  regulation  of  metabolism.  Identification  of  fully  coupled  modules  is
introduced  in the study of  Papin et al.,  (2004).  Fully coupled modules explain better co-
regulation  of  metabolic  genes  than  the  modules  that  are identified  by  network  distance
(Notebaart et al., 2008). To address the co-regulation of fully coupled modules, I used gene-
expression  data  of  mouse  liver  samples  and  found  moderately  high  co-expression  of
metabolic genes which is inline with the study of Notebaart et al., (2008). 
To the best of my knowledge the identification of most relevant fully coupled modules that
may be involved in liver disease using gene expression data of mouse liver samples was not
performed before.  There is  a tool,  ConsensusPathDB (Kamburov et  al.,  2011a), that  can
perform a module analysis based on enrichment analysis. In ConsensusPathDB modules are
predefined while in my study modules are identified based on  the  structure of metabolic
networks. In this study I identified important fully coupled modules related to liver disease.
For example, a module of cholesterol metabolism was identified and linked to the apoptosis
(Figure 3.4).  Furthermore, some other modules  related to pathways  such as  fatty acid, D-
alanine and creatine metabolism were identified and linked to oxidative stress (Figure 3.4).
The transport of carnitine shuttle system was found to be affected (Figure 3.4). Moreover, the
non-oxidative phase of pentose phosphate pathway and a module of pyrimidine catabolism
were found to be perturbed (Figure 3.4). In addition, a module of cysteine that may be linked
to the  SAMe metabolism  was identified.  The  SAMe metabolism  may be involved in the
development of steatohepatitis (Mato et al., 2013).   
I  have  identified  the  most  relevant  modules  that  may  be  related  to liver  disease  using
elementary flux  modes  and  liver-specific  molecular  data  (Figure  3.10).  For  example,   a
module  presented in Figure 3.10a comprises  L-arginine,  ornithine  and  putrescine, another
module  (Figure  3.10b)  comprises  D-glucose,  L-glutamine  and  L-asparagine.  The
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aforementioned  metabolites  along  with  some  genes  of  the  modules  were found  to  be
differentially regulated in all three mouse strains (Figure 3.11a). Furthermore, some of genes
of the module in Figure 3.10a were found to be deregulated at different levels among mice;
also this  module comprises several cross-talks of pathways such as arginine metabolism,
urea cycle, vitamine A metabolism (Figure 3.10a). These modules might be good candidates
to  construct  more  detailed  kinetic  models for  understanding  the  regulation  of  metabolic
concentrations.  Rezola  et  al.,  (2013) proposed  an  approach  to  obtain  tissue  specific
elementary  flux  modes  that  uses  tissue  specific  gene  expression  data.  They applied  the
approach to data  of liver samples  and identified elementary flux modes (EFMs) associated
with bile acid synthesis which is one of the main functions of hepatocytes  as well as urea
cycle.   I identified EFMs associated with the urea cycle  and  degradation of various amino
acids: glutamine, ornithine and asparagine  which is inline with the study of  Rezola et al..
However,  my approach of  EFMs enrichment  differs  from the  approach of  Rezola  et  al.
(section 3.3.2). Here, I propose to enrich EFMs using deregulated gene expression data and
metabolic  profiles,  while Rezola  et  al.  uses  gene  expression  data.  The  identified  EFMs
(Figure 3.10) which have deregulation at  upstream (e.g., gene expression) and downstream
(e.g.,  metabolic  profiles)  levels  covered  by  molecular  data can  be  more  convincing  for
further experimental investigation. 
Fatty acid module. A module of fatty acid metabolism comprises the process of α-oxidation,
that converts pristanic acid from phytanic acid after removal of its one carbon atom (Figure
3.4a). Phytanic acid induces proliferator-activated receptor alpha (PPARalpha) in vivo and in
vitro (Ellinghaus et al., 1999). PPARalpha deficient mice have defects in fatty acid oxidation
that  leads  to severe  fatty  acid  overload  in  liver,  which  causes severe  steatosis  or
steatohepatitis  (Reddy, 2001).  PPARalpha activation is sufficiently powerful to prevent the
development of dietary steatohepatitis  (Ip et  al.,  2003). Furthermore,  PPARalpha may be
involved in the progression of NAFLD  (Domenici et al., 2013). In short, one may expect
different levels of fluxes throughout the module and concentrations of phytanic acid due to
changes at different levels of Aladh3a2 expression among mouse strains, which may affect
PPARalpha by phytanic acid  and subsequently may develop steatohepatitis-like phenotype.
Ehhadh and Acaa1a are involved in the fatty acid β-oxidation in peroxisome. The elevated
expression of  Ehhadh and  Acaa1a in  mice with high-glucose diet  suggests an increased
oxidative stress  (Du et  al.,  2010).  Oxidative  stress  can be induced by lipids that causes
steatohepatitis in mice fed an atherogenic diet  (Matsuzawa et al., 2007). Thus, the elevated
expression of Ehhadh in A/J and C57Bl6 mice with a DCC supplemented diet may lead to
steatohepatitis, which is inline with their steatohepatitis-like phenotype. Furthermore, Weng
et  al.,  (2013) studied  pathogenic  link  between  nonalcoholic  fatty  liver  and  peroxisome
biogenesis and in this study an elevated expression of Acaa1a was observed. However, in my
study a downregulation of Acaa1a expression was observed in A/J and C57Bl6 mice which
is not inline with the study of Weng et al., (2013).  
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Carnitine shuttle system. I have identified another module which may affect the transport
of  fatty  acid  in  the  cell  which  acts  through  carnitine  shuttle  system  (Figure  3.4d).  The
expression  of  Acadm was  found  to  be  elevated  in  PWD and  C57Bl6  mice,  while it  is
downregulated in mice with reduced hepatic steatosis and lipid peroxidation (Harano et al.,
2006). The elevated expression of Acadm was found in a study of NAFLD patients (Greco et
al., 2008; Mitsuyoshi et al., 2009). Elevated expression of Acadm for PWD and C57Bl6 mice
in my study was inline with the study of Greco et al. and Mitsuyoshi et al,  while results for
A/J  mice  did  not  show  this  behavior.  Based  on  expression  patterns  of  Acadm in  the
aforementioned studies along with my study for PWD and C57Bl6 mice one might speculate
that the flux through the carnitine shuttle system is disturbed.  
Creatine  metabolic  module. Another module  that  was  identified is  related  to  creatine
metabolism  (Figure  3.4b).  The  concentration  of  creatinine  was found  to  be  upregulated
(>1.5-fold) only in liver samples of A/J mice. This is inline with the study of Clarke et al.,
(2013) in NASH patients. Furthermore, the elevated concentration of plasma homocysteine
is a predictor of steatohepatitis in patients with NAFLD (Gulsen et al., 2005). However, there
is a study where creatinine is not found in abnormal range in NASH patients (Crespo et al.,
2001). A transgenic mouse model of Huntington's disease (HD), where HD is characterized
by  weight  loss  despite  of  caloric  intake,  was administrated  with  creatine  analog  beta
guanidinopropionic acid (GPA) that  reduced ATP and phosphocreatine levels in  both the
cerebral  cortex  and  striatum  (Chaturvedi  et  al.,  2010).  Furthermore,  this  administration
impairs activation  of  liver  PPARγ  coactivator-1α  and  promotes  development  of hepatic
steatosis with accumulation of lipids (Chaturvedi et al., 2010). The reduced creatine kinase
activity described in Chaturvedi et al. is inline with the expression of Ckm for all three mice
along with the expression of  Ckmt2 for A/J and C57Bl6 mice in  my study (Figure 3.5).
However,  the elevated expression of  Ckmt2 for PWD mice that  is characterized by high
steatosis,  is  not  inline with Chaturvedi  et  al.  Moreover,  a  study reports that an elevated
alanine aminotransferase activity is a predictor of NASH; however, levels of creatine kinase
and creatine did not changed  markedly (Puljiz et al., 2010). In contrast  with the study of
Puljiz et al. the expression of  Ckm and Ckmt2 was found to be perturbed in  my study.  In
short, molecular data of creatine module are perturbed in my study as well as in the study of
Chaturvedi et al.,  suggesting that  the flux throughout the creatine metabolic system system
may be perturbed.  
Glycogen module.  A module  related  to  glycogen metabolism was identified in analysis.
(Figure  3.4c).  The  elevated  expression  of  a  gene  of  the  module  glucan  (1,4-alpha-),
branching enzyme 1 (Gbe1)  was  found  in A/J and C57Bl6 mice,  and its expression  was
downregulated for PWD mice (Figure 3.8). The elevated expression of  Gbe1 was found in
mice fed a high-fat diet that induced hepatosteatosis (Oyadomari et al., 2008), which is inline
with  the  expression  of  A/J  and  C57Bl6  mice.  Furthermore, a low-choline  diet  supports
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development  of hepatosteatosis,  liver  and  muscle  damage,  and  lymphocyte  apoptosis  in
humans  (Niculescu et  al.,  2007). In the study of Niculescu et  al.  Gbe1 was found to be
overexpressed which is inline with my study in A/J and C57Bl6 mice. Genes Pygb and Pygl
of the module catalyze the synthesis  of glycogen.  The elevated expression of  Pygb was
found for all  three mice (Figure 3.8).  The expression of  glycogen  Pygl was found to be
downregulated  in C57Bl6 and PWD mice.  Sun et al.,  (2012)  showed that mice with liver-
specific deletion of histone deacetylase 3 display severe hepatosteatosis and elevation of the
Pygl expression which is not inline with the expression of Pygl observed in my study, but its
inline with the expression of  Pygb  in my study.  Expression data  of glycogen module is
perturbed  in  my study as  well  as  in  the  aforementioned  study.  These findings raise  the
possibility for further experimental investigation of the flux through the glycogen module.
D-alanine metabolism. The expression of Slc16a7 was found to be upregulated for all three
mose strains under DDC-treatment in the module of D-alanine metabolism (Figure 3.4e  &
3.5). The regulation of Slc16a7 expression in the study of Jansen et al., (2009) is inline with
my  study for all three  strains. Although supplied with sufficient monocarboxylate-derived
energy, glucose-deprived cleavage stage mouse embryos undergo oxidative stress and exhibit
elevated reactive oxygen species which cause elevation of PPARalpha and Slc16a7 that are
markers of peroxisome proliferation. Thus, this module might be linked to oxidative stress. 
Cholesterol  metabolic  module. This module is a part of cholesterol biosynthesis  (Figure
3.4f). The expression of Dhcr24 in the module is decreased after bariatric surgery in obese
subjects with type 2 diabetes (Berisha et al., 2011).  Obesity and type 2 diabetes are know to
be  an  important  factors  for  NAFLD  (Youssef  and  McCullough,  2002).  Based  on
aforementioned studies one can speculate the overexpression of Dhcr24 may cause NAFLD
and interestingly Dhcr24 is found to be overexpressed  for all  three  mice in  my study.  The
overexpression of Dhcr24 is a consequence of oxidative stress (Wu et al., 2004). Thus, this
module might be linked to fatty liver disease as well as to oxidative stress. 
Pyrimidine catabolism. This  module  is  related to  pyrimidine metabolism which may play
an important role in liver. The expression of gene Dpyd was found to be elevated in the study
of Yoon et al., (2011) in subject of HCC patients, while its expression in our study was found
to be downregulated for all three mouse strains.  Furthermore, hepatic steatosis and plasma
dyslipidemia  is  induced by a high sucrose diet in rats  and is reversed by the acute leptin
administration  because leptin  plays  a  major  role  in  weight  loss  and in  regulation  of  fat
deposition  (Sharma  et  al.,  2010).  The  expression  of  Dpyd gene  was found  to  be
downregulated in HepG2 cells treated with baicalein which is hepatoprotective against liver
injury in mice (Qin et al., 2012). The expression of Dpyd is downregulated in both studies of
Sharma et al. and Qin et al. which is in disagreement with the expression for all the mice of
my analysis.  It seems to be  pyrimidine catabolism  is deregulated  differently  in my study
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compared to other studies such as Sharma et al  and Qin et al.  This might occur because in
my study molecular data were derived from mouse strains while in Qin et al. it was derived
from human HepG2 cells. 
Cysteine  metabolic  module.  This  module  comprises a  part  of  the  L-cysteine  and L-
methionine  synthesis  pathway  (Figure 3.4h).  Cbs deficiency  causes  severe
hyperhomocysteinemia that is characterized by an abnormally high level of homocystein in
the  blood  and  is  a  consequence  of  impaired  methionine/cysteine  metabolism.
Hyperhomocysteinemia  in  liver  of  mice  is  induced  by  Cbs deficiency,  that  promotes
oxidative stress, fibrosis and steatosis  (Namekata et al., 2004; Robert et al., 2005). In my
analysis, Cbs was found to be downregulated for A/J and C57Bl6 mice, which may lead to
steatosis and oxidative stress that fulfill partially the two-hit theory of NAFLD. Mice fed a
high  fat-diet  display hyperglycemia,  hyperinsulinemia,  reduced  glucose  tolerance  and
hepatic triacylglycerol accumulation,  while the Cth expression did not change (Dahlhoff et
al., 2013)  which is inline with the C57Bl6 mice in  my analysis.  Furthermore,  Ames dwarf
mice  showed mitochondrial oxidant generation and oxidative  damage  (Brown-Borg et al.,
2001)  and the expression of  Cth is upregulated in the Ames dwarf mouse relative to wild-
type mice, which is inline with the PWD mice in my study.
Pentose metabolic module. The nonoxidative phase of pentose phosphate pathway (PPP) is
identified as an important module that may be involved in liver disease progression (Figure
3.4i). In order to clarify metabolic pathways involved in hepatic lipoapoptosis Noguchi et al.
(2009) performed a study using metabolic flux analysis in H4IIEC3 hepatoma cells treated
with  either  palmitate  alone  (PA) or  both  palmitate  and  oleate  (PA/OA) in  combination
(Noguchi et al.,  2009).  It showed that PA induces the decoupling of glycolysis and TCA
cycle fluxes which leads to the onset of apoptosis, whereas PA/OA treatment restores fluxes
to normal levels which results in lipid accumulation and prevents apoptosis (Noguchi et al.,
2009).  Furthermore,  metabolomics  were measured  in H4IIEC3  hepatoma  cells  that
developed lipoapoptosis and steatosis  (Noguchi et al., 2011).  The  correlation networks  of
metabolites demonstrate that PA treated cells induce a dissociation among PPP metabolites,
whereas PA/OA treated cells restore this dissociation  (Noguchi et al., 2011). Furthermore,
abnormal fluxes of PPP along with increased adenosine level, may suggest the decoupling of
glycolysis,  resulting in lipoapoptosis (Noguchi et al., 2011). The elevated expression of Tkt
of this  module may alter  the fluxes of PPP module  to an abnormal level  along with the
elevated  combined  concentration  PPP  components  ribose  5-phosphate  and  ribulose
phosphate in A/J and C57Bl6 mice, may  indicate apoptosis which is inline with the study of
Noguchi et al.. However, aforementioned combined concentration was found to be elevated
in PWD mice which is not inline with the apoptosis phenotype (section 3.1.1). 
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4.2 Inclusion of gene expression into flux balance analysis
In order to understand the regulation of fluxes I integrated liver-specific gene expression data
into a metabolic model (section 2.1) using the methods mGX-FBA and E-Flux (section 2.3 &
2.4). These methods can be used to explore metabolic states (which is relatively difficult to
measure)  from gene  expression  state  (which  is  relatively  simple  to  measure  in  many
conditions).  I applied these methods  to gene expression  datasets  containing two different
states   (control and DDC-treatment) for three mouse strains (A/J, C57Bl6 and PWD). After
integration of aforementioned datasets I identified different degrees of flux regulation among
mouse strains through glucose metabolism such as glycolysis,  gluconeogenesis,  glycogen
synthesis  and degradation,  TCA cycle,  and pentose phosphate  pathway  along  with  lipid
metabolism such as carnitine shuttle system, cholesterol biosynthesis, bile synthesis and fatty
acid activation. Perturbation in experimental metabolic concentration may be expected due to
the flux through the glycolysis and gluconeogenesis was found to be perturbed my in silico
analysis.  The flux through the pentose phosphate pathway and experimental concentrations
of  ribose  5-phosphate  and  ribulose  5-phosphate  together were  found  to  be  perturbed.
Furthermore,  desmosterol is a downstream component of cholesterol biosynthesis and  the
flux through the pathway was found to be perturbed (section 3.3). 
Challenges in the integration of expression data.  Both  methods, integrating expression
profiles  with  the  constraint-based  metabolic  models,  depend  on  the  assumption  that
expression profiles are a strong indicator for the amount of protein activity. For instance, E-
Flux method assumes that the expression profile indicates the amount of available enzyme
which  can  be  proportional  to  maximum  flux  (e.g.  Vmax).  Hence,  expression  profiles
approximate as an  upper bound on the potential flux through the corresponding reactions.
mGX-FBA method  uses  relative  levels  (between  two  conditions)  of  expression  profiles
within the  rigid  framework of  metabolic  constraints  for  optimization  problem.  However,
some studies  acknowledge that  the  validity  of  this  assumption,  which  correlates  mRNA
expression  to  protein  levels, is  highly questionable.  Using  the  Pearson product  moment
correlation  coefficient,  a  measure  of  linear  dependence  between  two  variables,   the
correlation coefficient of mRNA and protein expression was estimated to be 0.356 for yeast
data (Gygi et al., 1999). Furthermore, yeast cells were grown on galactose and ethanol and
mRNA and protein level were measured  (Griffin and Vidal-Puig, 2008). Using Spearman
rank  correlation  method  that  is  a  non-parametric  approach,  the  correlation  of  ratios
(galactose vs. ethanol) between mRNA and protein level was found to be 0.21 for yeast data
(Griffin and Vidal-Puig, 2008). Another study indicated that the correlation coefficient was
0.45 between mRNA and protein expression for yeast data using Spearman rank correlation
method (Washburn et al., 2003). Furthermore, in mice, the average correlation coefficient of
transcripts and proteins was calculated to be 0.27 using a R package, and the authors argue
that the coefficient is varying depending on the cellular location and biological function of
the gene (Ghazalpour et al., 2011). Taken together, these studies suggest that only a modest
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correlation between transcripts and proteins can be found in yeast and mammals.  A possible
reason of  weak correlation is  the  presence of  many  regulatory  levels  in cells  after  gene
transcription,  such  as,  post-transcriptional,  translational,  post-translational  regulation  and
metabolite feedback regulation  (Zhang et  al.,  2010). These studies acknowledge a  strong
discrepancy between studies where expression profile was used to determine protein level or
upper  bound  on  fluxes.  However,  integrating  expression  data  into  flux  balance  models
improves simple FBA, which can  benefit the understanding  of  the cellular metabolism on
large scale.
Cyclic adenosine monophosphate (cAMP) signalling and transcriptional regulator of
gluconeogenesis
The  flux  through  glycolysis  and  gluconeogenesis  as  well  as  experimental  glucose
concentration were found to be perturbed in  all  three mouse strains  (section 3.3,  Figure
3.12).  This  flux  can  be  affected  by  transcriptional  regulator  of  gluconeogenesis  that  is
interacted  with  cAMP  signalling.  The  interaction  network  of  cAMP  signalling  and
transcriptional regulator of  glycolysis and gluconeogenesis  is shown in Figure 4.1a.  Ratio
(DDC-treated vs control) of cAMP concentrations and expression of genes that participate in
the interaction network is shown in Figure 4.1b.  The concentration of cAMP was found to
upregulated for  all  three  mouse strains  due  to  DDC-treatment  (Figure 4.1b).  cAMP  was
identified as a second messenger that acts to transmit signals from a receptor to a target. It is
involved in many biological processes, e.g.,  the  cellular response to many hormones and
neurotransmitters (Fimia and Sassone-Corsi, 2001). 
The cAMP level  is regulated by the activity of  the  enzyme adenylyl cyclase (AC)  that  is
encoded  by a  large  number  of  genes.  The  expression  patterns  of  these  genes and  their
mechanisms  of  regulation  can  differ  (Fimia  and  Sassone-Corsi,  2001).  Protein  kinase  A
(PKA) was identified  as a target of cAMP.  In turn, many transcription factors  (e.g. CREB
and ATF-1) are regulated by PKA which is mainly achieved by direct phosphorylation of
transcription  factors.  The  phosphorylated  PKA  activates  CREB  and  ATF-1  that  were
originally identified as the activators.  A promoter analysis revealed that the CREB directly
activates the  transcription  of  gluconeogenic genes including PEPCK, G6Pase, Fbpase, and
PC (Fimia and Sassone-Corsi, 2001; Hanson and Reshef, 1997). 
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PKA is encoded by genes Prkx, Prkaa1, and Prkaa2 that are upregulated for A/J and C57Bl6
mice (Figure 4.1b). The expression of Prkx is up regulated for PWD mice (Figure 4.1b). The
quantity of upregulation (ratios) of these genes differs between all three mouse strains. In the
study of Ryan et al.,  (2011)  which  concerns hepatic  steatosis  in human, the  expression of
cAMP-activated kinases  (Prkaa1)  is  not  differentially expressed which is  inline with  the
expression of PWD mice  in my study.  An upregulation of  Prkaa1 was found  in  A/J and
C57Bl6 mice which is inline with the study of Kursawe et al., (2010) that is associated with
insulin resistance and hepatic steatosis  of obese  adolescents,  while it  is not inline  with the
pattern observed in PWD mice. An upregulation of Prkaa1 leads to downregulation of sterol
regulatory  element  binding  protein-1  (SREBF1),  because  Prkaa1  regulates  SREBF1
negatively  (Rayner et  al.,  2011).  Interestingly,  the expression of  SREBF1 is  found to be
downregulated in A/J (0.77-fold), C57Bl6 (0.48-fold), and PWD (0.56-fold) mice. SRBEF1
is a transcriptional regulator of enzymes acetyl-CoA carboxylase alpha (ACACA) and fatty
acid Synthase (FASN) (Croft et al., 2011) that is involved in de novo synthesis of fatty acids.
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Figure 4.1. cAMP signalling network and its genes. a) AC, adenylyl cyclase; PKA,
protein kinase A; CREB, cAMP response element binding protein; ATF-1, A-kinase
anchoring protein; PEPCK, phosphoenolpyruvate carboxykinase;  G6Pase, glucose-6-
phosphatase;  1,6-bisphosphatase,  FBPase;  PC,  pyruvate  carboxylase;  PGC-1α,
peroxisome  proliferator-activated  receptor  gamma  co-activator  1  alpha.  cAMP is
produced  by  ATP by AC. Subsequently, cAMP activates PKA that  further activates
transcription factors CREB and ATF-1 which can lead to activation in gluconeogenesis
genes, e.g.,  PEPCK, FBPase and G6Pase. b)  cAMP is a metabolite (*).  Enzymes are
encoded by genes, such that AC, Adcy7; PKA, Prkx, Prkaa1, Prkaa2;  G6Pase, G6pc,
G6pc3; FBPase,Fbp1,Fbp2; PEPCK, Pck1; PGC-1α, Ppargc1a. 
4 Discussion
Downstream of cAMP signalling (e.g.,  CREB) activates peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC-1α)  that  is a  protein  encoded by the  Ppargc1a
gene. A role of PGC-1α is the formation of lipid droplets in mice and human (Koves et al.,
2013).  The formation of lipid droplets  is  enhanced by the mRNA and protein level of  fat
storage-inducing  transmembrane  protein 1(FITM1/FIT1)  which  raises PGC-1α  (Mormeneo
et al., 2012). Furthermore, PGC-1α controls the expression of cell death-inducing DFFA-like
Effector  A (CIDEA)  that is  an  important  regulatory  factor  in  adipose  cell  function  and
obesity (Hallberg et al., 2008). Ectopic expression of CIDEA induces the formation of lipid
droplets  in  nonadipogenic  cell  lines.  Lipid  droplets  are a  marker  of  hepatic  steatosis
(Anderson and Borlak, 2008).  The expression of  Ppargc1a is upregulated for C57Bl6 and
PWD mice, while slightly downregulated in A/J mice (Fig 4.1 b). Upregulation of Ppargc1a
in PWD mice may be an explanation of the lipid droplets formation which is inline with its
steatosis phenotypes (section 3.1.1). 
A marked reduction was found in A/J mice in the expressions of G6pc, Pck1 and Fbp1 that
encode  G6pase,  PEPCK,  and fructose-1,6-phosphatase,  respectively.  Wang  et  al.,  (2012)
proposed  inhibition of gluconeogenesis  induces hepatocellular carcinoma (HCC)  in mouse
model.  Thus,  A/J  mice have a  potential  to develop HCC due to  high steatohepatitis-like
phenotypes  observed  in  this  strain (section  3.1).  Interestingly,  the  expression  of
gluconeogenesis enzymes (G6pc, Pck1 and Fbp1) was found to be downregulated which is
inline with the study of  Wang et al.,  (2012).  However, Kuo et  al.,  (2012)  proposed  that
curcumin protects hepatocytes from mitochondrial dysfunction and free fatty acid-mediated
hepatic  lipoapoptosis  by  inhibiting  key  enzymes  of  gluconeogenesis,  e.g.,  phosphoenol
pyruvate  carboxykinase  (PEPCK) and  glucose-6-phosphatase  (G6pase).  According to  the
study of Kuo et al. downregulation of gluconeogenesis can protect against apoptosis. As A/J
mice show a higher degree of apoptosis  (section 3.1) one can expect that the expression of
G6pc3 in A/J mice is in agreement with the study of Kuo et al., (2012), while the expression
of gluconeogenesis enzymes (G6pc, Pck1 and Fbp1) is not in agreement (Figure 4.1b). 
Cholesterol biosynthesis. The flux through the reaction of cholesterol biosynthesis, LSTO1r
(chstol/Cholesta-7,24-dien-3beta-ol  ->  ddsmsterol/  desmosterol),  was found  to  be
upregulated  in C57Bl6 and PWD mice.  Experimentally,  the concentration of desmosterol
was found to be upregulated in C57Bl6 and PWD mice. The serum desmosterol, a precursor
of  cholesterol  in  the cholesterol  biosynthesis  pathway,  was found to  be increased  in  the
subject  of  NASH  compared  to  the  subject  of  simple  steatosis  and  normal  human  liver
(Simonen et  al.,  2013).  An increased concentration of  desmosterol  in  C57Bl6 mice  was
found in my study which is in agreement with  the study of Simonen et al.  due to C57Bl6
mice  show low steatohepatitis-like phenotypes,  while  it  is  not inline  with A/J  and PWD
mouse  strains  because  desmosterol  concentration  did  not  change  in  A/J  mouse  strain
although  it  shows high  steatohepatitis-like  phenotypes and  desmosterol  concentration  is
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elevated in PWD mouse strains although it shows unspecific steatohepatitis-like phenotypes.
Cholesterol  synthesis  was found to be increased for  a  mouse  model  of  hepatic  steatosis
which is induced by high-fat diets  (Oosterveer et al.,  2009). Due to increased cholesterol
synthesis one may expect  an increase in its precursor desmosterol  which is inline with  the
expectation in PWD mice (section 3.1.1).  
Carnitine shuttle system. The flux through a part of fatty acid metabolism (carnitine shuttle
system)  was found to be perturbed in  all  three mouse strains  (Figure 3.13a).  Due to  an
increase in flux through the carnitine shuttle system the production of carnitine is expected to
be higher in PWD and C57Bl6 mice.  Malaguarnera et al.,  (2010) proposed that  a carnitine
supplemented  diet  improves  liver  function,  glucose  plasma  level,  lipid  profile,  and
histological manifestations of NASH. Thus, one may expect less steatohepatitis in PWD and
C57Bl6 mice than  in  A/J mice which  is inline with steatohepatitis-like phenotypes of all
three mouse strains (section 3.1.1). 
Fatty acid activation. The flux through the reactions FACOAL1812 and FACOAL1813 that
are catalyzed by acyl-CoA synthetase long-chain family member 1 (ACSL1) was found to be
upregulated in C57BL6 and PWD mice,  while it was downregulated in A/J mice (Fig 3.16
c).  ACSL1 converts free long-chain fatty acid to acyl-CoA, thereby plays an important role
in lipid biosynthesis and fatty acid degradation. Gene expression of ACSL1 was found to be
downregulated  (< 2-fold) in all three mouse strains.  Although the expression of ACSL1 was
downregulated,  the  flux  through  the  ACSL1  catalyzed  reactions  (FACOAL1812  and
FACOAL1813 in  Figure 3.16c) was found to be upregulated for C57Bl6 and PWD mice.
This  result   suggests that  the  regulation  of  flux  may not  be  judged  based  on  single
perturbation of enzyme. Thus, the complex interaction of metabolism plays an important role
in the regulation of flux.  Li et al., (2009) studied the function of ACSL1 in liver where liver-
specific loss of ACSL1 decreases triacylglycerol synthesis, acyl-CoA, and beta-oxidation and
alters phospholipid fatty acid composition.  Beta-oxidation is the major process by which
fatty acids are broken down to generate energy, especially when  the  glucose level is low
during periods of starvation. Beta-oxidation of fatty acid occurs in both mitochondria and
peroxisomes. Diet derived  short-, medium-, and long-chain fatty acids  are broken down in
mitochondria which generates acetyl-CoA, and this pathway constitutes the major process by
which fatty acids are oxidized to generate energy. Peroxisomes are involved in the beta-
oxidation where very long chain fatty acids shorten and in the process H2O2 is produced.  The
first  step  of  peroxisomal  beta-oxidation  process  catalyzed  by  acyl-CoA oxidase  (AOX)
which converts fatty acyl-CoA to 2-trans-enoyl-CoA. Fan et al.,  (1998) proposed that mice
deficient  in  AOX  exhibit  steatohepatitis.  Diet  derived  fatty  acids,  e.g.,  elaidic  acid  and
vaccenic acid that  are  involved in FACOAL1813 and FACOAL1812, respectively, can be
oxidized  to  generate  energy  using  beta-oxidation  pathway.  The  flux  through  the
FACOAL1813  and  FACOAL1812  was found  to  be  decreased  in A/J  mice  indicating a
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decrease in beta-oxidation which may develop steatohepatitis.  The latter  finding is inline
with the steatohepatitis-like phenotype of A/J mice.  
Bile acid synthesis. Bile acids are the end products of cholesterol utilization. Bile acids are
used as signaling molecules and inflammatory agents that activate nuclear receptors and cell
signaling  pathways  that  regulate  several  metabolic  pathways  such as  lipid,  glucose,  and
energy metabolism.  Bile acids synthesis is the major pathway of cholesterol catabolism in
mammals. The excretion of excess cholesterol is occurred in the form of bile acid. Although
several of the enzymes that are involved in synthesis of bile acid are active in many tissues,
the liver is the only organ where de novo synthesis of bile acid takes place (Chiang, 2009).
The genes encoding the enzymes of bile acid synthesis pathway should be tightly controlled
in order to ensure the necessary level of bile acid production that coordinates changes of the
metabolic conditions. Many bile acid metabolites are cytotoxic and due to this their synthesis
needs to be tightly controlled. However, bile acid  was  found to be protective  against the
fructose-induced hepatic  steatosis  in mice  (Volynets  et  al.,  2010).  Metabolite  taurocholic
acid/tchola  is  a  yellowish  crystalline  bile  acid,  it is  the  end  product  derived  from
cholesterol/chsterol (Figure 3.16b). The flux through the bile acid synthesis pathway  was
found to be downregulated in A/J mice, and to be upregulated in PWD mice, and unchanged
in C57Bl6 mice (Figure 3.16b). Levels of bile acid were found to be elevated in the liver of
patients  with  steatohepatitis  (Aranha et  al.,  2008) and in  a  murine  steatohepatitis  model
induced by the methionine-choline-deficient (MCD) diet (Gyamfi et al., 2008). Experimental
concentration of  taurocholic acid was found to be upregulated in AJ mice which  can be in
agreement with the study of Aranha et al., (2008) and Gyamfi et al., (2008).  Farnesoid X
receptor  (FXR),  a  ligand-activated  nuclear  receptor  belonging  to  the  nuclear  receptor
superfamily,  is  a  central  regulator  and sensor  for bile  acids.  FXR deficiency leds to  the
development  of  nonalcoholic  steatohepatitis  in  low-density  lipoprotein  receptor-knockout
mice  fed  a  high-fat  diet  by  altering  the  bile  acid  homeostasis  (Kong  et  al.,  2009).
Perturbation of the flux through bile acid synthesis   (Figure 3.16b)  among mice may alter
bile acid homeostasis which is inline with the study of Kong et al., (2009). Cholesterol 7α-
hydroxylase (Cyp7a1) catalyzes the rate-limiting step that converts cholesterol to bile acids
in the liver. After feeding a DDC supplemented diet the expression of Cyp7a1 is found to be
upregulated  2.85-fold  and  1.45-fold  in  A/J  and  C57Bl6  mice,  respectively,  and  to  be
downregulated  0.63-fold in PWD  mice.  Chronic  cholesterol  feeding  in  mice  results  in
suppression  of  hepatic  Cyp7a1 expression  that  is  associated  with  an increase  in  hepatic
cholesterol content  (Henkel et  al.,  2011),  which  is  in agreement with the  expression and
steatosis phenotypes of PWD mice.  On the contrary, Henkel et al., (2011) proposed that the
acute cholesterol feeding results in upregulation of hepatic Cyp7a1 expression. Furthermore,
Ha and Kim,  (2013)  studied the effects of fucoxanthin on gene expression related to lipid
metabolism in rats  with a high-fat  diet.  Consumption of  fucoxanthin improves  lipid and
cholesterol metabolism in rats with a high fat diet  and  in addition to  this it  increases the
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mRNA expression  Cyp7a1 that is inline with an upregulation of  Cyp7a1 expression in A/J
and  C57Bl6  mice  with  a  DDC supplemented  diet. FXR plays  an  important  role  in  the
regulation of cholesterol and glucose metabolism  (Lambert et al., 2003; Ma et al., 2006).
Hepatic FXR responds to bile acids and represses the  Cyp7a1 expression  (Chiang et  al.,
2000). Histological features of liver of FXR deficient (FXR KO) mice display higher degree
of  steatosis,  perisinusoidal/sinusoidal  foam  cells,  ballooning  degeneration  and  lobular
inflammation compared to wild mice, which may indicate liver damage and steatohepatitis-
like phenotypes in FXR KO mice (Bjursell et al., 2013).
Furthermore, Tanaka et al., (2013) proposed that restricted intake of dietary phosphate plays
an important role for the development of fatty liver disease which is induced by a high-
cholesterol diet and the hepatic mRNA levels of Cyp7a1 are observed to be increased. The
expression of  Cyp7a1 in A/J and C57Bl6 mice  is inline with the study of  Bjursell et al.,
(2013) and Tanaka et al., (2013). 
4.3 Drug target candidates in liver disease 
There are few drugs to cure the liver disease: steatosis, steatohepatitis and HCC. Thus, I have
performed an  in  silico analysis  in  which the metabolic  candidate  genes are identified as
potential  drug  targets  in  aforementioned  liver  disease  (section  3.4).  I  have  formulated
biomass functions for steatosis and steatohepatitis and these biomass functions are used to
identify potential  drug targets of diseases. 26 drug targets were  found to be  common in
steatosis, steatohepatitis, and HCC (Table 3.1). Out of 26 drug targets, 13 were identified in
cholesterol metabolism, while 6 and 3 were triacylglycerol synthesis and inositol phosphate
metabolism, respectively. Folger et al., (2011) performed an in silico drug target analysis in
cancer using human metabolic network and found that a marked number of drug targets is
from cholesterol metabolism which is inline with my study. Interestingly,  there are some
common targets such as Fdps, Hmgcr, Lss. Folger et al. also recognized NSDHL and SOAT1
as potential drug targets, which were not identified in my work. On the other hand in this
study I  identified  potential  drug targets  such as  Agpat1  and  Agpat2 form  triacylglycerol
synthesis along with potential drug targets such as Isyna1 and Impa1 from inositol phosphate
metabolism which were not found in the study of Folger et al.. Furthermore, Acaca is a key
enzyme gene of fatty acid metabolism and this is identified as a potential drug target in my
study (steatosis and steatohepatitis but not in HCC) as well as in the study of Folger et al..
Moreover, drug targets such as Sptlc1, Sptlc2 and Kdsr were found to be from sphingolipid
metabolism in the study of Folger et al. and in my study.
Fdps  is  involved in cholesterol metabolism  and is  identified as a potential  candidate for
drugs in liver disease. There are some drugs such as pamidronate, zoledronate, alendronate,
ibandronate,  and risedronate  which target  Fdps  (Ahmed et al.,  2011). Zein et  al.,  (2005)
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proposed that alendronate improves bone mineral density in primary biliary cirrhosis (PBC).
PBC is an autoimmune disease characterized by inflammation of small bile ducts, and in
some patients the development of fibrosis and cirrhosis  (Hirschfield and Gershwin, 2013).
Furthermore,  another  candidate  of  cholesterol  metabolism,  Hmgcr,  was identified  as  a
potential candidate for drugs  such as NADH, pravastatin, lovastatin  (Ahmed et al., 2011).
Statins  such as  pravastatin  can  be used safely in patients with NAFLD  (Calderon et  al.,
2010). Gene Sc4mol is  another candidate of cholesterol metabolism which can be targeted
by drugs NADH and indomethacin (Ahmed et al., 2011). Murali et al.,(2012) proposed that
fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis
in mice.  Taken together, there are some drugs for genes of cholesterol metabolism such as
Hmgcr, Fdps, Sc4mol which might be used for liver disease such as steatosis, steatohepatitis,
and  HCC but of course  this needs  an experimental  validation. Some other candidates  of
cholesterol metabolism such as Mvd and Lss were identified as a target in this study. These
candidates are novel and may be used as a potential drug targets in liver disease but this need
further experimental investigation. 
L-serine  is  a  drug  which  can  inhibit  Sptlc1,  Sptlc2 (Ahmed  et  al.,  2011).  L-serine is
synthesized from glycine or threonine.  L-Serine  is non-essential and it  can also be derived
from the diet and the degradation of protein and/or phospholipids (Mardinoglu et al., 2014).
L-serine is involved in the formation of lipids such as sphingosine and phosphatidylserine as
well as other building blocks and cofactors, such as protein (glycine and cysteine), creatine,
porphyrins, glutathione and nucleotides (Mardinoglu et al., 2014). The expression of Sptlc1
in the study of  Mardinoglu et al.,  (2014)  were found to be upregulated in NASH patient
which is inline  with expression pattern, observed in A/J and C57Bl6 mouse strains  in my
study (section 3.1.1).  Furthermore,  Mardinoglu et al. identified phosphoserine phosphatase
(PSPH) as potential therapeutic targets for the treatment of NASH which is inline with my
study where  Psph (Table 3.1) is identified for  the  treatment of HCC.  The amplification of
PSPH in  the  serine synthesis  pathway may also decrease the flux through pyruvate and
lactate formation in cytosol  (Mardinoglu et al., 2014).  The  increased pyruvate and lactate
levels were previously reported in NASH patients (Kalhan et al., 2011b). The experimentally
measured  concentrations  of  pyruvate  together  with  oxaloacetate  were found  to  be
upregulated (> 1.5-fold) in mouse strain A/J and C57Bl6 which is inline with the study of
Kalhan et  al.,  (2011b).  Taken together,  both results  of my work along with  the work of
Mardinoglu  et  al.,  (2014)  indicate  that  one  needs  to  validate  experimentally  PSPH as
potential  therapeutic  targets  for  the  treatment  of  NASH. Moreover,  Mardinoglu  et  al.
identified  SHMT1 and  BCAT1  as potential therapeutic targets for the treatment of NASH,
while these targets are not identified in my in silico drug target analysis  it might be due to
use of different metabolic models in both studies.
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4.4 Arachidonic acid metabolism 
In pathway analysis AA metabolism was identified as being the most affected due to DDC
treatment  in all of three mouse strains.  I proposed a dynamic model of AA metabolism to
study the DDC treatment effects. The fitted model provides good  correspondence between
the experimental and simulated metabolic data using the respective gene expression data. 
To determine regulatory roles of important enzymes in the upregulation of metabolic levels
of the AA/eicosanoid pathway due to DDC-treatment, a sensitivity analysis was performed
by reverting to the activity of the enzymes at normal, untreated conditions. The combination
of the enzymes ALOX5AP, PERK, PKCD, STAT3, and PTGS1 is able to revert the DDC-
treated metabolic state to normal. This multi-target inhibition might likely become relevant
in the context of individualized medicine. A study suggests that multi-target cancer therapy
has higher probability of success than single-target,  because it can better reflect the diversity
in genetics among individuals (Broekman et al., 2011; Lu et al., 2012).
Furthermore,  I performed in silico drug testing of several model enzymes.   Inhibition of
PTGS1 and ALOX5AP caused downregulation of PGH2 and PGD2 or 5-HPETE and LTA4,
suggesting that PTGS1 and ALOX5AP might be potential  drug targets of steatohepatitis.
PTGS1 (COX-1), for instance,  can be inhibited by mofezolac, SC-560, and others (Perrone
et al., 2010). Inhibition of ALOX5AP (also known as 5-lipoxygenase activating protein or
FLAP) may be useful in the prevention of hepatotoxin-induced necro-inflammatory injury
(Titos et al., 2005). Drug molecules can interact with multiple targets to alter the state and
function of the associated biological network. Licofelone is a novel 5-LOX/Cox-inhibitor
which  inhibits  two  enzymes  to  avoid  side  effects  (Ulbrich  et  al.,  2005). Overall,  the
dynamics  of the AA model can be used for in  silico drug studies of multiple  drugs and
potential  drug  targets.  AA model  can  confirm  the  upregulation  of  PGD2  due  to  DDC
treatment  found experimentally.  It  is  connected with the key transcription factors/ligand-
activated nuclear receptors such as PPARδ which was implicated as a key regulator of energy
homeostasis and may represent future research avenues to study the interaction of metabolic
and signaling pathways (Wang and DuBois, 2010). 
The spectrum of NAFLD and NASH can be characterized by specific alterations in hepatic
lipid  composition.  A comprehensive  analysis  of  plasma lipids  and eicosanoids  in  human
revealed a stepwise increase in lipoxygenase metabolites 5-HETE, 8-HETE and 15-HETE in
NAFLD  and  NASH  (Puri  et  al.,  2009).  This  correlates  with  our  observations  in  the
experimental  and  simulated  data,  where  concentrations  of  5-HETE  and  15-HETE  were
increased in DDC mice. Another study reported overexpression of cyclooxygenase-2 (COX-
2)  in  hepatocellular  carcinoma  (HCC)  patients  (Giannitrapani  et  al.,  2009).  Using
immunohistochemistry  they  studied  COX-2  overexpression  in  different  chronic  liver
diseases including NASH, chronic hepatitis, and liver cirrhosis. Here, I found overexpression
of PTGS1 (COX-2) in DDC mice, which is a key regulator of prostaglandin formation.
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Martínez-Clemente et al.,  (2010) demonstrated that hyperlipidemia-prone apolipoprotein E-
deficient (ApoE(-/-)) mice exhibit hepatic steatosis and increased susceptibility to hepatic
inflammation and advanced fibrosis. They experimentally found that the proinflammatory 5-
lipoxygenase  (5-LO)  pathway  is upregulated  and  thus  causes  liver  inflammation  and
fibrogenesis. They also found that the inhibition of the 5-LO pathway results in a significant
reduction in liver inflammation. Our data supports an upregulation of ALOX5AP through 5-
LO pathway due to DDC treatment in A/J, C57Bl6, and PWD, leading to an upregulation of
the downstream component 5-HPETE in the model that is supported by our experimental
data. 
In conclusion, considering mRNA expression data for mathematical modeling of metabolic
systems  provides  a  very  useful  way  to  understand  cellular  metabolism,  although  the
correlation  between  transcripts  and  proteins  can  deviate  depending  on  cellular  location,
biological  function,  and  organism  (Ghazalpour  et  al.,  2011).  I identified  AA/eicosanoid
metabolism as highly perturbed in DDC-induced mice using a combination of in silico and
experimental approaches. The analysis of the AA/eicosanoid metabolic pathway presented in
this work suggests that 5-HETE, 15-HETE and PGD2 are perturbed in DDC mice. Therefore
this  work demonstrates that  a  dynamic  model  can  be  used  for  qualitative  prediction  of
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